TW503237B - Intermediate in manufacture of heterocyclic compounds having anti-diabetic activity - Google Patents

Intermediate in manufacture of heterocyclic compounds having anti-diabetic activity Download PDF

Info

Publication number
TW503237B
TW503237B TW087114283A TW87114283A TW503237B TW 503237 B TW503237 B TW 503237B TW 087114283 A TW087114283 A TW 087114283A TW 87114283 A TW87114283 A TW 87114283A TW 503237 B TW503237 B TW 503237B
Authority
TW
Taiwan
Prior art keywords
group
substituted
cns
page
please read
Prior art date
Application number
TW087114283A
Other languages
Chinese (zh)
Inventor
Takashi Fujita
Takao Yoshioka
Toshihiko Fujiwara
Minoru Oguchi
Hiroaki Yanagisawa
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of TW503237B publication Critical patent/TW503237B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/36Oxygen atoms in position 3, e.g. adrenochrome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

There is provided an important intermediate compound of formula (I) useful in the preparation of a compound of formula (II), having an excellent biological activities. Compound of formula (I); compound of formula (II): wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Y' represents an oxygen atom or a sulfur atom; Q represents a lower alkoxycarbonyl group, a formyl group, a protected formyl group, a carboxyl group or a hydroxy group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5.

Description

503237 A7 B7 五、發明説明() 發明背景 本發明係關於一条列具有降血糖和抗糖尿病活性之雜 環化合物之製造用中間體。 已知類似該雜環化合物,内含其他喀唑啶二酮或垮 唑啶二酮基經由伸甲基或亞甲基連接至苯環之化合物具 有此類型活性,此一般類型化合物掲示於歐洲專利公報 No.008203, 139(21, 4 4 1605,208420,528734, 177353, 30622 8 vo 356含 14,和於 W092/0 /8 50,92/07839,91/07107, 92/Ο25/2Ο和32/03425中。吾等現今發現包含於此類化合 物中的某些持定雙環含氮環条統造成化合物更加改善活 性。 發明之簡單摘要 因此,本發明之一目的在於提供重要中間體以製造一 条列新穎之化學化合物,其被視為噻唑聢和唑啶衍生 物。 因此,本發明提供式(I)化合物和其鹽:503237 A7 B7 V. Description of the invention () Background of the invention The present invention relates to a series of intermediates for the production of heterocyclic compounds having hypoglycemic and anti-diabetic activities. It is known that compounds similar to this heterocyclic compound, which contain other carbazidinedione or diazoridinone groups attached to the benzene ring via a methyl or methylene group, have this type of activity. This general type of compound is shown in the European patent. Bulletin No. 008203, 139 (21, 4 4 1605, 208420, 528734, 177353, 30622 8 vo 356 with 14, and W092 / 0/8 50, 92/07839, 91/07107, 92 / Ο25 / 2〇 and 32 / 03425. We have now discovered that certain fixed bicyclic nitrogen-containing ring systems contained in such compounds result in compounds with improved activity. A brief summary of the invention Therefore, one object of the present invention is to provide important intermediates to make a compound. List of novel chemical compounds, which are considered as thiazolium and azole derivatives. Therefore, the present invention provides compounds of formula (I) and their salts:

Q—(CH2)EQ— (CH2) E

裝 訂Binding

經 濟 部 中 央 標 準 局 員 工 消 合 作 社Staff Association of the Central Standards Bureau of the Ministry of Economic Affairs

(I) 其中: . .V. 0 Q為低烷氧羰基,甲醯基,被保護甲醯基,錢基或羥 基 Y為0或S ; Y ·為0或S ; -3~ 本紙張尺度適用中國國家標準(CNS ) A4規格(210x297公釐) 503237 A7 B7 五、發明説明() R為氫原子,Ci - 4烷基,Ci - 4烷氧基,鹵原子, 羥基,硝基,芳烷基其中Ci — 5烷基為被取代以具有 6至10個環磺原子之芳基,或式Rb , 其中Ra和!^為相同或不同且各為氫原子,Ci - 8 烷基,芳烷基其中Ci - 5烷基為被取代以具有6至 10個環碩原子之芳基,具有6至10個環碩原子之芳基, L u脂族羧酸醯基,C2 - 6脂族羧酸醯基且被取 代以具有6至10個環磺原子之芳基,或芳香羧醒基 其中芳基部分具有6至10個環磺原子, ro為整數1至5。 此中間體即可轉變成具有生物活性之如下式(II)化合 物 ^ch2)^y(I) Where:.. V. 0 Q is a low alkoxycarbonyl group, a methylamino group, a protected methylamidino group, a chloro or hydroxy group Y is 0 or S; Y · is 0 or S; -3 ~ this paper size Applicable to China National Standard (CNS) A4 specification (210x297 mm) 503237 A7 B7 V. Description of the invention () R is hydrogen atom, Ci-4 alkyl group, Ci-4 alkoxy group, halogen atom, hydroxyl group, nitro group, aromatic group Alkyl where Ci-5 alkyl is an aryl group substituted with 6 to 10 ring sulfo atoms, or the formula Rb, where Ra and! ^ Is the same or different and each is a hydrogen atom, Ci-8 alkyl group, aralkyl group wherein Ci-5 alkyl group is an aryl group substituted with 6 to 10 ring atoms, and 6 to 10 ring atoms Aryl, Lu aliphatic carboxylic acid fluorenyl, C2-6 aliphatic carboxylic acid fluorenyl and substituted with an aryl having 6 to 10 ring sulfo atoms, or an aromatic carboxyl group in which the aryl moiety has 6 to 10 ring sulfo atoms, ro is an integer of 1 to 5. This intermediate can be transformed into a compound of formula (II) with biological activity ^ ch2) ^ y

經濟部中央標準局員工消費合作社印製 其中: X為吲昤基,吲丨g啉基,吖吲呤基,吖吲哚_基,眯 唑並吡啶基或眯唑並嘧啶基其為未取代或被取代以至 少一個取代基選自如下定義之取代基α ; R , Υ , Υ 1及ίο各同前。 -4-本紙張尺度適用中國國家標準(CNS )八杉1格(21〇 Χ297公釐) 503237 A7 B7 五、發明説明() 各所述取代基《為(^ - 4烷基,C6 - !〇芳基,三氟甲 基,Cl - 4烷硫基,Cl - 4烷氧基,苄氧基,鹵原子 ,羥基,乙醯氣基,苯硫基,硝基,芳烷基,或式 -NRaRb,其中11曰和1^如上定義; 取代基or中所包含之該方基和該芳烷基之芳基部分為具 有6至10個環磺原子之碩環芳香基且為未取代或被取代 以至少一値取代基選自如下定義之取代基冷; 各所述取代基点為Ci - 4烷基,Ci - 4烷氧基,鹵原 子,羥基,硝基,苯基,三氟甲基,或式- NRaRb,其 中1^和111)如上定義。 發昍:> 洚細淄沭 於本發明化合物中,於X為衍生自吲呤環之基方面, 其例如可為吲呤-1 -基,吲呤-2 -基,吲昤-3 -基,吲昤 -4-¾ , B引ί朵一 5鑛基,雜引媒朵盡6猶基或Β引ί朵一7 -基。 於X為衍生自吲昤啉環之基方面,其例如可為吲跺啉 -1-基,吲昤啉-2-基,吲呤啉-3-基,吲哚啉-4-基,吲 Ιί朵啉-5-基,吲呤啉-6-基或吲哚啉-7-基。 於X為衍生自吖吲呤環之基方面,其例如可為4 -吖吲 Ϊ朵-1 -基,4 -吖吲哚-2 -基,4 -吖吲哚-3 -基,4 -吖吲Ϊ朵 -4-¾ , 4 一BY J 引 IT朵-5-基,4-霞丫 Ϊ引時垂6·基,4-ιιγ bsi ¢^-7-基,5-吖吲呤-1-基,5-吖吲呤-2-基,5-吖吲昤-3-基, 5 - ?丫 11引,朵一4 ·基,5 -眞丫 Ϊ引IT朵· 5 -基,5鶴》丫 B引ί朵一6 -基,5-吖吲昤-7-基,6-吖吲呤-卜基,6-吖吲呤-2-基,6-吖 Β引ί朵-3 -基,6 -吖吲Ιί朵-4 -基,6 -吖吲I朵-5 -基,6 -吖吲 -5- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) 請 先 閲 讀 背 面 之 注 意 項 經濟部中央標準局員工消費合作社印製 經濟部中央標準局員工消費合作社印製 503237 A7 B7 五、發明説明() II朵-6-基,6-吖吲ί朵-7-基,7-吖吲ί朵-1-基,7-吖吲IT朵 -2-¾ , 7 - ΪΪ P3I - 3 - S , 7-1 丫 ,引時一4-基,7-ΠΓ Β引 ί朵一5-基,7-11丫 Β引(if -6-基。 於X為衍生自吖吲呤啉環之基方面,其例如可為4 -吖 吲昤_ -1-基,4-吖吲呤啉-2-基,4-吖吲呤啉-3-基,4-吖吲哚啉-5 -基,4 -吖吲哚啉-6 -基,4 -吖吲哚啉-7 -基, 5-吖吼呤啉-卜基,5-吖吲呤啉-2-基,5-吖吲呤啉- 3-基,5 -吖吲呤啉-4 -基,5 -吖吲呤啉-6 -基,5 -吖吲哚啉 -7 -基,6 -吖吲呤啉-1 -基,6 -吖吲哚啉-2 -基,6 -吖B引 孩朵_ - 3 -基,6 -吖吲哚啉二4 -基,6 -吖吲哚_ - 5 -基,6 -吖吲昤啉-7-基,7-吖吲哚_ -卜基,?-吖吲哚啉-2-基, 7 · mr p引》朵咐一3 -基,7 - rr p引if朵咐一4 -基,7 - rr p引?朵赙本一5 · 基或卜吖吲哚啉-6 -基 於X為衍生自眯唑並吡啶環之基方面,其例如可為眯 唑並〔4,5-b〕吡啶-1-基,眯唑並〔4,5-b〕吡啶-2-基 ,眯唑並〔4,5-b〕吡啶-7-基,眯唑並〔4,5-b〕吡啶 -5 -基,昧睡並〔4,5-b〕唯症-6-基,味睡並〔4,5-c〕 吡啶-1-基,眯唑並〔4,5-c〕吡啶-2-基,眯唑並 〔4,5-c〕吡啶-4-基,眯唑並〔4,5-c〕吡啶-6-基,眯 唑並〔4,5-c〕吡啶-7-基, 咪唑並〔5,4-b〕吡啶- 3-基,眯唑並〔5,4-b〕Sft啶-2-基,眯唑並〔5,4-b〕吡啶 -7-基,眯唑並〔5,4-b〕吡啶-5-基,咪唑並〔5,4-b〕 吡啶-6-基,眯唑並〔5,4-c〕吡啶-3-基,眯唑並〔5,4-c〕 吡啶-2-基,咪唑並〔5,4-c〕吡啶-4-基,眯唑並〔5,4-c〕 -6~ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) •裝_ 503237 A7 B7 五、發明説明() 請 先 閲 % 背 面 之 注 意 事 項 吡啶-6-基,眯唑並〔5,4-c〕吡啶-7-基,眯唑並〔l,2-a〕 吡啶-2-基,眯唑並〔i,2-a〕吡啶-3-基,眯唑並〔1,2-a〕 吡啶-8-基,眯唑並〔1,2-a〕吡啶-5-基,眯唑並〔1,2-a〕 吡啶-6-基或眯唑並〔1,2-a〕吡啶-7-基。 於X為衍生自咪脞並嘧啶環之基方面,其例如可為眯 唑並〔4,5-b〕嘧啶-7-基,眯唑並〔4,5-b〕嘧啶-8-基 或眯唑並〔4,5-b〕嘧啶-9-基。 上逑X所代表之任何基可為未取代或可被取代以至少 一値如上定義和如下列舉之取代基α。於被取代方面, 對於取代基之數目並無特別限制,除了被可取代位置之 數目,或偶而被立體阻礙所限。然而,一般以1至3値 取代基為較佳,1或2値取代基為最佳。對於任何此類 取代基之位置亦無特別限制。 R C ,基 於鏈基甲 支丙為· 基 «員 代4β, 取4基 ^_ 申二 μ 其丙, Η ¾基,罾自Γ m 為g基 Θ包T 基Jtll ^ ^ 0二, 或fl基 α , * 或 佳 異 直 較 經濟部中央標準局員工消費合作社印製 直 , 為基 可氧 其乙 面基 方氧 基甲 氧括 烷包 為例 点其 基且 代 , 取基 或氣 α 烷 基 4 代 - 取 1 C R 鍵 於支 或 和 基 氣 丁 二 第 基 氣 丁 〇 異基 ,氣 基甲 氣為 丁佳 ,較 基中 氣其 丙 , 異基 , 氧 基丁 氣三 丙第 基 代 取 或 a 基 代 取 子 原 碘 〇 或佳 氟最 ,為 氛子 R > 原 於溴氯 為以 面 方 子 原 0 為 溴 為 佳 較 中 其 可 如 例 其 子 原 氤 和 氨 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 503237 A7 B7 五、發明説明() 於R為芳烷基方面,此基之烷基部分具有1至5値磺 原子且可為被芳基取代之直或支鐽基,其本身可為如上 定義和如下列舉者。芳烷基總共較佳具有7至11値磺原 子。此類基之烷基部分之實例包括甲基,乙基,丙基, 異丙基,丁基,異丁基,第二丁基,第三丁基,戊基, 異戊基,新戊基和第三戊基,較佳為甲基和乙基。芳基 之實例為其後關於取代基σ所列舉者。此類芳烷基之特 別例包括苄基,2 -苯乙基(二苯乙基),1-苯乙基,3 -苯 丙基,2-苯丙基,1-苯丙基,4-苯丁基,1-苯丁基,5-苯戊基,1-#甲基和2-萘甲基,其中以苯乙基和苄基為 較佳,以苄基為最佳。 另外地,R,取代基α或取代基>3可為式- NRaRb之 胺基或被取代胺基,其中可相同或不同選自下 列: (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印裝 (1 )氫原子; (2 )C 1 - 8 烷 基 $ 其 可 為 直 或 支 鏈 基 例 如 甲 基 9 乙 基 $ 丙 基 f 異 丙 基 丁 基 9 異 丁 基 9 第 二 丁 基 9 第 三 丁 基 $ 戊 基 $ 2- 戊 基 > 3- 戊 基 f 2- 甲 基 丁 基 J 3- 甲 基 丁 基 1, 1 - 二 甲 基 丙 基 f 1 , 2· 二 甲 基 丙 基 9 2 , 1 - 二 甲 基 丙 基 己 基 9 2- 己 基 t 3- 己 基 f 甲 基 戊 基 9 3- 甲 基 戊 基 $ 4- 甲 基 戊 基 9 1 , 1 - 二 甲 基 丁 基 t 1 , 2- 二 甲 基 丁 基 t 1 , 3- 二 甲 基 丁 基 9 2 , 2- .二 甲 基 丁 基 f 2 , 3- 二 甲 基 丁 基 % 3 , 3- ‘二 甲 基 丁 基 f 1 , 1, 2- .rr 甲 基 丙 基 $ 1 , 2 , 2- '— 甲 基 丙 基 * 庚 基 $ 2- 庚 基 $ 3- .庚 基 9 4- .庚 基 $ 3 , 3- .二 甲 基 戊 基 » 辛 基 9 -8~ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 503237 A7 _B7__ 五、發明説明() 1-甲基庚基,2-乙基己基和1,1,3, 3-四甲基丁基,其中 較佳為直或支鏈之Ci- 6烷基,且最佳為直或支鏈之 C 1 - 4烷基;以甲基和乙基為最佳; (3) 關於R所代表之如上定義和如下列舉之芳烷基, 且此類基較佳具有7至11値磺原子; (4) C6_ 10芳基,例如苯基,卜萘基和2 -萘基; (5) 脂族羧酸醯基,其可為直或支鐽Ci- u者,例如 ,甲醯基,乙醯基,丙醯基,丁醯基,異丁醯基,待戊 醯基,戊醯基,己醯基,庚醯基,辛醯基,壬醯基,癸 醯基和十一醯基; (6) C2_ 6脂族羧酸醯基且可被如上定義之芳基所取 代,且其各較佳具有總計8至12値磺原子;脂族醯基部 分之實例為包含於上述卩3,Rb所代表脂族醯基中之 C2- 6醯基者(較佳為乙醯基和丙醯基),且芳基部分 之實例為包含於上逑芳基所列舉者(較佳為苯基和萘基 ,待別為苯基);較佳之芳香-取代脂族醯基之特別例包 括苯乙醯基,3-苯丙醯基,4-苯丁醯基,5-苯戊醯基, 6 -苯己醯基,α-甲基苯乙醯基和or,cr-二甲基苯乙醯 基,其中以苯乙醯基為較佳; (7) 磺環芳香羧酸_基,其中芳基如上定義和列舉(較 佳為苯基和萘基,待別為苯基);較佳基為具有7至11 傾磺原子者,且其例包括苄醯基,1-萘醯基和2-#醯基 ,其中以苄醯基為較佳。 - 9- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) -裝· 訂 經濟部中央標準局員工消費合作社印製 503237 A7 B7 五、發明説明() R,取代基α或取代基所代表之此類胺基的待別例 包括下列: U)被取代胺基其中Ra和Rb之一為氫原子且其他之 Ra和Rb為烷基,如甲胺基,乙胺基,丙胺基,異丙胺 基,丁胺基,異丁胺基,第二丁胺基,第三丁胺基,戊 胺基,2-戊胺基,3-戊胺基,2-甲基丁胺基,3-甲基丁 胺基,1,1-二甲基丙胺基,1,2-二甲基丙胺基,2,2-二 甲基丙胺基,己胺基,2-己胺基,3-己胺基,2-甲基戊 胺基,3-甲基戊胺基,4-甲基戊胺基,1,1-二甲基丁胺 基,1,2-二甲基丁胺基,1,3-二甲基丁胺基,2,2-二甲 基丁胺基,2,3-二甲基丁胺基,3,3-二甲基丁胺基,1, 1,2-三甲基丙胺基,1,2,2-三甲基丙胺基,庚胺基,2-庚胺基,3 -庚胺基,4 -庚胺基,3, 3 -二甲基戊胺基,辛 胺基,1-甲基庚胺基,2 -乙基己胺基和1,1,3,3 -四甲基 丁胺基; (2) 被取代胺基,其中RaRb之一為氫原子且其他之 R a和R b為芳烷基,如苄胺基,2-苯乙胺基,1-苯乙胺 基,3-苯丙胺基,2-苯丙胺基,1-苯丙胺基,4-苯丁胺 基,1-苯丁胺基,5-苯戊胺基,1-萘甲胺基和2-萘甲胺 基; (3) 被取代胺基,其中之一為氫原子且其他 之Ra*Rb為芳基,如苯胺基,1-萊胺基和2-萘胺基; -10- 本紙張尺度適用中國國「家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) •裝- 、tr 503237 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明() (4) 被取代胺基,其中之一為氫原子且其他 之1^和1^為脂族醯基,如甲醯胺基,丙醯胺基,丁醯 胺基,異丁醯胺基,特戊醯胺基,戊醯胺基,己醯胺 基,庚醯胺基,辛醯胺基,壬醯胺基,癸醯胺基和十一 醯胺基; (5) 被取代胺基,其中之一為氫原子且其他 之1^和1^為芳香取代脂族醯基,如苯乙醯胺基,3-苯 丙醯胺基,4-苯丁 _胺基,5-苯戊醯胺基,6-苯己醯胺 基,α-甲基苯乙醯胺基和cr,cr-二甲基苯乙醯胺基; (6) 被取代胺基,其中Ra和Rb為氫原子且其他之Ra 和Rb為芳香醯基,如苄醯基,卜萘醯胺基和卜萘醯胺 基; (7) 被取代胺基,其中Ra和Rb均為烷基,其各可為 相同或不同,如二甲胺基,二乙胺基,N -甲基-N-乙胺 基和N -甲基戊胺基; (8) 被取代胺基,其中1^和1^之一為烷基且其他之 !^和1^為芳烷基,如N-乙基-N-苄胺基,N-第三丁基 -N-苄胺基和N-己基苄胺基; (9) 被取代胺基,其中Ra和Rb之一為烷基且其他之 1^和1^為芳基,如N-甲基-N-苯胺基,N-乙基-N-苯胺 基和N -辛基-N-苯胺基; (10) 被取代胺基,其中1^和1^之一為烷基且其他之 -11- 本紙張尺度適用中國國家標準(CNS ) 格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) •裝· 、1Τ .«線 經濟部中央標準局員工消費合作社印製 503237 A7 B7 五、發明説明()Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs where: X is indino, indolino, azinoline, azindolinyl, oxazopyridyl or oxazolopyrimidyl, which is unsubstituted Or substituted with at least one substituent is selected from the substituents α defined below; R, Υ, Υ 1 and ο are the same as before. -4- This paper size applies to the Chinese National Standard (CNS), Yasugi 1 cell (21〇 × 297 mm) 503237 A7 B7 V. Description of the invention () Each of the substituents "is (^-4 alkyl, C6-! 〇 Aryl, trifluoromethyl, Cl-4 alkylthio, Cl-4 alkoxy, benzyloxy, halogen atom, hydroxyl, acetamino, phenylthio, nitro, aralkyl, or formula- NRaRb, where 11 and 1 ^ are as defined above; the aryl part of the square group and the aralkyl group contained in the substituent or is a macrocyclic aromatic group having 6 to 10 ring sulfo atoms and is unsubstituted or substituted Substitution with at least one substituent is selected from the substituents defined below; each of the substituent points is Ci-4 alkyl, Ci-4 alkoxy, halogen atom, hydroxyl, nitro, phenyl, trifluoromethyl , Or formula-NRaRb, where 1 ^ and 111) are as defined above. Hairpin: > In the compound of the present invention, in the case where X is a group derived from an indine ring, it may be, for example, indino-1-yl, indino-2-yl, indino-3- The base is Indio-4-¾, B is referred to as a 5 ore base, and the heterogeneous reference medium is made up of 6 bases or B is referred to as a 7-base. With respect to X being a group derived from an indolinoline ring, it may be, for example, indinoline-1-yl, indinoline-2-yl, indolinolin-3-yl, indolin-4-yl, ind Idololin-5-yl, indolin-6-yl or indolin-7-yl. In terms of X being a group derived from an acridine ring, it may be, for example, 4-azindino-1 -yl, 4-azindole-2 -yl, 4-azindole-3 -yl, 4- Acridine-4--4-, 4-by-J, IT-dosyl-5-yl, 4-xia-yamidine, hexadecyl-6-yl, 4-ιιγ bsi ¢ ^ -7-yl, 5-acridin- 1-based, 5-acridin-2-yl, 5-acridin-3-yl, 5-? 11, 5 -yl, 5-y, 5 -yl, "5 Cranes", yB 6-yl, 5-azindino-7-yl, 6-azinine-phenyl, 6-azindin-2-yl, 6-azine β- 3-based, 6-acridinyl-4-based, 6-acridinyl-5-based, 6-acridin-5- This paper is sized for China National Standard (CNS) A4 (210 X 297) Li) Please read the note on the back first. Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. 503237 A7 B7. D-7-yl, 7-azindol-1-yl, 7-azindol IT-2-2-, 7-fluorene P3I-3-S, 7-1 yah -ΠΓ Β to give a 5-base, 7-11 γ (if -6-base. Derived from X In terms of the radical of the acridineline ring, it may be, for example, 4-azindino-1-yl, 4-azindolin-2-yl, 4-azindolin-3-yl, 4-azindin Indolin-5-yl, 4-azindolin-6-yl, 4-azindolin-7-yl, 5-azolinolin-yl, 5-azindolin-2-yl, 5-azinolinolin-3-yl, 5-azinolinolin-4-yl, 5-azindolin-6-yl, 5-azindolin-7-yl, 6-azindolinyl -1 -yl, 6-azindolin-2-yl, 6-azinyl-B-indol-6-yl, 6-azindolinyldi 4-yl, 6-azindolinyl-5 -yl , 6-azindinoline-7-yl, 7-azindolinyl-? Yl,? -Azindolin-2-yl, 7 · mr p, a 3 -yl, 7-rr p If it is a 4-base, 7-rr p, it is a 5-base or abuindolin-6. Based on X being a radical derived from an oxazolopyridine ring, it may be, for example, Azolo [4,5-b] pyridin-1-yl, oxazo [4,5-b] pyridin-2-yl, oxazo [4,5-b] pyridin-7-yl, oxazolo [4,5-b] pyridin-5-yl, insomnia and [4,5-b] phenotypic-6-yl, insomnia [4,5-c] pyridin-1-yl, oxazo [ 4,5-c] pyridin-2-yl, oxazo [4,5-c ] Pyridin-4-yl, oxazo [4,5-c] pyridin-6-yl, oxazo [4,5-c] pyridin-7-yl, imidazo [5,4-b] pyridine- 3-yl, oxazolo [5,4-b] Sftpyridin-2-yl, oxazolo [5,4-b] pyridin-7-yl, oxazolo [5,4-b] pyridine-5 -Yl, imidazo [5,4-b] pyridin-6-yl, oxazolo [5,4-c] pyridin-3-yl, oxazolo [5,4-c] pyridin-2-yl, Imidazo [5,4-c] pyridin-4-yl, pyrazolo [5,4-c] -6 ~ This paper size applies to China National Standard (CNS) A4 (210X297 mm) (Please read the back first Please pay attention to this page before filling in this page) • Packing _ 503237 A7 B7 V. Description of the invention () Please read the notes on the back of%. Pyridine-6-yl, pyrazolo [5,4-c] pyridine-7-yl, Oxazolo [1,2-a] pyridin-2-yl, oxazolo [i, 2-a] pyridin-3-yl, oxazolo [1,2-a] pyridin-8-yl, oxazolyl And [1,2-a] pyridin-5-yl, oxazo [1,2-a] pyridin-6-yl or oxazo [1,2-a] pyridin-7-yl. With respect to X being a group derived from an imidazopyrimidine ring, it may be, for example, oxazo [4,5-b] pyrimidin-7-yl, oxazo [4,5-b] pyrimidin-8-yl, or Oxazo [4,5-b] pyrimidin-9-yl. Any group represented by the above X may be unsubstituted or may be substituted with at least one of the substituents α as defined above and listed below. In terms of substitution, there is no particular limitation on the number of substituents, except for the number of substitutable positions, or occasionally limited by steric hindrance. However, 1 to 3 値 substituents are generally preferred, and 1 or 2 値 substituents are most preferred. There is no particular restriction on the position of any such substituent. RC, based on the chain group methyl group C, the group «member generation 4β, take 4 groups ^ _ Shen 2 μ, C, ¾ ¾, 罾 from Γ m for g group Θ package T group Jtll ^ ^ 0 two, or fl The base α, * or Jiayizhi is printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. The base is oxo, its ethoxy, methoxymethoxy alkane, and the base is substituted. Alkyl 4 generation-Take 1 CR bond to the branch or radical and dioxobutyryl isopropyl group, and the alkyl radical is Ding Jia, which is more than the radicals, isopropyl, oxetane tripropadiene Basic substitution or a basic substitution is based on original iodine 0 or fluoro, which is the scent R > original bromochlorine is noodles, and original 0 is bromine. The scale is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 503237 A7 B7 V. Description of the invention () In terms of R being an aralkyl group, the alkyl portion of this group has 1 to 5 sulfonium atoms and can be The straight or branched fluorenyl group substituted by an aryl group may itself be one as defined above and listed below. The aralkyl group preferably has 7 to 11 sulfonium atoms in total. Examples of such alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, second butyl, third butyl, pentyl, isopentyl, neopentyl And tertiary amyl, preferably methyl and ethyl. Examples of aryl are those enumerated below with regard to the substituent σ. Specific examples of such aralkyl groups include benzyl, 2-phenethyl (diphenethyl), 1-phenethyl, 3-phenylpropyl, 2-phenylpropyl, 1-phenylpropyl, 4- Phenylbutyl, 1-phenylbutyl, 5-phenylpentyl, 1- # methyl and 2-naphthylmethyl, with phenethyl and benzyl being preferred, and benzyl being most preferred. In addition, R, substituent α or substituent > 3 may be an amine group or a substituted amine group of the formula-NRaRb, which may be the same or different and selected from the following: (Please read the precautions on the back before filling this page) (1) Hydrogen atom; (2) C 1-8 alkyl group which can be a straight or branched chain group such as methyl 9 ethyl $ propyl f isopropyl butyl 9 Isobutyl 9 second butyl 9 third butyl $ pentyl $ 2-pentyl > 3-pentyl f 2-methylbutyl J 3-methylbutyl 1, 1-dimethylpropyl f 1, 2 · dimethylpropyl 9 2, 1-dimethylpropylhexyl 9 2-hexyl t 3-hexyl f methylpentyl 9 3-methylpentyl $ 4-methylpentyl 9 1 , 1-dimethylbutyl t 1, 2-dimethylbutyl t 1, 3-dimethylbutyl 9 2, 2-. Dimethylbutyl f 2, 3-dimethylbutyl% 3,3-'dimethylbutyl f 1,1,2-.rr methylpropyl $ 1,2,2 -'- methylpropyl * heptyl $ 2-heptyl $ 3-.heptyl 9 4-.heptyl $ 3,3-. Methylpentyl »Octyl 9 -8 ~ This paper size is applicable to Chinese National Standard (CNS) A4 (210X297 mm) Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 503237 A7 _B7__ V. Description of the invention () 1-A Heptyl, 2-ethylhexyl and 1,1,3,3-tetramethylbutyl, of which Ci-6 alkyl is preferably straight or branched, and C1 is most preferably straight or branched -4 alkyl groups; methyl and ethyl are preferred; (3) aralkyl groups as defined above and listed below with respect to R, and such groups preferably have 7 to 11 sulfonium atoms; (4) C6-10 aryl groups, such as phenyl, p-naphthyl, and 2-naphthyl; (5) aliphatic carboxylic acid fluorenyl groups, which may be straight or branched Ci-u, for example, methylamino, ethylamino, propylamino , Butyl fluorenyl, isobutyl fluorenyl, pentyl fluorenyl, pentyl fluorenyl, hexyl fluorenyl, heptyl, octyl fluorenyl, nonyl fluorenyl, decyl fluorenyl and undecyl fluorenyl; (6) C2-6 aliphatic carboxylic acid fluorenyl And may be substituted by an aryl group as defined above, each of which preferably has a total of 8 to 12 sulfonium atoms; an example of an aliphatic fluorenyl moiety is C2- contained in the aliphatic fluorenyl group represented by the above fluorene 3, Rb 6 醯Groups (preferably ethenyl and propionyl), and examples of the aryl moiety are those included in the above-mentioned aryl groups (preferably phenyl and naphthyl, to be phenyl); more preferred Specific examples of the aromatic-substituted aliphatic fluorenyl group include phenethylfluorenyl, 3-phenylpropylfluorenyl, 4-phenylbutylfluorenyl, 5-phenylpentylfluorenyl, 6-phenylhexylfluorenyl, α-methylphenethylfluorenyl And or, cr-dimethylphenethylfluorenyl, of which phenethylfluorenyl is preferred; (7) sulfo ring aromatic carboxylic acid group, in which aryl is as defined and listed above (preferably phenyl and naphthyl , To be other than phenyl); the preferred group is one having 7 to 11 desulfuric atoms, and examples thereof include benzylfluorenyl, 1-naphthylfluorenyl, and 2- # fluorenyl, with benzylfluorenyl being preferred. -9- This paper size is in accordance with Chinese National Standard (CNS) A4 (210X297 mm) (Please read the precautions on the back before filling out this page)-Binding and printing printed by the Central Consumers Bureau of the Ministry of Economic Affairs Consumer Cooperative 503237 A7 B7 V. Description of the invention () R, Substitute α or other examples of such amine groups represented by the substituents include the following: U) Substituted amine groups in which one of Ra and Rb is a hydrogen atom and the other Ra and Rb are Alkyl groups such as methylamino, ethylamino, propylamino, isopropylamine, butylamine, isobutylamine, second butylamino, third butylamino, pentylamino, 2-pentylamino, 3-pentylamino, 2-methylbutylamino, 3-methylbutylamino, 1,1-dimethylpropylamine, 1,2-dimethylpropylamine, 2,2-dimethylpropylamine Methyl, hexylamino, 2-hexylamino, 3-hexylamino, 2-methylpentylamino, 3-methylpentylamino, 4-methylpentylamino, 1,1-dimethylbutyl Amine, 1,2-dimethylbutylamino, 1,3-dimethylbutylamino, 2,2-dimethylbutylamino, 2,3-dimethylbutylamino, 3,3 -Dimethylbutylamino, 1,1,2-trimethylpropylamino, 1,2,2-trimethylpropylamino, heptylamine, 2-heptyl Base, 3-heptylamino, 4-heptylamino, 3,3-dimethylpentylamino, octylamino, 1-methylheptylamino, 2-ethylhexylamino and 1,1,3 , 3-tetramethylbutylamino; (2) a substituted amine group, wherein one of RaRb is a hydrogen atom and the other Ra and Rb are aralkyl groups, such as benzylamino, 2-phenylethylamino, 1-Phenethylamino, 3-Phenylamino, 2-Phenylamino, 1-Phenylamino, 4-Phenylamino, 1-Phenylamino, 5-Phenylamino, 1-Naphthylamino and 2-naphthylmethylamino; (3) substituted amines, one of which is a hydrogen atom and the other Ra * Rb is an aryl group, such as aniline, 1-lylamido and 2-naphthylamine; -10- This paper size applies to China's "National Standards (CNS) A4 specifications (210X297 mm) (Please read the precautions on the back before filling out this page)."-Tr 503237 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 5. Description of the invention () (4) A substituted amine group, one of which is a hydrogen atom and the other 1 ^ and 1 ^ are aliphatic fluorenyl groups, such as methylamino, propylamino, butylamino, Isobutyrimidine, pentamidine, pentamidine, hexamidine, heptylamine, Fluorenylamino, nonamylamino, decylamino and undecylamino; (5) substituted amines, one of which is a hydrogen atom and the other 1 ^ and 1 ^ are aromatic substituted aliphatic fluorenyl groups, Such as acetophenamino, 3-phenylpropanamido, 4-phenbutaminino, 5-phenpentamidine, 6-phenylhexamide, α-methylphenethylamino and cr , cr-dimethylphenethylamino group; (6) substituted amine group, in which Ra and Rb are hydrogen atoms and other Ra and Rb are aromatic fluorenyl groups, such as benzyl fluorenyl, naphthylamino Naphthylamine; (7) substituted amines, where Ra and Rb are both alkyl groups, each of which may be the same or different, such as dimethylamino, diethylamino, N-methyl-N-ethylamine And N-methylpentylamino; (8) substituted amino groups, in which one of 1 ^ and 1 ^ is an alkyl group and the other! And 1 ^ are aralkyl groups, such as N-ethyl-N- Benzylamino, N-tert-butyl-N-benzylamino and N-hexylbenzylamino; (9) substituted amino, wherein one of Ra and Rb is alkyl and the other 1 and 1 are Aryl, such as N-methyl-N-aniline, N-ethyl-N-aniline and N-octyl-N-aniline; (10) substituted amine groups, one of 1 ^ and 1 ^ Is alkyl and others -11- This paper size applies to the Chinese National Standard (CNS) grid (210X297 mm) (please read the precautions on the back before filling out this page) • Install · 1T. «Printed by the Central Consumers Bureau of the Ministry of Economy System 503237 A7 B7 V. Description of the invention ()

RalRb為脂族醯基,如N-丙基乙醯胺基,N-戊基 -卜丙酸胺基,和卜乙基-卜己醛胺基, (11) 被取代胺基,其中之一為烷基且其他之 Ra和!^為芳香-取代羧酸脂族醯基,如N -乙基-N-苯乙 醯胺基,卜異丙基-卜(2-苯丙醯基)胺基和N-甲基- N-( 6-苯己醯基)胺基; (12) 被取代胺基,其中Ra*Rb之一為烷基且其他之 1^和1^為芳香醯基,如N -甲基苄醯胺基,卜第二 丁基苄醯胺基和N-庚基苄醯胺基; (13) 被取代胺基,其中1^和^均為芳烷基,其各可 為相同或不同,如二苄胺基,N-苄基- N-(3-苯丙基)胺 基和N -苄基- N- (2 -萘甲基)胺基; (14) 披取代胺基,其中Ra和Rb之一為芳烷基且其他 之1^和1^為芳基,如N -苄基苯胺基和N-(3 -苯丙基) -N-苯胺基; (15) 被取代胺基,其中之一為芳烷基且其他 之Ra和Rb為脂族_基,如N -苄基-N-乙醯胺基,N -苄 基-卜丙醯胺基和N-苄基戊醯胺基; (16) 被取代胺基,其中1^和1^之一為芳院基且其他 之1^和1^為芳香-取代脂族羧酸醯基,如N-苄基-N-苯 乙醯胺基和N -苄基- N- (4 -苯丁醯胺基)胺基; (17) 被取代胺基,其中之一為芳烷基且其他 -12- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝·RalRb is an aliphatic fluorenyl group, such as N-propylacetamido, N-pentyl-butyric acid amine, and ethyl-butanal amine, (11) substituted amines, one of which is an alkane Ki and other Ra sum! ^ Aromatic-substituted carboxylic acid aliphatic fluorenyl groups, such as N-ethyl-N-phenylethylfluorenylamino, isopropyl-phenyl (2-phenylpropanyl) amino, and N-methyl-N- (6-phenylhexyl) amino; (12) substituted amine, wherein one of Ra * Rb is alkyl and the other 1 ^ and 1 ^ are aromatic fluorenyl groups, such as N-methylbenzylfluorenylamino (B) a second butyl benzamidine group and an N-heptyl benzamidine group; (13) a substituted amine group, wherein 1 ^ and ^ are both aralkyl groups, each of which may be the same or different, such as dibenzyl Amine group, N-benzyl-N- (3-phenylpropyl) amino group and N-benzyl-N- (2-naphthylmethyl) amine group; (14) Substituted amino groups, of which Ra and Rb One is aralkyl and the other 1 ^ and 1 ^ are aryl groups, such as N-benzylaniline and N- (3-phenylpropyl) -N-aniline; (15) substituted amino groups, of which One is an aralkyl group and the other Ra and Rb are aliphatic groups, such as N-benzyl-N-acetamidino, N-benzyl-propanamidino and N-benzylpentaminino; (16 ) Substituted amine groups, where one of 1 ^ and 1 ^ is aromatic and the other 1 ^ and 1 ^ are aromatic-substituted aliphatic carboxylic acid fluorenyl groups, such as N-benzyl-N-phenylethylfluorenylamino And N-benzyl-N- (4-phenylbutamidino) amine (17) Substituted amine group, one of which is aralkyl group and others -12- This paper size applies to Chinese National Standard (CNS) A4 specification (210X297 mm) (Please read the precautions on the back before filling in this Page)

、1T 503237, 1T 503237

A B7 明説 明發五 和 基 胺 醯 苄 隹 N - 基 苄 - N 如 基 ; 醛基 香胺 芳醯 為苄 - b N R I α ) f基 a R 乙 之苯 基 芳 為 1 之 b R 和 a R 中 其 基 胺 代 取 被 可 各 其 基 胺 苯二 如 同 不 或 同 相 為 基 和 基 胺 苯 基 萘 基 胺 苯 基 醯 ,酸 基羧 胺族 代脂 取為 被 b R 19和 中 其 之 他 其 且 基 芳 為 1 之 b R 和 如 和 基 胺0 丙 - N - 基 苯 代 ,取 基T 胺香 代芳 取為 被 b \7 R 20和 基 苯 I N 和 基 胺0 基 Rbil 和酸 T a羧 基Ξ二 苯$脂f I 其 基 胺 醯 乙_ ·, T基 基胺 苯II N 己 基 醯 之 基 胺 基 芳 為 如 基 苯 之乙 他苯 其N-且- (請先閱讀背面之注意事項再填寫本頁) 中基 其 _ ,酸 基羧 胺香 代芳 取為 被 b \1/ R 21和 和 如 之基 b 苯 之 他 其 且 基 芳 為 和 基 胺 醯 苄 基基 醯胺 # 代 2 取 T被 N \—/ * 2 基(2 苯 基 胺 基0 酸 羧 族 脂 為 均 b R 和 a R 中 其 基 胺 ,Ν醯 N J 如- Ν > 觸 同基 不醯 或丁 同Η-相和 為基 可胺 各醯 其丙 基 胺0 乙二 基 醯 乙 經濟部中央標準局員工消費合作社印製 其芳 ,為 基 b ί. 胺 代 被之f 3)他-N (2其基 且醯 基 b R 胺 和醯 a 乙 基 胺 代 7取 基披 醯4) 胺0 乙 苯 中香 N-基 基 醯 酸 羧 族 脂 為 1 之 b R 和 和 乙 - 基 N胺 如)r ,基 基醯 醯 丁 酸苯 錢4- 族T 旨-Ν Bn I 代基 取醯 -乙 基 醯 酸 羧 族 脂 為 1 之 b R 和 a R 中 其 苄 讀 N I 基0 乙 篇 N 如基 基’ Ϊ _ 基 酸醛 羧萘 香-芳 為T b 基 ORB ί 丁 a - R N 之和 他基 其胺 且醯·A B7 indicates that penta-Hexylamine, benzyl, N-benzyl-N, and the like; aldolamine is benzyl- b NRI α) f group a R ethyl phenyl aromatic is 1 b R and a The base amine in R is replaced by the base amine, which is not the same or in the same phase, and the base is phenylphenylnaphthylamine phenyl hydrazone, and the acid carboxamide family is replaced by b R 19 and Other radicals are b R with 1 and radicals such as and amines 0 prop-N-yl phenyl, and radicals T amine aromatics are taken as b \ 7 R 20 and radicals IN and radicals 0 radicals Rbil and acids T a carboxyl, diphenyl, lipid, f I its amine 醯 ethyl _, T yl amine benzene II N hexyl fluorinated amine aryl is acetophenone and its N- and-(Please read the back first For the matters needing attention, please fill in this page again.) In the base group, _, the acid carboxyamine aromatized aromatic group is taken as b \ 1 / R 21 and Hezhi group b benzene other and the base aromatic group is benzyl group 醯 benzyl group 醯The amine # is replaced by 2 and is substituted by N \ — / * 2 groups (2 phenylamino 0 acid carboxylic aliphatic amines are the basic amines in both b R and a R, Ν 醯 NJ such as-Ν > Contact with the same base or butyl with the same phase-phase and ketoamine each with its propylamine 0 ethylenediyl ethene printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs, printed as aromatic radicals. f 3) he-N (2 its base and fluorenyl b R amine and fluorene a ethyl amine 7 substituted hydrazone 4) amine 0 ethylbenzene middle N-yl phosphono carboxylic acid aliphatic ester 1 b R And and ethyl-amino N amines such as) r, phenyl-butyric acid, benzene, 4-group T, and -N Bn I-substituted groups are taken from b- and a- Benzene reads NI group 0 and B N such as the group 'Ϊ _ carboxylic acid aldehyde carnaphthyl-aryl is a T b group ORB ί butyl a-RN and talyl amine and 醯 ·

2 /V 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 503237 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明() (2 5 )被取代胺基,其中R a和R b均為芳香-取代脂族 羧酸醯基,其各可為相同或不同,如N,N -二苯乙醯胺基 ,N-苯乙_基1-(2-苯丙醯基)胺基和N-苯乙醯基- N-(4-苯丁醯基)胺基; (26) 被取代胺基,其中均為芳香-取代脂族 羧酸醯基且其他之Ra和1^為卜苯乙醯基- N-苄醯胺基 和N -苯乙醯基- N- (2 -萘醯基)胺基; (27) 被取代胺基,其中Ra和1^均為芳香羧酸_基, 其各可為相同或不同,如Ν,Ν -二苄乙醯胺基和卜苄醯基 -Ν - ( 2 -萘醯基)胺基。 於取代基α為烷硫基方面,其可為直或支鐽之Cl - 4 烷硫基,例如,甲硫基,乙硫基,丙硫基,異丙硫基, 丁硫基,異丁硫基,第二丁硫基和第三丁硫基。 於取代基α為C6- 10芳基方面,此基可為未取代或 被取代以至少一値取代基選自取代基办。未取代芳基例 包括,例如,苯基,1-莆基和2-萘基。 於取代基>5為Cl - 4烷基,Ci - 4烷氧基,鹵原子 ,羥基,硝基,苯基或三氟甲基或式- NRaRb2胺基方 面,此烷基,烷氣基或胺基和鹵原子可如上關於取代基 α &定義和列舉者。 (請先閱讀背面之注意事項再填寫本頁) -裝· 訂 «線 -14- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐了 經濟部中央標準局員工消費合作社印裝 503237 A7 B7 五、發明説明(A ) 於被取代芳基之情形中,對於所出現之取代基α的數 目並無特別限制,僅有的限制為受限於可取代位置之數 目和立體障礙。通常,以1至5個取代基為較佳,以1 至3個為更佳而以1或2個為最佳。 此類被取代芳基之實例包括下列: 1) 芳基被取代以至少一値^ - 4烷基,如4 -甲基苯基, 4-乙基苯基,4-丙基苯基,4-異丙基苯基,4-丁基苯基 ,4-異丁基苯基,4-第二丁基苯基,4-第三丁基苯基, 4 -甲基-1-蔡基,5 -乙基-1-蔡基,8 -丙基-1-蔡基,4- 馨 異丙基-1-萘基,5-丁基-1-#基,4-異丁基-1-#基, 4-第二丁基-1-萘基,4-第三丁基-1-萘基,4-甲基- 2-蔡基,5 -乙基-2-蔡基,8 -丙基- 2- #基,4 -異丙基-2 -萘基,5-丁基-2-萘基,8-異丁基-2-萘基,4-第二丁基 -2-萘基或5-第三丁基-2-萘基。 2) 芳基被取代以至少一値Ci- 4烷氧基,如4 -甲氧苯 基,4-乙氣苯基,4-丙氣苯基,4-異丙氧苯基,4-丁氣 苯基,4-異丁氧苯基,4-第二丁氧苯基,4-第三丁氧苯 基,4 -甲氧基-1-蔡基,5 -乙氧基-1-蔡基,8 -丙氧基-1-蔡基,4-異丙氧基-1-萘基,5-丁氣基-1-萘基,4-異丁 氣基-1-萘基,4-第二丁氣基-1-萘基,4-第三丁氧基-1-萘基,4-甲氧基-2-萘基,5-乙氣基-2-萘基,8-丙氧基 -2-萘基,4-異丙氧基-2-萘基,5-丁氣基-2-萘基,8- 異丁氧基-2-萘基,4-第二丁氧基- 2-#基或5-第三丁氧 基-2-萘基; -15- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ---------«裝-- (請先閲讀背面之注意事項再填寫本頁) 訂 it 503237 A7 B7 五、發明説明(,〇 3) 芳基披取代以鹵原子,如4-溴苯基,4-氯苯基,4-氟 苯基,4-碘苯基,3-氯苯基,3-氟苯基,3-溴苯基,3-碘苯基,4-溴-1-萘基,4-氯-1-萘基,4-氟-1-#基, 4:碘-1-萘基,5-氯-1-萘基,5-氟-卜萦基,5-溴-1-萘 基,8 -氛-1-黎基,4 -氟-2-蔡基,4 -溴-2-蔡基,4 -氯 -2 -蔡基,4 -碘-2-黎基,5 -漠-2-蔡基,5 -氛-2-蔡基, 5-氟-2-黎基和5-碘-2-蔡基; 4) 芳基被取代以羥基,如2-羥苯基,3-羥苯基,4-羥苯 基,4 -羥基-1-蔡基,5 -經基-1-#基,8 -羥基-1-蔡基 ,4-羥基-2-萘基,5-羥基-2-萘基或8-羥基-2-#基; 5) 芳基被取代以硝基,如2-硝苯基,3-硝苯基,4-硝苯 基,4-硝基-1-#基,5-硝基基,8-硝基-1-萘基, 4 -硝基-2-蔡基,5 -硝基-2-蔡基或8 -硝基-2-黎基; 6) 芳基被取代以苯基,如3-苯基苯基,4-苯基苯基,4-苯基-1-萘基,5-苯基-1-#基,8-苯基-1-萘基,4-苯 基-2-萘基,5-苯基-2-萘基或8-苯基-2-萘基; 經濟邹中夬樣隼¾貝X.消費合阼狂印S. (請先閱讀背面之注意事項再填寫本頁) 7) 芳基被取代以三氟甲基,如3-三氟甲基苯基,4-三氟 甲基苯基,4-三氟甲基-1-萘基,5-三氟甲基-1-萘基, 8-三氟甲基-1-萘基,4-三氟甲基-2-萘基,5-三氟甲基 -2-萘基或8-三氟甲基-2-萘基, 8) 芳基被取代以至少一個未取代或被取代胺基,如被未 取代胺基所取代者,例如,2-胺苯基,3-胺苯基,4-胺 苯基,4 -胺基-1-#基和8 -胺基- 2- #基和被取代以被取 代之胺基,例如: -16- 本紙張尺度適用中國國家標準(CNS } Μ規格(2丨〇X29*7公釐) 經濟部中央標準局貝工消費合作杜印製 503237 A7 B7 五、發明説明( i) 芳基被取代以被取代之胺基,其中Ra和Rb之一為 氫原子且其他之1^和1^為烷基,如3 -甲胺苯基,4-乙胺苯基,3-丙胺苯基,3-異丙胺苯基,4-丁胺苯基 或3-異丁胺苯基; ii) 芳基被取代以被取代之胺基,其中之一 為氫原子且其他之為芳烷基,如4-苄胺苯基 ,4-(2-苯乙胺基)苯基,4-(1-苯乙胺基)苯基,4-(4-苯丁胺基)苯基或4-(1-桊甲胺基)苯基; iii) 芳基被取代以被取代之胺基,其中113和1^之一 為氫原子且其他之Ea*Rb為芳基,如4-苯胺基苯基 ,4-(1-萘胺基)苯基; iv) 芳基被取代以被取代之胺基,其中Ra和Rb之一 為氫原子且其他之為脂族醯基,如4 -甲醯胺 苯基,4-乙醯胺苯基,4-丁醯胺苯基,4-特戊醯胺苯 基,4-己醯胺苯基,4-辛醯胺苯基或4-十一 _胺苯基; V)芳基被取代以被取代之胺基,其中之一為 氫原子且其他之Ra和Rb為芳香-取代脂族醯基,如 4-苯乙醯胺苯基,4-(4-苯丁醯胺基)苯基,4-(6-苯 己醯胺基)苯基,4-U-甲基苯乙醯胺基)苯基或4-U ,cr -二甲基苯乙醯胺基)苯基; vi) 芳基被取代以被取代之胺基,其中Ra和Rb之一 為氫原子且其他之為芳香醯基,如4 -苄醯胺 苯基,4-(1-萘醯胺基)苯基或4-(2-萘酸胺基)苯基; vii) 芳基被取代以被取代之胺基,其中!^和^均為 -17 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29*7公釐) 裝 訂 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印袈 503237 A7 B7 五、發明説明( 烷基,其各可為相同或不同,如4-二甲胺苯基,4-二 乙胺苯基或4-(N -甲基乙胺基)苯基; viii) 芳基被取代以被取代之胺基,其中!^3和116之 一為烷基,且其他之R a和R b為芳烷基,如4 - ( N-乙 基-卜苄胺基)苯基,4-(N-第三丁基-N-苄胺基)苯基或 4- (N-己基苄胺基)苯基; ix) 芳基被取代以被取代之胺基,其中83和8 &之一 為烷基且其他2Ra*Rb為芳基,如4-U-甲基-N-苯 胺基)苯基或4-(N-辛基-N-苯胺基)苯基; X)芳基被取代以被取代之胺基,其中之一為 烷基且其他之113和^為脂族醯基,如4-(卜丙基-N-乙醒胺基)苯基或4-(N-乙基-N-己_胺基)苯基; xi) 芳基被取代以被取代之胺基,其中Ra和βb之一為 烷基且其他之為芳香-取代脂族醯基,如4-(N -乙基苯乙醒胺基)苯基或4-〔N -甲基- N- (6 -苯 己醯基)胺基〕苯基; xii) 芳基被取代以被取代之胺基,其中Ra和1^之一 為烷基且其他之1^和1^為芳香醯基,如4-(N -甲基-N-苄醯胺基)苯基或4-(N-庚基-N-苄醯胺基)苯基; xiii) 芳基被取代以被取代之胺基,其中1?3和1?13均 為芳烷基,其各可為相同或不同,如4-二苄胺苯基或 4-〔4_苄基- N_(2-萘甲基)胺基〕苯基; xiv) 芳基被取代以被取代之胺基,其中Ra和Rb之一 為芳烷基且其他之1^和1^為芳基,如4-(N -苄基- N- -18- 本紙張尺度適用中國國家標準(CNS ) A4*i格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)2 / V This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 503237 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 5. Invention Description () (2 5) The substituted amine group, Wherein R a and R b are both aromatic-substituted aliphatic carboxylic acid fluorenyl groups, each of which may be the same or different, such as N, N -diphenylethylfluorenylamino, N-phenethyl-yl 1- (2-benzene (Propanyl) amino and N-phenethylfluorenyl-N- (4-phenylbutylfluorenyl) amino; (26) substituted amino groups, all of which are aromatic-substituted aliphatic carboxylic acid fluorenyl groups and other Ra and 1 ^ is phenylethylfluorenyl-N-benzylfluorenylamino and N-phenylethylfluorenyl-N- (2-naphthylfluorenyl) amino; (27) substituted amino groups, wherein Ra and 1 ^ are both Aromatic carboxylic acid groups, each of which may be the same or different, such as N, N-dibenzylacetamido and benzobenzyl-N- (2-naphthyl) amino. As far as the substituent α is an alkylthio group, it may be a straight or branched Cl-4 alkylthio group, for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutyl Thio, second butylthio and third butylthio. As far as the substituent α is a C6- 10 aryl group, this group may be unsubstituted or substituted with at least one substituent selected from the substituent group. Examples of the unsubstituted aryl group include, for example, phenyl, 1-fluorenyl and 2-naphthyl. This alkyl, alkanoyl group is such that the substituent > 5 is Cl-4 alkyl, Ci-4 alkoxy, halogen atom, hydroxyl, nitro, phenyl or trifluoromethyl or amino group of formula-NRaRb2 Or the amine group and the halogen atom may be as defined and enumerated above with respect to the substituent α &. (Please read the precautions on the back before filling this page)-Binding and binding «Line-14- This paper size applies to China National Standard (CNS) Α4 specifications (210X297 mm printed by the Consumer Standards Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 503237 A7 B7 V. Description of the invention (A) In the case of substituted aryl groups, there is no particular limitation on the number of substituents α appearing, the only limitations are limited by the number of substitutable positions and steric obstacles. Usually 1 to 5 substituents are preferred, 1 to 3 are more preferred and 1 or 2 is most preferred. Examples of such substituted aryl groups include the following: 1) aryl groups are substituted with at least one値 ^ -4 alkyl, such as 4-methylphenyl, 4-ethylphenyl, 4-propylphenyl, 4-isopropylphenyl, 4-butylphenyl, 4-isobutylbenzene , 4-second butylphenyl, 4-third butylphenyl, 4-methyl-1-zeyl, 5-ethyl-1-zeyl, 8-propyl-1-zeyl, 4-Isopropyl-1-naphthyl, 5-butyl-1- # yl, 4-isobutyl-1- # yl, 4-second butyl-1-naphthyl, 4-tert-butyl 1-naphthyl, 4-methyl-2-zeyl, 5-ethyl-2-zeyl, 8-propyl-2- 2-yl, 4-isopropyl -2 -naphthyl, 5-butyl-2-naphthyl, 8-isobutyl-2-naphthyl, 4-second butyl-2-naphthyl or 5-third butyl-2-naphthyl . 2) The aryl group is substituted with at least one Ci-4 alkoxy group, such as 4-methoxyphenyl, 4-ethoxyphenyl, 4-propanyl, 4-isopropoxyphenyl, 4-but P-phenylene, 4-isobutoxyphenyl, 4-second butoxyphenyl, 4-third butoxyphenyl, 4-methoxy-1-zetyl, 5-ethoxy-1-tsai , 8-propoxy-1-zeinyl, 4-isopropoxy-1-naphthyl, 5-butanyl-1-naphthyl, 4-isobutanyl-1-naphthyl, 4- Second butanyl-1-naphthyl, 4-third butoxy-1-naphthyl, 4-methoxy-2-naphthyl, 5-ethoxy-2-naphthyl, 8-propoxy 2-naphthyl, 4-isopropoxy-2-naphthyl, 5-butanyl-2-naphthyl, 8-isobutoxy-2-naphthyl, 4-second butoxy- 2- # based or 5-tert-butoxy-2-naphthyl; -15- This paper size applies to China National Standard (CNS) A4 (210X297 mm) --------- «Packing- -(Please read the notes on the back before filling out this page) Order it 503237 A7 B7 V. Description of the invention (, 〇3) The aryl group is replaced with a halogen atom, such as 4-bromophenyl, 4-chlorophenyl, 4 -Fluorophenyl, 4-iodophenyl, 3-chlorophenyl, 3-fluorophenyl, 3-bromophenyl, 3-iodophenyl, 4-bromo-1-naphthyl, 4-chloro-1- Naphthyl 4-fluoro-1- # yl, 4: iodo-1-naphthyl, 5-chloro-1-naphthyl, 5-fluoro-pyridinyl, 5-bromo-1-naphthyl, 8-l-1-enyl , 4-fluoro-2-zeeki, 4-bromo-2-zeeki, 4-chloro-2-zeeki, 4-iodine-2-leki, 5-mo-2-zeeki, 5- 2-Czechyl, 5-fluoro-2-Ryzyl and 5-iodo-2-Czechyl; 4) Aryl is substituted with hydroxyl, such as 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl , 4-hydroxy-1-zekiyl, 5-meryl-1- # yl, 8-hydroxy-1-zekiyl, 4-hydroxy-2-naphthyl, 5-hydroxy-2-naphthyl or 8-hydroxy -2- # group; 5) aryl group is substituted with nitro group, such as 2-nitrophenyl group, 3-nitrophenyl group, 4-nitrophenyl group, 4-nitro-1- # group, 5-nitro group , 8-nitro-1-naphthyl, 4-nitro-2-zeyl, 5-nitro-2-zeyl or 8-nitro-2-ryl; 6) aryl is substituted with phenyl , Such as 3-phenylphenyl, 4-phenylphenyl, 4-phenyl-1-naphthyl, 5-phenyl-1- # yl, 8-phenyl-1-naphthyl, 4-phenyl -2-naphthyl, 5-phenyl-2-naphthyl or 8-phenyl-2-naphthyl; economic Zou Zhong 夬 夬 隼 ¾ 隼 X. Consumption combined with crazy printing S. (Please read the precautions on the back before (Fill in this page) 7) aryl is substituted with trifluoromethyl, such as 3-trifluoromethylphenyl, 4-trifluoro Phenyl, 4-trifluoromethyl-1-naphthyl, 5-trifluoromethyl-1-naphthyl, 8-trifluoromethyl-1-naphthyl, 4-trifluoromethyl-2-naphthyl Group, 5-trifluoromethyl-2-naphthyl or 8-trifluoromethyl-2-naphthyl, 8) aryl is substituted with at least one unsubstituted or substituted amine group, as by unsubstituted amine group Substituents, for example, 2-aminophenyl, 3-aminephenyl, 4-aminophenyl, 4-amino-1- # and 8-amino-2- # and substituted amines Basis, for example: -16- This paper size applies to Chinese National Standards (CNS} M specifications (2 丨 〇X29 * 7mm) Printed by the Department of Shellfish Consumer Cooperation of the Central Standards Bureau of the Ministry of Economic Affairs 503237 A7 B7 V. Description of the invention (i ) An aryl group is substituted with a substituted amine group in which one of Ra and Rb is a hydrogen atom and the other 1 ^ and 1 ^ are alkyl groups, such as 3-methylaminephenyl, 4-ethylaminephenyl, 3- Propylamine phenyl, 3-isopropylamine phenyl, 4-butylamine phenyl or 3-isobutylamine phenyl; ii) aryl is substituted with substituted amine, one of which is a hydrogen atom and the other is aromatic Alkyl, such as 4-benzylaminophenyl, 4- (2-phenylethylamino) phenyl, 4- (1-phenylethylamino) phenyl, 4- (4-phenylbutylamino) phenyl 4- (1-fluorenylmethylamino) phenyl; iii) aryl group is substituted to be substituted amine group, in which one of 113 and 1 ^ is a hydrogen atom and the other Ea * Rb is an aryl group, such as 4-aniline Phenyl, 4- (1-naphthylamino) phenyl; iv) aryl is substituted with a substituted amine, wherein one of Ra and Rb is a hydrogen atom and the other is an aliphatic fluorenyl, such as 4- Formamidine phenyl, 4-acetamidine phenyl, 4-butamidine phenyl, 4-pentamidine phenyl, 4-hexamide phenyl, 4-octylamine phenyl or 4-decamethyl -Aminephenyl; V) an aryl group is substituted with a substituted amine group, one of which is a hydrogen atom and the other Ra and Rb are aromatic-substituted aliphatic fluorenyl groups, such as 4-phenylethylaminophenyl, 4- (4-phenylbutylamidinoamino) phenyl, 4- (6-phenylhexylamido) phenyl, 4-U-methylphenethylamido) phenyl or 4-U, cr -di Methylphenethylamido) phenyl; vi) an aryl group substituted with a substituted amine, wherein one of Ra and Rb is a hydrogen atom and the other is an aromatic fluorenyl, such as 4-benzylamidophenyl, 4- (1-naphthylamino) phenyl or 4- (2-naphthylamino) phenyl; vii) aryl groups are substituted with substituted amine groups, where! Both ^ and ^ are -17-This paper size applies to Chinese National Standard (CNS) A4 (210X29 * 7mm) binding (please read the precautions on the back before filling this page) Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs袈 503237 A7 B7 V. Description of the invention (alkyl groups, each of which may be the same or different, such as 4-dimethylaminephenyl, 4-diethylaminephenyl or 4- (N-methylethylamino) phenyl Viii) aryl is substituted with substituted amine, where! One of 3 and 116 is an alkyl group, and the other R a and R b are aralkyl groups, such as 4- (N-ethyl-benzylamino) phenyl, 4- (N-third-butyl- N-benzylamino) phenyl or 4- (N-hexylbenzylamino) phenyl; ix) an aryl group substituted with a substituted amine group, one of 83 and 8 & is an alkyl group and the other 2Ra * Rb is an aryl group, such as 4-U-methyl-N-aniline) phenyl or 4- (N-octyl-N-aniline) phenyl; X) an aryl group is substituted to be substituted, One of them is an alkyl group and the other 113 and ^ are aliphatic fluorenyl groups, such as 4- (propyl-N-ethoxyamino) phenyl or 4- (N-ethyl-N-hexan-amino) benzene Xi) an aryl group is substituted with a substituted amine group, wherein one of Ra and βb is an alkyl group and the other is an aromatic-substituted aliphatic fluorenyl group, such as 4- (N-ethylphenylethylamino) Phenyl or 4- [N-methyl-N- (6-phenylhexyl) amino] phenyl; xii) an aryl group substituted with a substituted amine group, wherein one of Ra and R is alkyl And other 1 ^ and 1 ^ are aromatic fluorenyl groups, such as 4- (N-methyl-N-benzylamido) phenyl or 4- (N-heptyl-N-benzylamido) phenyl; xiii) aryl is substituted with substituted amine, where 1? 3 And 1-13 are both aralkyl groups, each of which may be the same or different, such as 4-dibenzylaminophenyl or 4- [4-benzyl-N_ (2-naphthylmethyl) amino] phenyl; xiv ) An aryl group is substituted with a substituted amine group, wherein one of Ra and Rb is an aralkyl group and the other 1 ^ and 1 ^ are aryl groups, such as 4- (N-benzyl-N--18- The scale is applicable to Chinese National Standard (CNS) A4 * i (210X297 mm) (Please read the precautions on the back before filling this page)

經濟部中央標準局貝工消費合作社印装 503237 A7 B7 五、發明説明(4 ) 苯胺基)苯基或4-〔N-(3-苯丙基苯胺基)苯基; xv) 芳基被取代以被取代之胺基,其中1^和1^.之一為 芳烷基且其他之1^3和!11>為脂族醯基,如4-(N-苄基-N-乙醯胺基)苯基或4-(N-苄基- N-戊醯胺基)苯基; xvi) 芳基被取代以被取代之胺基,其中Ra和Rb之一 為芳烷基且其他之Ra和1^15為芳香-取代脂族醯基, 如4-(N-苄基苯乙_胺基)苯基或4-〔N-苄基- N-( 4-苯丁醯基)胺基〕苯基; xvii) 芳基被取代以被取代之胺基,其中之 一為芳烷基且其他之113和{^為芳香醯基,如4-(N-苄基-N-苄醯胺基)苯基或4-〔N-(2-苯乙基)-N-苄醯 胺基〕苯基; xviii) 芳基被取代以被取代之胺基,其中均 為芳基,其各可為相同或不同,如4-二苯胺苯基或4- 〔N- (2-萘基)-N-苯胺基〕苯基; xix) 芳基被取代以被取代之胺基,其中之一 為芳基且其他之反3和^為脂族醯基,如4-(卜丙基 乙醯胺基)苯基或4-(N-苯基-N-己醯胺基)苯基; XX)芳基被取代以被取代之胺基,其中R a和R b之一 為芳基且其他之卩3和卩5為芳香-取代脂族醯基,如 4-(N-苯基-N-苯乙胺基)苯基或4-〔N-苯基- N-(4-苯 丁醯基)胺基〕苯基; xxi)芳基被取代以被取代之胺基,其中1^和^之一 為芳基且其他之1^和1^為芳香_基,如4-(N-苯基- -19- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) i装. 訂 503237Printed by the Central Bureau of Standards, Ministry of Economic Affairs, Shellfish Consumer Cooperative, 503237 A7 B7 V. Description of the invention (4) Anilino) phenyl or 4- [N- (3-phenylpropylaniline) phenyl; xv) aryl is substituted With substituted amine groups, one of 1 ^ and 1 ^. Is an aralkyl group and the other 1 ^ 3 and 1! 11 > is an aliphatic fluorenyl group, such as 4- (N-benzyl-N-acetamido) phenyl or 4- (N-benzyl-N-pentamidoamino) phenyl; xvi) aryl is Substituted with a substituted amine group in which one of Ra and Rb is an aralkyl group and the other Ra and 1 ^ 15 are aromatic-substituted aliphatic fluorenyl groups, such as 4- (N-benzylphenethyl-amino) benzene Or 4- [N-benzyl-N- (4-phenylbutylfluorenyl) amino] phenyl; xvii) aryl is substituted with substituted amine, one of which is aralkyl and the other 113 and { ^ Is an aromatic fluorenyl group, such as 4- (N-benzyl-N-benzylfluorenylamino) phenyl or 4- [N- (2-phenethyl) -N-benzylfluorenylamino] phenyl; xviii) Aryl groups are substituted with substituted amine groups, all of which are aryl groups, each of which may be the same or different, such as 4-diphenylaminephenyl or 4- [N- (2-naphthyl) -N-aniline] Phenyl; xix) an aryl group substituted with a substituted amine group, one of which is an aryl group and the other 3 and ^ are aliphatic fluorenyl groups, such as 4- (butylpropylacetamido) phenyl or 4- (N-phenyl-N-hexylamino) phenyl; XX) aryl is substituted with substituted amine, wherein one of Ra and Rb is aryl and the other 卩 3 and 卩 5 are aromatic -Substituted aliphatic hydrazone , Such as 4- (N-phenyl-N-phenylethylamino) phenyl or 4- [N-phenyl-N- (4-phenylbutylfluorenyl) amino] phenyl; xxi) aryl is substituted to be Substituted amine groups, in which one of 1 ^ and ^ is aryl and the other 1 ^ and 1 ^ are aromatic groups, such as 4- (N-phenyl- -19-) This paper applies Chinese National Standard (CNS) A4 size (210X297mm) (Please read the precautions on the back before filling this page) i Pack. Order 503237

A B7 明説 明發五 中 其 基 胺 之 代 取 披 ; 以 基代 苯取 丨被, %» 醯)5族 苄11脂 一 X ^ N X 為 如 同 不 或 同 相 為 可 各 其 b 胺 和乙 a 二 均 苯 基 基之 胺代日 0 ^ aR. 己被之 N-以他0 ^ Μ ri^» -T基 ϋ (Ν芳族 4 .1 脂 或11為 基XX一 和 之^ 0 一族 和脂 a 代 R 取 中T 其香 ,芳 基為 基 胺 醯 乙 苯A B7 indicates that the substitution of the base amines in the fifth is based on the substitution of the base benzene;% »醯) Group 5 benzyl 11 lipids-X ^ NX as if they are not or in the same phase, they can each have b amine and ethyl a Diamino group of di-phenylphenyl group 0 ^ aR. Has been N- to other 0 ^ Μ ^ ^--T group Ν (N aromatic 4. 1 lipid or 11 as the group XX 1 and the ^ 0 family and Lipid a substitutes R for T and its aryl group is arylamine ethylbenzene

基 胺 之 代 取 被 基):以 醛基代 乙胺取 N-醯被 -(乙基 Π4苯ί方 如 Γ } Ν V f 鑛 «1 基基XX 基 苯 或 基 苯 中 其 和 _ 之 --------·裝— (請先閲讀背面之注意事項再填寫本頁) 0 族Τ 脂基 為11 一 乙 其 且 基 基-醯基 香醛 芳 丁 為N- b C R I Π 4 ί或 a β 基 之苯 他 } 基 胺 醯 苄 如 醯萘Substitute base for amine): Take N-fluorene- (ethyl Π4benzene) such as Γ} Ν V f for aldehyde ethylamine and its _ -------- · Packing— (Please read the notes on the back before filling in this page) 0 Group T lipid group is 11 ethyl and its base-fluorenyl aldehyde butyl is N-b CRI Π 4 ί or a β-based benzyl} ylamine

胺 ) V 基 X 基 芳 為 均 b R 和 a R 中 其 基 胺 之 代 取 被 以 •,代 基 取 苯被 丨基 基0 族 脂 代 取 - 香 芳Amine) V-based X-based aryl is homogeneous b R and a R in which the amine is replaced by •, the substituted group is benzene and the group 0 aliphatic is substituted-fragrant aromatic

苯 \n/ 基 胺 醯 乙 苯 二 - N 同| 不基 或醯 同乙 相苯 為N-可C 各4 其或 ,基 苯 之 b R 和 a R 中 其 基 胺 之 代 取 被 ; 以 基代 苯取 3被 基基 胺芳 \—/ \—/ 基VI ϋχχ 醯 香 芳 為 b R 和 a R 之 他 其 且 基0 族 脂 代 取 - 香 芳 為1 訂 經濟部中央樣率局員工消費合作杜印«. 基 如 或 基 苯 \/ 基 胺0 苄 - ϋρ - 基 醯 乙 苯Benzene \ n / base amine ethylbenzene di-N with | unradical or fluorene with ethyl phase benzene is N-but C 4 or OR, the base amine in b R and a R is substituted by quilt; Basic benzene is taken by 3 amine amines. — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —— — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — Cooperation Du Yin «. Such as or phenyl benzene / amine 0 Benzyl-ϋρ-Benzene ethylbenzene

被 基以 11代 萘取 2-被 T基 N t - 芳 基U _vi 乙XX 基 胺 基 苯 苯 均 b R 和 a R 中 其 基 胺 之 代 取 代 取 未 同)|為 不基可 或醯其 同萘 , 相2-面 為-(方 可-N基 各基烷 其醯芳 ,苄為 基Ν-α 醯 t 基 香4-代 芳或取 為基於 本紙張尺度適用中國國家標舉(CNS ) A4洗格(2丨0X297公釐) 如 基 胺 基 苯 或 苯 以 胺 代 醯 取 ί卞io被 503237 A7 B7 五、發明説明(·2 ) 一値或以上如上定義和列舉之取代基α。此基(包括其 任何取代基)較佳内含7至11値磺原子。芳烷基之烷基 部分為Ci- 5烷基^此類芳烷基之例包括苄基,2-苯 乙基,1-苯乙基,3-苯丙基,2-苯丙基,1-苯丙基,4-苯丁基,1-苯丁基,5-苯戊基,卜萘甲基和2-萘甲基。 於被取代芳烷基之倩形中,對於所出現之取代基々的 數目並無特別限制,僅有的限制為受限於可取代位置之 數目和立體障礙。通常,以1至5痼取代基為較佳,以 1至3値為更佳而以1或2傾為最佳。 此類被取代芳烷基之實例包括下列: 1)芳烷基被取代以至少一値Ci- 4烷基,如4 -甲苄基, 4 - 乙 苄 基 > 4-丙苄基, 4 -異丙苄基, 4 _ 丁 苄 基 $ 4-異丁 苄 基 $ 4 - 第 二丁苄基, 4 -第三丁苄基 4 - 甲 基 -1 -萘甲 基 9 5- 乙 基 _ 1 -萘 甲基 $ 8-丙基-1-萘 甲 基 t 4 - 異 丙基-1 萘 甲 基 t 5- 丁基- 1 -蔡 甲 基,4-異丁基- 1 - 萘 甲 基 ,4-第 二 丁 基 -1 -蔡甲基 ,4- 第 三丁基-1-萘 甲 基 f 4- 甲 基+ 萘 甲 基 5- 乙基- 2 -黎 甲 基,8-丙基- 2- 萘 甲 基 $ 4-異丙 基 -2 -萘甲基,5- 丁基 -2 -萘甲基,8- 異 丁 基 -2 -萘甲基, 4- 第 二 丁 基 •2_萘 甲基 或 5-第三丁基- 2- 莆 甲 基 經濟部中央標準局員工消費合作社印装 (請先閲讀背面之注意事項再填寫本頁) 2)芳烷基被取代以至少一個Ci- 4烷氧基,如4 -甲氧 苄基,4-乙氧苄基,4-丙氧苄基,4-異丙氣苄基,4-丁 氣苄基,4-異丁氧苄基,4-第二丁氧苄基,4-第三丁氧 苄基,4-甲氧基-1-萘甲基,5-乙氧基-1-萘甲基,8-丙 氣基-1-萘甲基,4-異丙氣基-1-萘甲基,5-丁氣基-1-萘 -21- 本紙張尺度適用中國國家標準(CNS)A4規格(210X297公釐) 503237 A7 B7 五、發明説明(d ) 甲基,4-異丁氧基-1-萘甲基,4-第二丁氧基-1-萘甲基, 4-第三丁氧基-1-萘甲基,4-甲氣基-2-#甲基,5-乙氧基 -2-萘甲基,8-丙氧基-2-#甲基,4-異丙氧基-2-萘甲基 ,5-丁氣基-2-萘甲基,8-異丁氧基-2-萘甲基,4-第二 丁氧基-2-萘甲基或5-第三丁氣基-2-萦甲基; 3) 芳烷基被取代以鹵原子,如4 -溴苄基,4 -氯苄基,4-氟苄基,4-碘苄基,3-氯苄基,3-氟苄基,3-溴苄基, 3-碘苄基,4 -溴-1-萘甲基,4 -氯-1-藥甲基,4 -氟-1-萘 甲基,4-碘-1-萘甲基,5-氯-1-萘甲基,5-氟-1-桊甲 基,5-溴-卜萘甲基,8-氯-1-萘甲基,4-氟-2-萘甲基, 4 -溴-2-萘甲基,4 -氯-2-萘甲基,4 -碘- 2- #甲基,5-溴-2-萘甲基,5 -氯-2-萘甲基,5 -氟-2-萘甲基和5 -碘 -2-萊甲基; 4) 芳烷基被取代以羥基,如2-羥苄基,3-羥苄基,4-羥 苄基,4-羥基-1-萘甲基,5-羥基-1-萘甲基,8-羥基-1-萘甲基,4-羥基-2-萘甲基,5-羥基- 2-#甲基或8-羥基-2-萘甲基; 經濟部中央標準局員工消費合作社印裝 (請先閱讀背面之注意事項再填寫本頁) 5) 芳烷基被取代以硝基,如2-硝苄基,3-硝苄基,4-硝 苄基,4-硝基-1-萘甲基,5-硝基-1-萘甲基,8-硝基-1-萘甲基,4-硝基-2-萘甲基,5-硝基-2-萘甲基或8-硝基 -2 -蔡甲基; 6) 芳烷基被取代以苯基,如3-苯基苄基,4-苯基苄基, 4 -苯基-1-蔡甲基,5 -苯基-1-蔡甲基,8 -苯基-1-蔡甲 基,4-苯基-2-萘甲基,5-苯基-2-萘甲基或8-苯基- 2- -22- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標隼局員工消費合作社印裝 503237 A7 B7 五、發明説明(/ ) 萘甲基; 7) 芳烷基被取代以三氟甲基,如3-三氟甲基苄基,4-三 氟甲基苄基,4-三氟甲基-1-萘甲基,5-三氟甲基-1-萘 甲基,8-三氟甲基-1-萘甲基,4-三氟甲基- 2-#甲基, 5 -三氟甲基-2-萘甲基或8 -三氟甲基-2-蔡甲基, 8) 芳烷基被取代以至少一個未取代或被取代胺基,如被 取代以未取代之胺基,例如2-胺苄基,3-胺苄基,4-胺 苄基,4-胺基-1-萘甲基和8-胺基-2-萘甲基及被取代以 被取代之胺基,例如: i) 芳烷基被取代以被取代之胺基,其中Ra.Rb之一 為氫原子且其他之βa和Rb為烷基,如3-甲胺苄基, 4-乙胺苄基,3-丙胺苄基,3-異丙胺苄基,4-丁胺苄 基或3-異丁胺苄基; ii) 芳烷基被取代以被取代之胺基,其中^3和8^之一 為氫原子且其他之113和1^13為芳烷基,如4 -苄胺苄基 ,4-(2-苯乙胺基)苄基,4-(1-苯乙胺基)苄基,4-(4-苯丁胺基)苄基或4-(1-萘甲胺基)苄基; iii) 芳烷基被取代以被取代之胺基,其中之 一為氫原子且其他之為芳基,如4-苯胺基苄 基,4- (1-桊胺基)苄基; iv) 芳烷基被取代以被取代之胺基,其中之一 為氫原子且其他之為脂族醯基,如4 -甲醯胺 苄基,4-乙醯胺苄基,4-丁醯胺苄基,4-特戊醒胺苄 基,4 -己醯胺苄基,4 -辛醯胺苄基或4 -十一 g胺苯基; -23- 本紙張尺度適用中國國家標準(CNS) A4*i格(210X297公釐) ---------»裝-- (請先閱讀背面之注意事項再填寫本頁) 、ar -1% 經濟部中央標準局員工消費合作社印裝 503237 A7 _._ B7__ 五、發明説明(W ) v) 芳烷基被取代以被取代之胺基,其中Ra和Rb之一 為氫原子且其他之113和1113為芳香-取代脂族醯基,如 4-苯乙醯胺苄基,4-(4-苯丁醯胺基)苄基,4-(6-苯 .己醯胺基)苄基,4-U-甲基苯乙醯胺基)苄基或4-U ,σ-二甲基苯乙醯胺基)苄基; vi) 芳烷基被取代以被取代之胺基,其中之一 為氫原子且其他之為芳香醛基,如4-苄醯胺 苄基,4-(1-萘醯胺基)苄基或4-(2-萘醯胺基)苄基; vii) 芳烷基被取代以被取代之胺基,其中均 為烷基,其各可為相同或不同,如4-二甲胺苄基,4-二乙胺苄基或4-(N -甲基-N-乙胺基)苄基; viii) 芳烷基被取代以被取代之胺基,其中 之一為烷基且其他之1^和^為芳烷基,如4-(N-乙 基苄胺基)苄基,4-(N-第三丁基-N-苄胺基)苄基 或4-(N-己基-N-苄胺基)苄基; ix) 芳烷基被取代以被取代之胺基,其中之一 為烷基且其他之113和!^為芳基,如4-(N-甲基-N-苯 胺基)苄基或4-(N-辛基-N-苯胺基)苄基; X)芳烷基被取代以被取代之胺基,其中Ra和Rb之一 為烷基且其他之&3和1^13為脂族醯基,如4-(卜丙基-N-乙醯胺基)苄基或4-(N-乙基-N-己醯胺基)苄基; ’ xi)芳烷基被取代以被取代之胺基,其中Ra和 一為烷基且其他之Ra和!^13為芳香-取代脂族醯基, 如4-(N-乙基-N-苯乙醯胺基)苄基或4-〔N-甲基-卜(6 - 24- 本紙張尺度適用中國國家標率(CNS ) A4現格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 装- 訂 503237 經濟部中央標準局員工消费合作社印装 A7 B7五、發明説明(^ ) -苯己醯基)胺基〕苄基; xii) 芳烷基被取代以被取代之胺基,其中Ra和Rb之 一為烷基且其他之為芳香醯基,如4-(N -甲 基- N-苄醯胺基)苄基或4-(N-庚基-N-苄醯胺基)苄基; xiii) 芳烷基被取代以被取代之胺基,其中& 為芳烷基,其各可為相同或不同,如4 -二苄胺苯基或 4-〔4-苄基- N-(2-^甲基)胺基〕苄基; xiv) 芳烷基被取代以被取代之胺基,其中之 一為芳烷基且其他之1^和1^為芳基,如4-(N-苄基-N-苯胺基)苄基或4-〔N-(3-苯丙基)-卜苯胺基)苄基; xv) 芳烷基被取代以被取代之胺基,其中之 一為芳烷基且其他之1^和1^為脂族醯基,如4-(N-苄基-N-乙醯胺基)苄基或4-(N-苄基-卜戊醯胺基)苄 基; XV i)芳烷基被取代以被取代之胺基,其中和Rb之 一為芳烷基且其他之Ra和8^^為芳香-取代脂族醯基, 如4-(N-苄基-N-苯乙醯胺基)苄基或4-〔H-苄基- N-( 4-苯丁醯基)胺基〕苄基; xvii)芳烷基被取代以被取代之胺基,其中Ra和Rb之 一為芳烷基且其他之1^和1^為芳香醯基,如4-(N-苄基-N-苄醯胺基)苄基或4-〔N-(2-苯乙基)-N -苄醯 胺基〕苄基; X v i i i )芳烷基被取代以被取代之胺基,其中R a和R b 均為芳基,其各可為相同或不同,如4 -二苯胺苄基或 -25- (請先閱讀背面之注意事項再填寫本頁) •!.裝·The substituent is substituted by 11-generation naphthalene and 2-substituted by T group N t -aryl U _vi ethyl XX aminoamino phenylbenzene are substituted by the same amine in b R and a R) Its iso-naphthalene, phase 2-face is-(Fang Ke -N-based each alkane and its aromatic, benzyl is based on N-α 醯 t-based aromatic 4-generation aromatic or is based on the paper standard applicable Chinese national standard ( CNS) A4 (2 丨 0X297 mm) such as aminoaminobenzene or benzene substituted with amine 被 卞 io 503237 A7 B7 V. Description of the invention (· 2) One or more substituents as defined and listed above α. This group (including any substituents) preferably contains 7 to 11 sulfonium atoms. The alkyl portion of the aralkyl group is Ci-5 alkyl ^ Examples of such aralkyl groups include benzyl, 2-benzene Ethyl, 1-phenethyl, 3-phenylpropyl, 2-phenylpropyl, 1-phenylpropyl, 4-phenylbutyl, 1-phenylbutyl, 5-phenylpentyl, p-naphthylmethyl and 2-naphthylmethyl. In the form of substituted aralkyl groups, there is no particular limitation on the number of substituents 々 present, and the only limitations are limited by the number of substitutable positions and steric obstacles. Generally, 1 to 5 痼 substituents as a comparison 1 to 3 is more preferred and 1 or 2 is most preferred. Examples of such substituted aralkyls include the following: 1) Aralkyls are substituted with at least one Ci-4 alkyl, such as 4 -Methylbenzyl, 4-ethylbenzyl > 4-propylbenzyl, 4-isopropylbenzyl, 4-butylbenzyl 4-isobutylbenzyl $ 4-second butylbenzyl, 4-tertiary butylbenzyl 4-methyl 1-naphthylmethyl 9 5-ethyl-1 -naphthylmethyl 8-propyl-1-naphthylmethyl t 4 -isopropyl-1 naphthylmethyl t 5-butyl-1 -zeethymethyl, 4- Isobutyl-1-naphthylmethyl, 4-second butyl-1-zeolyl, 4-tert-butyl-1-naphthylmethyl f 4-methyl + naphthylmethyl 5-ethyl-2 -trimethyl , 8-propyl-2-naphthylmethyl 4-isopropyl-2 -naphthylmethyl, 5-butyl-2 -naphthylmethyl, 8-isobutyl-2 -naphthylmethyl, 4-th Dibutyl • 2-naphthylmethyl or 5-tert-butyl-2- 2-methylmethyl printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling this page) 2) aralkyl Is substituted with at least one Ci-4 alkoxy group, such as 4-methoxybenzyl, 4-ethoxybenzyl, 4-propoxybenzyl, 4-isopropylbenzyl, 4-butylbenzyl, 4-isobutoxybenzyl, 4-second butoxybenzyl, 4-third butoxybenzyl, 4-methoxy-1-naphthalene Methyl, 5-ethoxy-1-naphthylmethyl, 8-propanyl-1-naphthylmethyl, 4-isopropanyl-1-naphthylmethyl, 5-butanyl-1-naphthyl- 21- This paper size is in accordance with Chinese National Standard (CNS) A4 (210X297 mm) 503237 A7 B7 V. Description of the invention (d) Methyl, 4-isobutoxy-1-naphthylmethyl, 4-second butyl Oxy-1-naphthylmethyl, 4-tert-butoxy-1-naphthylmethyl, 4-methylamino-2- # methyl, 5-ethoxy-2-naphthylmethyl, 8-propyl Oxy-2- # methyl, 4-isopropoxy-2-naphthylmethyl, 5-butanyl-2-naphthylmethyl, 8-isobutoxy-2-naphthylmethyl, 4-th Dibutoxy-2-naphthylmethyl or 5-third butanyl-2-fluorenylmethyl; 3) aralkyl is substituted with a halogen atom, such as 4-bromobenzyl, 4-chlorobenzyl, 4 -Fluorobenzyl, 4-iodobenzyl, 3-chlorobenzyl, 3-fluorobenzyl, 3-bromobenzyl, 3-iodobenzyl, 4-bromo-1-naphthylmethyl, 4-chloro-1 -Drug methyl, 4-fluoro-1-naphthylmethyl, 4-iodo-1-naphthylmethyl, 5-chloro-1-naphthylmethyl, 5-fluoro-1-naphthylmethyl, 5-bromo-bu Naphthylmethyl, 8-chloro-1-naphthylmethyl, 4-fluoro 2-naphthylmethyl, 4-bromo-2-naphthylmethyl, 4-chloro-2-naphthylmethyl, 4-iodo-2--2-methyl, 5-bromo-2-naphthylmethyl, 5-chloro 2-naphthylmethyl, 5-fluoro-2-naphthylmethyl and 5-iodo-2-lylmethyl; 4) aralkyl is substituted with a hydroxyl group, such as 2-hydroxybenzyl, 3-hydroxybenzyl, 4-hydroxybenzyl, 4-hydroxy-1-naphthylmethyl, 5-hydroxy-1-naphthylmethyl, 8-hydroxy-1-naphthylmethyl, 4-hydroxy-2-naphthylmethyl, 5-hydroxy- 2- # methyl or 8-hydroxy-2-naphthylmethyl; printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions on the back before filling this page) 5) aralkyl is substituted with nitro, Such as 2-nitrobenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 4-nitro-1-naphthylmethyl, 5-nitro-1-naphthylmethyl, 8-nitro-1-naphthylmethyl Methyl, 4-nitro-2-naphthylmethyl, 5-nitro-2-naphthylmethyl or 8-nitro-2-naphthylmethyl; 6) aralkyl is substituted with phenyl, such as 3-phenylbenzyl Methyl, 4-phenylbenzyl, 4-phenyl-1-zemyl, 5-phenyl-1-zemyl, 8-phenyl-1-zemyl, 4-phenyl-2-naphthylmethyl, 5-benzene 2-naphthylmethyl or 8-phenyl- 2--22- This paper size applies to the Chinese National Standard (CNS) A4 (210X297 mm) Printed by the Labor Standards Cooperative of the State Standards Bureau 503237 A7 B7 V. Description of the invention (/) Naphthylmethyl; 7) Aralkyl is substituted with trifluoromethyl, such as 3-trifluoromethylbenzyl, 4-trifluoro Methylbenzyl, 4-trifluoromethyl-1-naphthylmethyl, 5-trifluoromethyl-1-naphthylmethyl, 8-trifluoromethyl-1-naphthylmethyl, 4-trifluoromethyl -2- # methyl, 5-trifluoromethyl-2-naphthylmethyl or 8-trifluoromethyl-2-zeemethyl, 8) aralkyl is substituted with at least one unsubstituted or substituted amine group, such as Substituted with unsubstituted amine groups such as 2-aminobenzyl, 3-aminobenzyl, 4-aminobenzyl, 4-amino-1-naphthylmethyl and 8-amino-2-naphthylmethyl and Substituted with substituted amine groups, for example: i) Aralkyl is substituted with substituted amine groups, where one of Ra.Rb is a hydrogen atom and the other βa and Rb are alkyl groups, such as 3-methylamine benzyl Group, 4-ethylamine benzyl, 3-propylamine benzyl, 3-isopropylamine benzyl, 4-butylamine benzyl or 3-isobutylamine benzyl; ii) arylalkyl substituted with substituted amine group Where one of ^ 3 and 8 ^ is a hydrogen atom and the other 113 and 1 ^ 13 are aralkyl groups, such as 4-benzylamine benzyl, 4- (2-phenylethylamino) benzyl, 4- (1 -Phenethylamine ) Benzyl, 4- (4-phenylbutylamino) benzyl or 4- (1-naphthylmethylamino) benzyl; iii) aralkyl is substituted with a substituted amine, one of which is a hydrogen atom And the others are aryl groups, such as 4-anilinobenzyl, 4- (1-fluorenylamino) benzyl; iv) the aralkyl group is substituted with a substituted amine group, one of which is a hydrogen atom and the other It is an aliphatic fluorenyl group, such as 4-formamidine benzyl, 4-acetamidine benzyl, 4-butamidine benzyl, 4-tetramethylammonium benzyl, 4-hexamidine benzyl, 4- Octylamine benzyl or 4-undecylamine phenyl; -23- This paper size applies to China National Standard (CNS) A4 * i (210X297 mm) --------- »pack- (Please read the notes on the back before filling out this page) ar -1% Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 503237 A7 _._ B7__ V. Description of the Invention (W) v) The aralkyl group is replaced by Substituted amine groups in which one of Ra and Rb is a hydrogen atom and the other 113 and 1113 are aromatic-substituted aliphatic fluorenyl groups, such as 4-phenylethylamidinobenzyl, 4- (4-phenbutylamidino) Benzyl, 4- (6-phenyl.hexylamino) benzyl, 4-U-methylphenethylamido) benzyl or 4-U, σ- Methylphenethylamido) benzyl; vi) aralkyl is substituted with substituted amine, one of which is a hydrogen atom and the other is an aromatic aldehyde, such as 4-benzylamine benzyl, 4- (1-naphthylamino) benzyl or 4- (2-naphthylamino) benzyl; vii) aralkyl groups substituted with substituted amino groups, all of which are alkyl groups, each of which may be the same or Different, such as 4-dimethylaminobenzyl, 4-diethylaminobenzyl or 4- (N-methyl-N-ethylamino) benzyl; viii) aralkyl is substituted with a substituted amine, One of them is an alkyl group and the other 1 and ^ are aralkyl groups, such as 4- (N-ethylbenzylamino) benzyl, 4- (N-third-butyl-N-benzylamino) benzyl Or 4- (N-hexyl-N-benzylamino) benzyl; ix) aralkyl is substituted with a substituted amine, one of which is alkyl and the other is 113 and! ^ Is an aryl group, such as 4- (N-methyl-N-aniline) benzyl or 4- (N-octyl-N-aniline) benzyl; X) aralkyl is substituted to be substituted amine One of Ra and Rb is an alkyl group and the others & 3 and 1 ^ 13 are aliphatic fluorenyl groups, such as 4- (propyl-N-acetamido) benzyl or 4- (N-ethyl -N-hexylamino) benzyl; 'xi) aralkyl is substituted with substituted amine, where Ra and one are alkyl and the other Ra and! ^ 13 is aromatic-substituted aliphatic fluorenyl group, such as 4- (N-ethyl-N-phenethylamido) benzyl or 4- [N-methyl-bu (6-24- This paper is applicable to China National Standard Rate (CNS) A4 (210X297 mm) (Please read the notes on the back before filling out this page) Pack-Order 503237 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 5. Invention Description (^) -Phenylhexyl) amino] benzyl; xii) aralkyl is substituted with substituted amine, wherein one of Ra and Rb is alkyl and the other is aromatic fluorenyl, such as 4- (N -formyl -N-benzylamino) benzyl or 4- (N-heptyl-N-benzylamino) benzyl; xiii) aralkyl is substituted with substituted amine, where & is aralkyl Groups, each of which may be the same or different, such as 4-dibenzylaminophenyl or 4- [4-benzyl-N- (2- ^ methyl) amino] benzyl; xiv) aralkyl is substituted with A substituted amine group, one of which is an aralkyl group and the other 1 ^ and 1 ^ are aryl groups, such as 4- (N-benzyl-N-aniline) benzyl or 4- [N- (3- Phenylpropyl) -phenylanilide) benzyl; xv) aralkyl substituted with substituted amine, one of which is aralkyl and Others 1 ^ and 1 ^ are aliphatic fluorenyl groups, such as 4- (N-benzyl-N-acetamido) benzyl or 4- (N-benzyl-pivalamido) benzyl; XV i) The aralkyl group is substituted with a substituted amine group, wherein one of Rb is an aralkyl group and the other Ra and 8 ^^ are aromatic-substituted aliphatic fluorenyl groups, such as 4- (N-benzyl-N -Phenethylamido) benzyl or 4- [H-benzyl-N- (4-phenylbutamidino) amino] benzyl; xvii) aralkyl is substituted with substituted amine, where Ra and Rb One is aralkyl and the other 1 ^ and 1 ^ are aromatic fluorenyl groups, such as 4- (N-benzyl-N-benzylamido) benzyl or 4- [N- (2-phenethyl) -N-benzylamino] benzyl; X viii) aralkyl is substituted to be substituted amine, wherein Ra and Rb are both aryl, each of which may be the same or different, such as 4-diphenylamine Benzyl or -25- (Please read the notes on the back before filling out this page) • !.

、1T 4 本紙張尺度適用中國國家標準(CNS )八4^格(210X29*7公釐) 503237 A7 B7 五、發明説明(W ) 4-〔 N-(2-萘基)-N-苯胺基〕苄基; xix)芳烷基被取代以被取代之胺基,其中Ra和Iίb之 一為芳基且其他之1^和1^為脂族醯基,如4-(N-丙基 - N-乙醯胺基)苄基或4-(N-苯基己醯胺基)苄基; XX)芳烷基被取代以被取代之胺基,其中之一 為芳基且其他之反3和1113為芳香-取代脂族醒基,如 4-(N-苯基-N-苯乙胺基)苄基或4-〔N-苯基- N-(4-苯 丁醯基)胺基〕苄基; xxi) 芳烷基被取代以被取代之胺基,其中 一為芳基且其他之1^和!^為芳香醯基,如4-(N-苯 基-N-苄醯胺基)苄基; xxii) 芳烷基被取代以被取代之胺基,其中^3和段6均 為脂族醯基,其各可為相同或不同,如4 -二乙醯胺苄 基或4-(N -丁醯基-N-己醯胺基)苄基; xxiii) 芳烷基被取代以被取代之胺基,其中 之一為脂族醯基且其他之Ra和I^b為芳香-取代脂族醒 基,如4-(N-乙醯基-N-苯乙醯胺基)苄基或4-(N-丁醯 基-N-苯乙醯胺基)苄基; 經濟部中央標準局員工消費合作社印装 (請先閲讀背面之注意事項再填寫本頁) xxiv) 芳烷基被取代以被取代之胺基,其中和Rb之 一為脂族醯基且其他2Ra和^為芳香醯基,如4-(N-乙醯基-N-苄胺基)苄基或4-〔Μ-丁醯基- N-(2-萘醯 基)胺基〕苄基; xxv) 芳烷基被取代以被取代之胺基,其中Ra和Rb均 為芳香-取代脂族醯基,其各可為相同或不同,如4-( -26- 本紙張尺度適用中國國家標隼(CNS ) A4規格(2丨OX297公釐) 經濟部中央標準局員工消費合作社印装 503237 A7 B7_ 五、發明説明(4 ) Ν,Ν-二苯乙醯胺基)苄基或4-〔N-苯乙醯基- N-(4-苯丁 醯基)胺基〕苄基; xxvi) 芳烷基被取代以被取代之胺基,其中R a和R b之 ,一為芳香-取代脂族基且其他之Ra和1^ &為芳香醯 基,如4-(N-苯乙醯基苄醯胺基)苄基或4-〔N-苯 乙醯基- 萘醯基)胺基〕苄基; xxvii) 芳烷基被取代以被取代之胺基,其中Ra和Rb 均為芳香醯基,其各可為相同或不同,如4 -二苄醇胺 苄基或4-〔N-苄醯基-N-(2-萘醯基)胺基〕苄基。 衍生自吲跺,吲哚啉,吖吲呤,吖吲哚啉,眯唑並吡 啶和眯唑並嘧啶環,其各可被取代以較佳1至3値取代 基α (其以X代表)之特別例包括例如: 吲哚環群,如 3 -三苯甲基吲ί朵-1 -基,1 -甲基吲Β朵-3 -基,1 -甲基吲 Ιί朵-2-基,1-乙基吲Ϊ朵-2-基,5 -甲氧基-1,2 -二甲基 課引¢$-3 -基,5 -翔基-1-甲基-基,1-異丙基B3I 呤-3-基,2 -乙基-1-甲基吲S朵-3-基,5 -甲氧基-1-甲 基吲If朵-3 -基,5 -羥基-1 , 2 -二甲基吲Ϊ朵-3 -基,5 - 丁 氧基-1 -甲基吲哚-3 -基,1 , 4 , 7 -三甲基吲Ϊ朵-3 -基, 1 , 3 -二甲基吲IT朵-3 -基,5 -溴-6 -氯-1 -甲基吲B朵-3 -基 ,5 -溴吲哚-3 -基,5 -羥基-1 -異丁基吲呤-3 -基,5 -氟-1 -甲基吲ί朵-2 -基,5 -羥基-1 -甲基吲ϊ朵-2 -基,4 -甲氣基-卜甲基吲Ιί朵-2 -基,5 -溴-1 -甲基吲Ϊ朵-2 -基, 1 -乙基-5 -硝吲呤-2 -基,1 , 5 -二甲基吲ϋ朵-2 -基,5 - -27- 本紙張尺度適用中國國家標準(CNS ) Α4規格(2丨ΟΧ29?公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 Λ 經濟部中央標準局員工消費合作杜印裝 503237 A7 _B7_ 五、發明説明(J ) 胺基-1-甲基吲呤-2-基,5 -乙醯胺基-1-甲基吲ί朵- 2-基,5-苄醯胺基-1-乙基吲哚-2-基,1-甲基-5-甲胺 基吲ί朵-2-基,5 -丁胺基-1-甲基吲Ϊ朵-2-基,5-(Ν -苄 .醯基-Ν-甲胺基)-1-甲基吲ί朵-2-基,1-甲基-5-苯胺 基吲呤-2-基,5-乙醛胺基吲哚-2-基,5-苄醯胺基-1-丁基吲Ϊ朵-2 -基,4 -氯-1 -甲基吲ί朵-2 -基,3 -甲氧基 -1-甲基吲呤-2-基,6 -氟-1-甲基吲If朵-2-基,6 -氯-1-乙基吲哚-2-基,6 -甲氣基-1-甲基吲Ϊ朵-2-基,5,6-二甲氧基-卜甲基吲《朵-2 -基,7 -甲氣基吲S朵-2 -基, 1 -甲基吲S朵-5 -基,1 - 丁基吲呤-5 -基,1 -乙基吲Ϊ朵-5 -基,1 -甲基吲呤-4 -基,1 -異丙基吲哚-4 -基和卜丁基 吲哚-4 -基; 吲昤啉環群,如 5 -甲氣基B引Ϊ朵啉-1 -基,1 -甲基吲哚啉-2 -基,1 -乙基 吲哚啉-2-基,卜丙基吲呤啉-2-基,卜丁基吲哚啉- 2-基和1 -異丙基吲呤_ - 2 -基; 吖吲哚環群,如 1 -甲基-7 -吖吲昤-3 -基,1 -異丙基-7 -吖吲哚-3 -基, 1 -甲基-7 -吖吲ί朵-2 -基和1 -甲基-6 -吖吲IT朵-2 _基; 吖吲哚吖環群,如 1 -甲基-7 -吖吲呤啉-2 -基,1 -乙基-7 -吖吲II朵啉-2 -基 ,1 -異丙基-7 -吖吲哚啉-2 -基和1 - 丁基-7 -吖吲哚啉 -2-基; 眯唑並吡啶環群,如 -28- 本紙張尺度適用中國國家樣準(CNS)A4規格(210X29*7公釐) (請先閲讀背面之注意事項再填寫本頁) >衣· 訂 503237 A7 ___B7_ 五、發明説明(外) 經濟部中央標準局貝工消費合作社印装 (請先閲讀背面之注意事項再填寫本頁) 7-甲基眯唑並〔4,5-b〕吡啶-2-基,1-丁基咪唑並 〔4,5-b〕吡啶-2-基,1-甲基眯唑並〔4,5-b〕吡啶 -2 -基,1-丙基眯唑並〔4,5-b〕吡啶-2-基,5 -氯-1-.甲基眯唑並〔4,5-b〕吡啶-2-基,5-甲氣基-1·甲基咪 唑並〔4,5-1)〕吡啶-2-基,6,8-二溴眯唑並〔1,21〕 吡啶-2-基,8-羥眯唑並〔1,2-a〕吡啶-2-基,6-氯 眯唑並 〔1,2-a〕吡啶-2-基,2 -甲基眯唑並〔1,2-a〕 吡啶,7-基,2-乙基眯唑並〔1,2-a〕吡啶-8-基,3-'甲基眯唑並〔5,4-b〕吡啶-2-基,3,7 -二甲基眯唑並 C 5 , 4-b]吡啶-2-基,5 -氛-3-甲基眯唑並〔5,4-b〕 吡啶-2-基,5 -氯-3-苯基眯唑並〔5,4-b〕吡啶-2-基 ,3 -溴-3-甲基眯唑並〔5,4-b〕吡啶-2-基,3 -甲基 -6-三氟甲基眯唑並〔5,4-b〕毗啶-2-基,3-異丙基 -6-三氟甲基眯唑並〔5,4-b〕吡啶-2-基,3-異丙基 -6-三氟甲基眯唑並〔5, 4-b〕吡啶-2-基,3-(3-氯苄 基)咪唑並〔5,4-b〕吡啶-2-基,3 -苄基眯唑並 〔5,4-b〕吡啶-2-基,3-(4-氛苄基)眯唑並〔5,4-b〕 吡啶-2-基,3-(4-苯基苄基)眯唑並〔5,4-b〕吡啶-2-基,6-溴-3-甲基咪唑並〔5,4-b〕吡啶-2-基,6-溴 -3 -乙基眯唑並〔5,4-b〕吡啶-2-基,6 -溴-3-苯基眯 唑並〔5,4-b〕吡啶-2-基,6 -氯-3-甲基眯唑並 〔5,4-b〕吡啶-2-基,3 -丁基-6-氯眯唑並〔5,4-b〕 吡啶-2-基,5 -甲氣基-3-甲基眯唑並〔5,4-b〕吡啶 -2 -基,3 -乙基-5-甲氣眯唑並〔5,4-b〕吡啶-2-基, -29- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 29*7公釐) 503237 A7 _B7_·_ 五、發明説明(〇 ) 5 -甲氣基-3-丙基眯唑並〔5,4-b〕吡啶-2-基,5 -甲 氣基-3-苯基眯唑並〔5,4-b〕吡啶-2-基,3 -苄基- 5-甲氣眯唑並〔5,4-b〕Btt啶-2-基,3-(3 -氛苯基)-5-甲氧眯唑並〔5,4-b〕吡啶-2-基,5 -羥基-3-甲基眯 唑並〔5,4-b〕吡啶-2-基,3 -乙基-5-羥眯唑並 〔5,4-b〕吡啶-2-基,3 -苄基-5-羥眯唑並〔5,4-b〕 吡啶-2-基,3 -苯基咪唑並〔5, 4-b〕吡啶-2-基,3-(4 -氯苯基)眯唑並〔5,4-b〕吡啶-2-基,3-(3 -氯苯 基)味哇並〔5,4-b〕哦淀-2-基,3-(3 -甲基苯基)味 睡並〔5,4-b〕咐淀-2-基,5 -氯- 3- (3 -氛苯基)眯唑 並〔5,4-b〕吡啶-2-基,5-甲氧基-3-(3-甲氣苯基) 眯唑並〔5,4-b〕吡啶-2-基,5 -羥基- 3,6 -二甲基咪 唑並 〔5,4-b〕Ϊ比啶-2-基,5 -甲氧基-3,6 -二甲基眯 唑並〔5,4-b〕吡啶-2-基,3 -甲基眯唑並〔5,4-b〕 吡啶-5-基,2 ,3 -二甲基眯唑並〔5, 4-b〕吡啶-5-基, 經濟部中夬標準局貝工消費合作社印裝 (請先閱讀背面之注意事項再填寫本頁) 3 -乙基-2-苯基眯唑並〔5, 4-b〕吡啶-5-基,2-〔2-(3 ,5-二-第三丁基-4-羥苯基)乙基〕-3-甲基眯唑並 〔5,4-b〕吡啶-5-基,2-(3 -氯苯基)-3 -甲基眯唑並 〔5,4-b〕吡啶-5-基,3 -甲基-5-苯硫眯唑並〔5,4-b〕 哦啶-2-基,5 -丁硫基-3-甲基咪唑並〔5,4-b〕毗啶 -2 -基,3 -甲基-5-苯基眯唑並〔5, 4-b〕吡啶-2-基, 5-(3,5-二-第三丁基-4-羥苯硫基)-3-甲基眯唑並 〔5, 4-b〕吡啶-2-基,5 -乙氣基-3-甲基眯唑並 〔5,4-b〕吡啶-2-基,5-異丙氣基-3-甲基眯唑並 -30- 本紙張尺度適用中國國家標率(CNS ) A4現格(210X297公釐) 503237 A7 __B7 _ 五、發明説明(4 ) 經脊郎中夹樣孥馬員X.消费合ftit印«. (請先閱讀背面之注意事項再填寫本頁) 〔5,4-b〕吡啶-2-基,5 -乙醯氧基-3-甲基眯唑並 〔5 , 4 - b〕吡啶-2 -基,3 -乙基-5 -苯氣基-6 -三氟甲基 眯唑並〔5,4-b〕毗啶-2-基,7 -氯-3-甲基眯唑並 〔5,4-b〕吡啶-2-基,7 -氯-3-丙基眯唑並〔5,4-b〕 吡啶-2-基,6 -羥基-3,5,7 -三甲基眯唑並 〔5,4-b〕 吡啶-2-基,3,5,卜三甲基-6-硝基眯唑並〔5, 4-b〕 吡啶-2-基,6 -胺基-3, 5,7 -三甲基眯唑並 〔5, 4-b〕 吡啶-2-基,3 -甲基-5-甲胺基眯唑並〔5,4-b〕吡啶 -2 -基,5 -二甲胺基-3 -甲基眯唑並〔5,4-b〕Ϊ比啶-2 -基,5-(N -丁基乙胺基)-3 -甲基咪唑並〔5,4-b〕 吡啶-2-基,3 -甲基-5-苯胺基眯唑並〔5,4-b〕毗啶 -2 -基,5 -苄胺基-3-甲基眯唑並〔5, 4-b〕哦啶-2-基 ,5-(N -乙基-N -苯胺基)-3 -甲基眯唑並〔5,4-b〕吡 啶-2-基,5-乙醯胺基-3-甲基眯唑並〔5,4-b〕吡啶 -2 -基,5 -苄醯胺基-3-甲基眯唑並〔5,4-b〕ϋ啶- 2-基,3 -甲基-6-硝基眯唑並〔5,4-b〕吡啶-2-基,6-胺基-3-甲基眯唑並〔5,4-b〕ϊ(±啶-2-基,6 -苄醯胺 基-3-甲基眯唑並 〔5,4-b〕吡啶-2-基,6 -戊醯基-3 -丁基眯唑並〔5,4-b〕吡啶-2-基,5 -苄氣基-3-甲基 昧唑並〔5,4-b〕哦陡·2 -基,2 -翔基-3-甲基眯唑並 〔5,4-b〕吡啶-5-基,2 -羥基- 3Η -眯唑並〔5,4-b〕 吡啶-5-基,2-羥基-3-苯基眯唑並〔5,4-b〕吡啶- 5-基,2 -甲硫基- 3H -眯唑並 〔5,4-b〕ί比啶-5-基,3 -甲 基-2-甲硫基眯唑並〔5,4-b〕吡啶-5-基,3 -苄基- 2- - 31- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(2丨Ox 297公羶) 經濟部中央樣準局員工消費合作社印装 503237 A7 B7 五、發明説明(^ ) 丁硫基眯唑並〔5,4-b〕吡啶-5-基,5 -第三丁胺基- 3-甲基眯唑並〔5 , 4 - b〕吡啶-2 -基,5 -第三丁胺基-3 -丙基眯唑並〔5,4-b〕吡啶-2-基,3 ,5,7 -三甲基眯唑 並〔5,4-b〕吡啶-2-基,3-(3 -氯苯基)-5,7 -二甲基 眯唑並〔5,4-b〕吡啶-2-基,3-(3,5 -二-第三丁基- 4-羥苄基)-5,7 -二甲基眯唑並〔5,4-b〕吡啶-2-基,5-乙醯氣基-3-甲基咪唑並〔5,4-b〕吡啶-2-基,5 -乙 醯氣基-3-乙基眯唑並〔5,4-b〕吡啶-2-基,6 -甲氧 基-3-甲基眯唑並〔1,2-a〕吡啶-2-基,1-甲基眯唑 並〔1,2-a〕吡啶-2-基,1-丁基眯唑並〔l,2-a〕吡 啶-2-基; 眯唑並嘧啶環群,如 3-甲基眯唑並〔5,4-d〕嘧啶-2-基,3-乙基眯唑並 〔5,4-d〕嘧啶-2-基和3-(3 -甲基苄基)眯唑並〔5,4-d〕 嘧啶-2-基^ 化合物(I I)中,較佳為式(I I)化合物和其鹽,其中: (A 1 ) X為吲哚基,吲哚_基,吖吲哚基,眯唑並吡啶基 或眯唑並嘧啶基,其為未取代或被取代以1至3個如下 定義之取代基α : 取代基cr為4烷基,Ci - 4烷氣基,苄氣基, 鹵原子,羥基,乙醯氣基,苯硫基,Cl - 4烷硫基 ,三氟甲基,硝基,式- NRaRb之胺基, 其中為相同或不同且各為氫原子,Ci- 8 烷基,C 7 - u芳烷基,C 6 - 10芳基,C i u脂族 一 32- 本紙張尺度適用中《國家螵率(CNS > Λ4規格(2丨OX297公釐) (請先閲讀背面之注意事項再填寫本頁) 裝- 訂 經濟部中央標準局員工消費合作社印製 503237 A 7 % B7 五、發明説明() 醯基,c 8 - 12芳基-取代脂族醯基或C 7 - U芳香 醯基, C 6 - 10芳基其為未取代或被取代以至少一値取代基 選自取代基冷, 該取代基々SCi - 4烷基,Ci - 4烷氧基,鹵原 子,羥基,硝基,苯基,三氟甲基或式_NRaRb之 胺基,其中!^和1^如上定義規定,若设3和^為 芳基或包括芳基之基,則該芳基不為其本身再被 式- NRa Rb之基所取代者; 或C 7 - u芳烷基其為未取代或被取代以至少一個取代 基選自取代基冷; 和/或 (A2) Y為氣或硫原子; 和/或 (A3) R為氫原子,Cjl - 4烷基,Ci - 4烷氧基或鹵 原子; 和/或 (A4) ίο為整數1至5 ; 且特別之化合物其中X如(A1)定義,Y如(A2)定義,R 如(A3)定義且m如(A4)定義。 更佳化合物(I I)為式(I I)化合物和其鹽,其中: - 33 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)、 1T 4 This paper size is in accordance with Chinese National Standard (CNS) 8 4 ^ grid (210X29 * 7 mm) 503237 A7 B7 V. Description of the invention (W) 4- [N- (2-naphthyl) -N-aniline group ] Benzyl; xix) aralkyl is substituted with a substituted amine group, wherein one of Ra and Ib is aryl and the other 1 ^ and 1 ^ are aliphatic fluorenyl groups, such as 4- (N-propyl- N-Ethylamino) benzyl or 4- (N-phenylhexylamino) benzyl; XX) aralkyl is substituted with substituted amine, one of which is aryl and the other is 3 And 1113 are aromatic-substituted aliphatic alkyl groups, such as 4- (N-phenyl-N-phenylethylamino) benzyl or 4- [N-phenyl-N- (4-phenylbutylfluorenyl) amino] benzyl Xxi) an aralkyl group is substituted with a substituted amine group, one of which is an aryl group and the other 1 ^ and! ^ Is an aromatic fluorenyl group, such as 4- (N-phenyl-N-benzylfluorenylamino) benzyl; xxii) an aralkyl group is substituted with a substituted amine group, wherein ^ 3 and paragraph 6 are both aliphatic fluorene Groups, each of which may be the same or different, such as 4-diethylamidobenzyl or 4- (N-butylamido-N-hexaneamido) benzyl; xxiii) arylalkyl substituted to be substituted amino , One of which is an aliphatic fluorenyl group and the other Ra and I ^ b are aromatic-substituted aliphatic radicals, such as 4- (N-ethylfluorenyl-N-phenylethylfluorenylamino) benzyl or 4- ( N-Butyl-N-phenethylamido) benzyl; printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling out this page) xxiv) arylalkyl substituted with substituted amine One of which and Rb are aliphatic fluorenyl groups and the other 2Ra and ^ are aromatic fluorenyl groups, such as 4- (N-ethylfluorenyl-N-benzylamino) benzyl or 4- [M-butylfluorenyl-N- (2-naphthylfluorenyl) amino] benzyl; xxv) an aralkyl group substituted with a substituted amine group, wherein Ra and Rb are both aromatic-substituted aliphatic fluorenyl groups, each of which may be the same or different, such as 4- (-26- This paper size applies to China National Standard (CNS) A4 specification (2 丨 OX297 mm) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 503237 A7 B7_ V. Description of the Invention (4) Ν, Ν-diphenylethylamido) benzyl or 4- [N-phenethylamido-N- (4-benzene Butanyl) amino] benzyl; xxvi) aralkyl is substituted with a substituted amine group, where one of R a and R b is an aromatic-substituted aliphatic group and the other Ra and R ^ are aromatic fluorene Group, such as 4- (N-phenethylfluorenylbenzylamidinyl) benzyl or 4- [N-phenethylfluorenyl-naphthylfluorenyl) amino] benzyl; xxvii) aralkyl is substituted to be substituted Amine groups in which Ra and Rb are both aromatic fluorenyl groups, each of which may be the same or different, such as 4-dibenzyl alcoholamine benzyl or 4- [N-benzylfluorenyl-N- (2-naphthylfluorenyl) Amine] benzyl. Derived from indolin, indolin, azindrine, azindolin, oxazolopyridine and oxazolopyrimidine rings, each of which may be substituted with a preferred 1 to 3 fluorene substituent α (which is represented by X) Specific examples include, for example: an indole ring group, such as 3-tritylindol-1-yl, 1-methylindyl-3-yl, 1-methylindyl-2-yl, 1-Ethylindoxy-2-yl, 5-methoxy-1,2-dimethylbenzyl-3-methyl, 5-xiangyl-1-methyl-yl, 1-isopropyl B3I, pyridin-3-yl, 2-ethyl-1-methylindole, 3-dolyl, 5-methoxy-1-methylindole, ifdol-3-yl, 5-hydroxy-1, 2 -Dimethylindino-3 -yl, 5-butoxy-1 -methylindole-3 -yl, 1, 4, 7-trimethylindino-3 -yl, 1, 3- Dimethylindo IT-3-yl, 5-bromo-6-chloro-1 -methylindole B 3-yl, 5-bromoindole-3 -yl, 5-hydroxy-1 -isobutyl Indolin-3 -yl, 5-fluoro-1 -methylindole-2 -yl, 5-hydroxy-1 -methylindole-2 -yl, 4-methylamino-methylindole- 2-yl, 5-bromo-1 -methylindino-2 -yl, 1 -ethyl-5 -nitroindolin-2 -yl, 1,5-dimethylindino-2 -yl, 5--27- This paper is in standard size National Standard (CNS) Α4 specification (2 丨 〇 × 29? Mm) (Please read the precautions on the back before filling out this page) Order Λ Consumer Cooperation of the Central Standards Bureau of the Ministry of Economic Affairs Du printed 503237 A7 _B7_ V. Description of the invention (J ) Amino-1-methylindolin-2-yl, 5-acetamido-1-methylindole-2-yl, 5-benzylamido-1-ethylindole-2- 1-methyl-5-methylamino indol-2-yl, 5-butylamino-1-methyl indol-2-yl, 5- (N-benzyl.fluorenyl-N- (Methylamino) -1-methylindolin-2-yl, 1-methyl-5-anilinindin-2-yl, 5-acetaldehyde indol-2-yl, 5-benzylhydrazone Amino-1-butylindole-2-yl, 4-chloro-1 -methylindole-2 -yl, 3-methoxy-1-methylindolin-2-yl, 6- Fluoro-1-methylindole Ifido-2-yl, 6-chloro-1-ethylindole-2-yl, 6-methylamino-1-methylindole-2-yl, 5,6 -Dimethoxy-p-methylindole "Dor-2-yl, 7-methylindo-Sd-2-yl, 1-methylind-S-5" -yl, 1-butylindin-5-yl , 1-ethylindolin-5-yl, 1-methylindolin-4-yl, 1-isopropylindole-4-yl and butylbutylindole-4-yl; indolinline ring group, 5-Methanyl B Gadoline-1 -yl, 1-methylindolin-2-yl, 1-ethylindolin-2-yl, propylindolin-2-yl, butylindolin-2-yl and 1-isopropylindin-2-yl group; azindole ring groups, such as 1-methyl-7-azindino-3-yl, 1-isopropyl-7-azindolin-3-yl , 1-methyl-7-acridin-2-yl and 1-methyl-6-acidin IT-2-2; azindole acyl ring group, such as 1-methyl-7-acridin Porphyrin-2-yl, 1-ethyl-7-acridinyl-II-Porphyrin-2-yl, 1-isopropyl-7-azindolinyl-2-yl, and 1-butyl-7-azindin Indolin-2-yl; oxazolopyridine ring groups, such as -28- This paper size applies to China National Standard (CNS) A4 (210X29 * 7 mm) (Please read the precautions on the back before filling this page ) > Clothes · Order 503237 A7 _B7_ V. Description of the invention (outside) Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling this page) 7-methyloxazole and [4, 5-b] pyridin-2-yl, 1-butylimidazolo [4,5-b] pyridin-2-yl, 1-methyloxazolo [4,5-b] pyridin-2-yl, 1 -Propyloxazolo [4,5-b] pyridin-2-yl, 5-chloro-1-. Methylpyrazolo [4,5-b] pyridin-2-yl, 5-methylamino-1.methylimidazo [4,5-1)] pyridin-2-yl, 6,8-dibromofluorene Azolo [1,21] pyridin-2-yl, 8-hydroxyxazolo [1,2-a] pyridin-2-yl, 6-chlorooxazolo [1,2-a] pyridin-2-yl , 2-methyloxazolo [1,2-a] pyridine, 7-yl, 2-ethyloxazolo [1,2-a] pyridin-8-yl, 3-'methyloxazolo [ 5,4-b] pyridin-2-yl, 3,7-dimethyloxazolo C 5, 4-b] pyridin-2-yl, 5-amino-3-methyloxazolo [5,4 -b] pyridin-2-yl, 5-chloro-3-phenyloxazo [5,4-b] pyridin-2-yl, 3-bromo-3-methyloxazo [5,4-b ] Pyridin-2-yl, 3-methyl-6-trifluoromethyloxazo [5,4-b] pyridin-2-yl, 3-isopropyl-6-trifluoromethyloxazolyl [5,4-b] pyridin-2-yl, 3-isopropyl-6-trifluoromethyloxazo [5, 4-b] pyridin-2-yl, 3- (3-chlorobenzyl) Imidazolo [5,4-b] pyridin-2-yl, 3-benzyloxazolo [5,4-b] pyridin-2-yl, 3- (4-azabenzyl) oxazolo [5, 4-b] pyridin-2-yl, 3- (4-phenylbenzyl) oxazo [5,4-b] pyridin-2-yl, 6-bromo-3-methylimidazo [5,4 -b] pyridin-2-yl, 6- -3 -ethyloxazolo [5,4-b] pyridin-2-yl, 6-bromo-3-phenyloxazolo [5,4-b] pyridin-2-yl, 6-chloro-3 -Methyloxazolo [5,4-b] pyridin-2-yl, 3-butyl-6-chlorooxazolo [5,4-b] pyridin-2-yl, 5-methylamino-3 -Methyloxazo [5,4-b] pyridin-2-yl, 3-ethyl-5-methazolo [5,4-b] pyridin-2-yl, -29- Applicable to China National Standard (CNS) A4 specification (210 X 29 * 7 mm) 503237 A7 _B7_ · _ V. Description of the invention (〇) 5 -methylamino-3-propyloxazolo [5,4-b] Pyridin-2-yl, 5-methylamino-3-phenyloxazo [5,4-b] pyridin-2-yl, 3-benzyl-5-methylazolido [5,4-b ] Bttidin-2-yl, 3- (3-aminophenyl) -5-methoxyoxazolo [5,4-b] pyridin-2-yl, 5-hydroxy-3-methyloxazolo [ 5,4-b] pyridin-2-yl, 3-ethyl-5-hydroxyoxazo [5,4-b] pyridin-2-yl, 3-benzyl-5-hydroxyoxazo [5, 4-b] pyridin-2-yl, 3-phenylimidazo [5, 4-b] pyridin-2-yl, 3- (4-chlorophenyl) oxazo [5,4-b] pyridine- 2-yl, 3- (3-chlorophenyl) amido [5,4-b] ohyn-2-yl, 3- (3-methylphenyl Taste and [5,4-b] Yodo-2-yl, 5-chloro-3 (3-aminophenyl) oxazo [5,4-b] pyridin-2-yl, 5-methoxy 3- (3-methylphenyl) oxazo [5,4-b] pyridin-2-yl, 5-hydroxy-3,6-dimethylimidazo [5,4-b] fluorene ratio Pyridin-2-yl, 5-methoxy-3,6-dimethyloxazolo [5,4-b] pyridin-2-yl, 3-methyloxazolo [5,4-b] pyridine -5-yl, 2,3-dimethylxazolo [5, 4-b] pyridin-5-yl, printed by Shelley Consumer Cooperative, Zhongluo Standard Bureau, Ministry of Economic Affairs (please read the notes on the back before filling (This page) 3-ethyl-2-phenyloxazo [5, 4-b] pyridin-5-yl, 2- [2- (3,5-di-tert-butyl-4-hydroxyphenyl) ) Ethyl] -3-methyloxazolo [5,4-b] pyridin-5-yl, 2- (3-chlorophenyl) -3 -methyloxazolo [5,4-b] pyridine -5-yl, 3-methyl-5-phenylthioxazo [5,4-b] oxidin-2-yl, 5-butylthio-3-methylimidazo [5,4-b] Pyridin-2-yl, 3-methyl-5-phenyloxazo [5, 4-b] pyridin-2-yl, 5- (3,5-di-tert-butyl-4-hydroxybenzene Thio) -3-methyloxazo [5, 4-b] pyridin-2-yl, 5-ethoxy-3-methyloxazolyl 5,4-b] pyridin-2-yl, 5-isopropanyl-3-methyloxazolo-30- This paper is applicable to China National Standard (CNS) A4 standard (210X297 mm) 503237 A7 __B7 _ V. Description of the invention (4) The spine-like horseman X. Consumption ftit printed in the spine «. (Please read the precautions on the back before filling this page) [5,4-b] pyridin-2-yl , 5-Ethyloxy-3-methyloxazolo [5, 4-b] pyridin-2-yl, 3-ethyl-5 -benzyl-6-trifluoromethyloxazolo [5 , 4-b] pyridin-2-yl, 7-chloro-3-methyloxazolo [5,4-b] pyridin-2-yl, 7-chloro-3-propyloxazolo [5, 4-b] pyridin-2-yl, 6-hydroxy-3,5,7-trimethyloxazo [5,4-b] pyridin-2-yl, 3,5, trimethyl-6- Nitroxazo [5, 4-b] pyridin-2-yl, 6-amino-3, 5,7-trimethyloxazo [5, 4-b] pyridin-2-yl, 3- Methyl-5-methylaminopyrazolo [5,4-b] pyridin-2-yl, 5-dimethylamino-3 -methyloxazolyl [5,4-b] pyridine-2 -Yl, 5- (N-butylethylamino) -3 -methylimidazo [5,4-b] pyridin-2-yl, 3-methyl-5-anilinopyrazolo [5,4 -b] pyridin-2-yl, 5-benzylamino- 3-methyloxazolo [5, 4-b] ohidin-2-yl, 5- (N -ethyl-N-aniline) -3 -methyloxazolo [5,4-b] pyridine 2-yl, 5-acetamido-3-methyloxazo [5,4-b] pyridin-2-yl, 5-benzylamido-3-methyloxazo [5,4 -b] pyrimidin-2-yl, 3-methyl-6-nitrooxazo [5,4-b] pyridin-2-yl, 6-amino-3-methyloxazo [5, 4-b] pyrene (± pyridin-2-yl, 6-benzylamido-3-methylpyrazolo [5,4-b] pyridin-2-yl, 6-pentamyl-3-yl Oxazolo [5,4-b] pyridin-2-yl, 5-benzyloxy-3-methylimidazo [5,4-b] oh-d 2-yl, 2-xiangyl-3- Methyloxazo [5,4-b] pyridin-5-yl, 2-hydroxy-3--oxazolo [5,4-b] pyridin-5-yl, 2-hydroxy-3-phenyloxazole Benzo [5,4-b] pyridine-5-yl, 2-methylthio-3H-oxazolo [5,4-b] pyridin-5-yl, 3-methyl-2-methylthio Oxazo [5,4-b] pyridin-5-yl, 3-benzyl- 2--31- This paper size applies to China National Standard (CNS) Λ4 specification (2 丨 Ox 297 cm) Central sample of Ministry of Economic Affairs Printed by the Consumer Cooperatives of the Associate Bureau 503237 A7 B7 V. Description of the Invention (^) Butylthioxazole [5,4-b] pyridin-5-yl, 5-tert-butylamino-3-methyloxazolo [5, 4-b] pyridin-2-yl, 5-tert-butylamino-3 -Propyloxazolo [5,4-b] pyridin-2-yl, 3,5,7-trimethyloxazolo [5,4-b] pyridin-2-yl, 3- (3-chloro Phenyl) -5,7-dimethyloxazolo [5,4-b] pyridin-2-yl, 3- (3,5-di-third-butyl-4-hydroxybenzyl) -5, 7-Dimethyloxazolo [5,4-b] pyridin-2-yl, 5-acetamido-3-methylimidazo [5,4-b] pyridin-2-yl, 5-ethyl Fluorenyl-3-ethyloxazo [5,4-b] pyridin-2-yl, 6-methoxy-3-methyloxazo [1,2-a] pyridin-2-yl, 1-methyloxazolo [1,2-a] pyridin-2-yl, 1-butyloxazolo [l, 2-a] pyridin-2-yl; oxazolopyrimidine ring groups, such as 3- Methyloxazo [5,4-d] pyrimidin-2-yl, 3-ethyloxazo [5,4-d] pyrimidin-2-yl, and 3- (3-methylbenzyl) oxazole Among [5,4-d] pyrimidin-2-yl ^ compounds (II), compounds of formula (II) and salts thereof are preferred, where: (A 1) X is indolyl, indolyl, and acryl Indolyl, oxazolopyryl or oxazolopyrimidyl, which is unsubstituted or substituted 1 to 3 substituents α as defined below: The substituent cr is a 4-alkyl group, a Ci-4 alkylamino group, a benzylamino group, a halogen atom, a hydroxyl group, an acetamino group, a phenylthio group, a Cl-4 alkylthio group , Trifluoromethyl, nitro, amine groups of the formula-NRaRb, wherein they are the same or different and each is a hydrogen atom, Ci-8 alkyl, C 7 -u aralkyl, C 6-10 aryl, C iu Aliphatic 32- This paper is applicable to the national standard (CNS > Λ4 specification (2 丨 OX297 mm) (please read the precautions on the back before filling this page) Cooperative printed 503237 A 7% B7 V. Description of the invention () fluorenyl, c 8-12 aryl-substituted aliphatic fluorenyl or C 7-U aryl fluorenyl, C 6-10 aryl is unsubstituted or substituted Substitution with at least one fluorene substituent is selected from the group consisting of substituents Sci-4 alkyl, Ci-4 alkoxy, halogen atom, hydroxy, nitro, phenyl, trifluoromethyl, or NRARb Amine, which! ^ And 1 ^ are as defined above. If 3 and ^ are aryl groups or groups including aryl groups, the aryl group is not itself replaced by a group of the formula-NRa Rb; or C 7-u arane Group is unsubstituted or substituted with at least one substituent selected from the group consisting of substituents; and / or (A2) Y is a gas or sulfur atom; and / or (A3) R is a hydrogen atom, Cjl-4 alkyl, Ci -4 alkoxy or halogen atom; and / or (A4) ο is an integer of 1 to 5; and special compounds in which X is defined as (A1), Y is defined as (A2), R is defined as (A3) and m is as (A4) Definition. The better compound (II) is the compound of formula (II) and its salts, in which:-33-This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) (Please read the precautions on the back before filling this page )

503237 A7 B7 五、發明説明(μ ) (B u X為吲昤基,吲昤啉基,眯唑並吡啶基或眯唑並嘧 啶基,其為未取代或被取代以1至3傾如下 定義之取代基α : 取代基α為Cl - 4烷基,Ci - 4烷氣基,苄氧基, 鹵原子,羥基,乙醯氣基,苯硫基,Cl - 4烷硫基 ,三氟甲基,硝基,式- NRaRb之胺基, 其中Ra和Rb為相同或不同且各為氫原子,Ci- 8 烷基,C 7 _ u芳烷基,C 6 - 10芳基,C i - u脂族 醯基,C8- 12芳基-取代脂族醯基或(^7_ u芳香 醯基, C 6 - 10芳基其為未取代或被取代以至少一個取代基 選自取代基>8 , 該取代基点為^ - 4烷基,Ci - 4烷氧基,鹵原 子,羥基,硝基,苯基,三氟甲基或式- NRaRb之 胺基,其中Ra和Rb如上定義, 或C7- :^芳烷基其為未取代或被取代以至少一個取代 基選自取代基; 和/或 經濟部中央樣隼局貝工消費合作社印*. (請先閱讀背面之注意事項再填寫本頁) (B2 ) Y為氣原子; 和/或 -34-本紙張尺度適用中國國家標牟(CNS ) Λ4規格(2丨〇X297公釐) 503237 A7 B7 五、發明説明( (B3) R為氫原子,C! - 4烷基,Ci - 4烷氣基或鹵 原子; 和/或 (B 4 ) hi為整數1至5 ; 且特別之化合物其中X如(B1)定義,Y如(B2)定義,R 如(B 3)定義且m如(B 4)定義。 又更佳化合物(I I)為式(I I)化合物和其鹽,其中: (C 1) X為吲呤基,吲呤啉基或眯唑並吡啶基,其為未取 代或被取代以1至3個如下定義之取代基σ : 取代基CT為Ci - 4烷基,Ci - 4烷氧基,苄氧基, 鹵原子,羥基,乙醒氣基,苯硫基,Ci - 4烷硫基 ,三氟甲基,硝基,式- NRaRb之胺基, 其中為相同或不同且各為氫原子,8 院基,C7 - 11芳院基,C6 - 10¾基,Cl - 11脂 族醯基,C8 - 芳基-取代脂族醯基或C7 -以芳 香_基, C6 - 10芳基其為未取代或被取代以1至3個取代基 選自取代基冷, 取代基々為Ci - 4烷基,Ci - 4烷氣基,鹵原子 f 脊 Ψ % (請先閱讀背面之注意事項再填寫本頁) ,羥基,硝基,苯基,三氟甲基或式- NRaRb之胺 基,其中R3和Rb如上定義, 或C 7 - u芳烷基其為未取代或被取代以至少一値取代 基選自取代基冷; 和/或 -35- 本紙張尺度適用中國國家標率(CNS ) A4現格(2丨0X297公簸} 經濟部中央標準局員工消費合作社印裝 503237 A7 _B7_ 五、發明説明() (C 2 ) Y為氣原子; 和/或 (C4) R為氫原子,甲氣基,乙氣基,氟原子或氯原子; 和/或 (C5 ) m為整數1至5 ; 且特別之化合物其中X如(C1)定義,Y如(C2)定義, 如(C3)定義,R如(C4)定義和ffi如(C5)定義。 又更佳化合物(I I)為式(I I)化合物和其鹽,其中: (D1)X為吲呤啉基或眯唑並吡啶基,其為未取代或被取 代以1至3個如下定義之取代基ct : 取代基a.Ci - 4烷基,CU - 4烷氧基,苄氧基, 鹵原子,苯硫基,Ci- 4烷硫基,三氟甲基或苯基; (D 2 ) Y為氣原子; 和/或 (D 3 ) ^為硫; 和/或 (D4) R為氫原子或甲氣基; 和/或 (D5 ) πι為整數1至5 ; 且特別之化合物其中X如(D1)定義,Y如(D2)定義,Y + 如(D3)定義,R如(D4)定義和m如(D5)定義。 -36 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I ^ 裝 ' _ _ 訂 線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央樣率局貝工消费合作社印«. 503237 A7 B7 五、發明説明(Μ ) 最佳化合物(I I)為式(I I)化合物和其鹽,其中·· (E 1 ) X為眯唑並吡啶基,其為未取代或被取代以1至3 値如下定義之取代基cr : 取代基α為甲基,乙基,異丙基,甲氧基,乙氧基, 丙氧基,異丙氧基,苄氧基,氟原子,氯原子,苯硫 基,甲硫基,乙硫基或苯基; 和/或 (Ε2 ) Υ為氣原子; 和/或 (Ε3) Υ 1為硫; 和/或 (Ε4) R為氫原子; 和/或 (Ε 5 ) m為整數1至5 ; 且特別之化合物其中X如(E1)定義,Y如(E2)定義, 如(E3)定義,R如(E4)定義和m如(E5)定義。 化合物(I)或(II)於其分子中各含有一鹼基,且因此可以 傳統方法與酸類轉變成鹽類〇對於此鹽類之性質並無待 別限制,只要此化合物於供醫藥使用時為藥理容許,即 其較母化合物為非較低活性或不容許之較低活性,且為 非更具毒性或不容許之更具毒性。然而,於此化合物為 供於做為非醫藥用途,如做為其他化合物製備中之中間 物時,則即使此限制亦無,且對於所形成鹽類之性質亦 無限制。此類鹽之例包括:與礦物酸,待別是氫鹵酸( 如氫氟酸,氫溴酸,氫碘酸或氫氛酸),硝酸,過氛酸 -37- 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) " (請先閲讀背面之注意事項再填寫本頁)503237 A7 B7 V. Description of the invention (μ) (B u X is indino, indolinolinyl, oxazolopyridyl or oxazolopyrimidinyl, which is unsubstituted or substituted with 1 to 3 as defined below Substituent α: Substituent α is Cl-4 alkyl, Ci-4 alkanoyl, benzyloxy, halogen atom, hydroxyl, ethanoyl, phenylthio, Cl-4 alkylthio, trifluoromethyl Group, nitro group, amine group of formula-NRaRb, wherein Ra and Rb are the same or different and each is a hydrogen atom, Ci-8 alkyl group, C 7_uaralkyl group, C 6-10 aryl group, C i- u aliphatic fluorenyl, C8-12 aryl-substituted aliphatic fluorenyl or (^ 7_u aryl fluorenyl, C 6-10 aryl which is unsubstituted or substituted with at least one substituent selected from substituents > 8. The substituent point is a ^ -4 alkyl group, a Ci-4 alkoxy group, a halogen atom, a hydroxyl group, a nitro group, a phenyl group, a trifluoromethyl group or an amine group of the formula-NRaRb, wherein Ra and Rb are as defined above, or C7-: ^ aralkyl which is unsubstituted or substituted with at least one substituent selected from the substituents; and / or printed by the Shellfish Consumer Cooperative of the Central Samples Bureau of the Ministry of Economic Affairs *. (Please read the notes on the back before filling (This page) (B2) Y is Atoms; and / or -34- This paper size applies to China National Standards (CNS) Λ4 specifications (2 丨 〇297297 mm) 503237 A7 B7 V. Description of the invention ((B3) R is a hydrogen atom, C!-4 alkane Group, Ci-4 alkanoyl group or halogen atom; and / or (B4) hi is an integer of 1 to 5; and special compounds wherein X is defined as (B1), Y is defined as (B2), and R is as (B 3 ) And m is as defined in (B 4). Still more preferred compound (II) is a compound of formula (II) and a salt thereof, wherein: (C 1) X is indolinyl, indolinolinyl or oxazolopyridyl , Which is unsubstituted or substituted with 1 to 3 substituents σ as defined below: Substituent CT is Ci-4 alkyl, Ci-4 alkoxy, benzyloxy, halogen atom, hydroxyl, ethoxy group , Phenylthio, Ci-4 alkylthio, trifluoromethyl, nitro, amine group of the formula-NRaRb, where they are the same or different and each is a hydrogen atom, 8 groups, C7-11 aromatic groups, C6 -10¾ group, Cl-11 aliphatic fluorenyl group, C8-aryl-substituted aliphatic fluorenyl group or C7-with aromatic group, C6-10 aryl group is unsubstituted or substituted with 1 to 3 substituents Self-substituting cold, the substituent 々 is Ci-4 alkyl, Ci -4 alkane group, halogen atom f ridge% (please read the notes on the back before filling this page), hydroxyl, nitro, phenyl, trifluoromethyl or amine group of formula-NRaRb, of which R3 and Rb As defined above, or C 7 -u aralkyl which is unsubstituted or substituted with at least one substituent selected from the group consisting of substituents; and / or -35- This paper applies the Chinese National Standard (CNS) A4 standard (2 丨 0X297)} Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 503237 A7 _B7_ V. Description of the invention () (C 2) Y is a gas atom; and / or (C4) R is a hydrogen atom, a methyl group, An ethylenyl group, a fluorine atom or a chlorine atom; and / or (C5) m is an integer of 1 to 5; and special compounds in which X is defined as (C1), Y is defined as (C2), as defined in (C3), and R is as (C4) is defined and ffi is defined as (C5). Still more preferred compound (II) is a compound of formula (II) and a salt thereof, wherein: (D1) X is an indolinyl group or an oxazolopyridyl group, which is unsubstituted or substituted with 1 to 3 as defined below Substituent ct: Substituent a. Ci-4 alkyl, CU-4 alkoxy, benzyloxy, halogen atom, phenylthio, Ci-4 alkylthio, trifluoromethyl or phenyl; (D 2 ) Y is a gas atom; and / or (D 3) ^ is sulfur; and / or (D4) R is a hydrogen atom or a methyl group; and / or (D5) π is an integer of 1 to 5; and particularly a compound thereof X is defined as (D1), Y is defined as (D2), Y + is defined as (D3), R is defined as (D4) and m is defined as (D5). -36-This paper size is in accordance with Chinese National Standard (CNS) A4 (210X297mm) I ^ installed '_ _ order (please read the precautions on the back before filling this page) Central sample rate bureau of the Ministry of Economic Affairs Cooperative seal «. 503237 A7 B7 V. Description of the invention (M) The best compound (II) is a compound of formula (II) and its salt, where (E 1) X is oxazolopyridyl, which is unsubstituted or Substituted with 1 to 3 cr as defined by cr: Substituent α is methyl, ethyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, benzyloxy, fluorine Atom, chlorine atom, phenylthio, methylthio, ethylthio or phenyl; and / or (Ε2) Υ is a gas atom; and / or (Ε3) Υ 1 is a sulfur; and / or (Ε4) R is Hydrogen atom; and / or (E 5) m is an integer of 1 to 5; and special compounds in which X is defined as (E1), Y is defined as (E2), as defined in (E3), R is defined as (E4) and m As defined in (E5). The compound (I) or (II) each contains one base in its molecule, and therefore can be converted into a salt by a conventional method and an acid. There is no restriction on the nature of the salt, as long as the compound is used in medicine It is pharmacologically acceptable, that is, it is non-lower or less tolerated than the parent compound, and it is not more toxic or more toxic not allowed. However, when this compound is used for non-medical purposes, such as intermediates in the preparation of other compounds, even this restriction does not apply, and there is no restriction on the nature of the salts formed. Examples of such salts include: with mineral acids, other than halogen acids (such as hydrofluoric acid, hydrobromic acid, hydroiodic acid or hydrofluoric acid), nitric acid, peroxyacid -37- Standard (CNS) A4 specification (2 丨 0X297 mm) " (Please read the precautions on the back before filling this page)

503237503237

AJ ___ BJ_ 五、發明説明(K ) ,磺酸,硫酸或磷酸之鹽類;與低烷磺酸,如甲烷磺酸 ,三氟甲烷磺酸或乙烷磺酸之鹽;與芳磺酸,如苯磺酸 或對-甲苯磺酸之鹽類;與有機羧酸,如醋酸,反丁烯 二酸,酒石酸,草酸,順丁烯二酸,蘋果酸,琥珀酸, 苄酸,扁桃酸,抗壞血酸,乳酸,葡萄糖酸或檸檬酸之 鹽類;和與胺基酸,如麩胺酸或天門冬胺酸之鹽類較 佳為製藥容許鹽類。 化合物(I)或(II)可以傳統方法與一鹼轉變成鹽。此類鹽 之例包括:與鹼金屬,如鈉,鉀或鋰之鹽類;與鹼土金 屬,如鋇或鈣之鹽類;和其他金屬,如鎂或鋁之鹽類。 較佳為製藥容許鹽類。 本發明之式(II)化合物因不對稱磺原子之出現而存在 有各種異構物型式β因此,於吲呤啉或吖吲哚啉環為在 2或3位置被取代時,在這些位置之碩原子為不對稱, 在5 -位置之磺原子為不對稱。雖然此些化合物均以 單一之分子式(I )或(I I)代表,但本發明包括個別 經濟部中夬樣李馬員工消費合作社印«- (請先閱讀背面之注意事項再填寫本頁) ,單離異構物和混合物,包括其消旋饈和可以此混合物 以任何比例存在之異構物〇於使用立體專一合成技術或 使用光學活性化合物做為起始物質時,可直接製備値別 之異構物;另一方面,若製備異構物之混合物,則可以 傳統的解析技術取得個別之異構物。 式(I)或(I I)化合物可分別如下列流程ex , /3所示以 各種互變異構物型式存在; _-38-_ 本紙張尺度通用中國國家標準(CNS > Λ4規格(2丨0X297公釐) " 503237 A7 B7 五、發明説明) 經濟部中央樣隼局員工消費合作杜印袈AJ ___ BJ_ 5. Description of the invention (K), salts of sulfonic acid, sulfuric acid or phosphoric acid; salts with low-alkane sulfonic acids, such as methanesulfonic acid, trifluoromethanesulfonic acid or ethanesulfonic acid; and aromatic sulfonic acids, Such as benzenesulfonic acid or p-toluenesulfonic acid salts; with organic carboxylic acids such as acetic acid, fumaric acid, tartaric acid, oxalic acid, maleic acid, malic acid, succinic acid, benzyl acid, mandelic acid, Salts of ascorbic acid, lactic acid, gluconic acid or citric acid; and salts with amino acids such as glutamic acid or aspartic acid are preferably pharmaceutically acceptable salts. The compound (I) or (II) can be converted into a salt by a conventional method with a base. Examples of such salts include: salts with alkali metals, such as sodium, potassium, or lithium; salts with alkaline earth metals, such as barium or calcium; and salts with other metals, such as magnesium or aluminum. Pharmaceutically acceptable salts are preferred. The compound of the formula (II) of the present invention has various isomer forms β due to the occurrence of asymmetric sulfonic atoms. Therefore, when the indolinoline or azindolino ring is substituted at the 2 or 3 position, The master atom is asymmetric, and the sulfon atom at the 5-position is asymmetric. Although these compounds are represented by a single molecular formula (I) or (II), the present invention includes the seal of the Li Ma employee consumer cooperative in the Ministry of Economic Affairs «-(Please read the precautions on the back before filling this page), Isomeric isomers and mixtures, including their racemic hydrazones and isomers that can exist in this mixture in any ratio. When stereospecific synthesis techniques are used or optically active compounds are used as starting materials, they can be directly prepared. Isomers; on the other hand, if a mixture of isomers is prepared, individual isomers can be obtained by traditional analytical techniques. Compounds of formula (I) or (II) can exist in various tautomeric forms as shown in the following schemes ex, / 3, respectively; _-38-_ This paper is in accordance with the Chinese National Standard (CNS > Λ4 Specification (2 丨0X297 mm) " 503237 A7 B7 V. Description of the invention) Du Yinye

(請先閱讀背面之注意事項再填寫本頁) 袈· 訂 本紙张尺度適用中國國家標準(CNS ) Λ4規格(2IOX 297公遘) 503237 A7 B7 五、發明説明(π )(Please read the precautions on the back before filling in this page) · Binding This paper size applies the Chinese National Standard (CNS) Λ4 specification (2IOX 297) 503237 A7 B7 V. Description of the invention (π)

AA

(請先閱讀背面之注意事項再填寫本頁) 於上式(I)或(II)中,其所有之互變體和此些互變體之等重 或非等重混合物以一式表示。因此,所有此些異構物和 此些異構物之混合物均包含於本發明中。 經濟部中央標率局貝工消費合作社印«. 更且,本發明亦包括所有式(I)或(II)化合物和其鹽之溶劑 化物,例如水合物,其中相對之化合物可形成一溶劑化 物。 本發明亦包括所有可於活哺乳動物體中,例如於人體 中,以代謝作用轉變成式(II)化合物或其鹽化合物,其 即稱為式(II)化合物和其鹽之「前體藥物」。 一 40- 本紙張尺度適/Π中WM家橾车(CNS ) Λ4現格(2丨0X297公釐) 503237 A7 B7 五、發明説明() 本發明化合物可以製備此型化合物之此藝熟知之各種 製法製備。例如,其可以下列反應流程A , B包括最後雜 環化合物(II)之製法,來製備:(Please read the precautions on the back before filling out this page.) In formula (I) or (II) above, all its tautomers and the equal or non-equivalent mixtures of these tautomers are represented in one formula. Therefore, all such isomers and mixtures of these isomers are included in the present invention. Printed by the Central Standards Bureau of the Ministry of Economic Affairs, Shellfish Consumer Cooperatives. Moreover, the present invention also includes all solvates of the compounds of formula (I) or (II) and their salts, such as hydrates, where the opposite compounds can form a solvate . The present invention also includes all "prodrugs" which can be metabolized into a compound of formula (II) or a salt compound thereof in a living mammal ". A 40- this paper is suitable for the standard / WM furniture (CNS) Λ4 present (2 丨 0297mm) 503237 A7 B7 V. Description of the invention () The compounds of the present invention can prepare various types of compounds known in the art Process method. For example, it can be prepared by the following reaction schemes A and B including the last heterocyclic compound (II):

反應流程A 0—(CH2)—Halo (III)Reaction Scheme A 0— (CH2) —Halo (III)

-裝· (請先閱讀背面之注意事項再填寫本頁) 步驟A1 鹼 Q 一 (ch2)『-Packing · (Please read the precautions on the back before filling this page) Step A1 Alkali Q 1 (ch2) 『

訂 經濟部中央標準局員工消費合作社印製 步驟A2 X—(CH2)—Order Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs Step A2 X— (CH2) —

本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 503237 A7 B7 五、發明説明() 於上式中: X如上定義,但較佳為眯唑並吡啶基或咪唑並時!症基; Q, Y,Yf,R和id如上定義; H a 1 〇為鹵原子。 步驟A1 於步驟A 1中,式(I)化合物為藉由令式(I I I)化合物 與式(I V )化合物於鹼存在下反應而製得。 對於所使用之鹼性質並無特別限制,且任何此型反應 中所一般使用之鹼均可使用。此類鹼之實例包括:無機 鹼,例如氫化物類(如氫化銷或氳化鉀)和磺酸鹽類(如 碩酸鉀或碩酸鈉);和有機鹼,如三乙胺。 反應一般且較佳於溶劑存在下進行。對於所使用溶劑 之性質並無特別限制,只要其對反應或所使用之試劑無 不良影镗且可溶解試劑至少至某些程度。適當溶劑例包 括:烴類,其為脂族或芳香族,如苯,甲苯,二甲苯, 己烷或庚烷;醚類,如二乙醚,四氫呋喃或二鸣烷;醯 胺類,如二甲基甲醯胺,二甲基乙醯胺或六甲基磷酸三 胺;和此些溶劑之任何兩種或以上之混合物。 反應可於廣範圍之溫度下進行,且本發明並無簌定精 確的反應溫度。一般,其便於在冰冷卻至加熱,如反應 混合液之迴流溫度下進行反應,反應所霈之時間亦廣泛 -42, 本紙張尺度適用中國國家標準(CNS ) A4g ( 210X297公釐) 裝 訂 線 (請先閲讀背面之注意事項再填寫本頁) 503237 A7 B7 五、發明説明(W ) 不同,視許多因素,主要視反應溫度和所使用之試劑和 溶劑性質而定。然而,只要反應在上述之較佳條件下進 行,則〇 . 5小時至數天之時段通常足夠。 反應最佳以冷卻或加熱或室溫下,於醒胺類或至少一 種醯胺與至少一種其他有機溶劑之混合液中,氫化鈉存 在下進行1至1 Q小時。 式(I)化合物(其為以此此製備)為新穎化合物且為 製備本發明式(I I)化合物之重要中間物。 步驟A2 於步驟A 2中,式(I I)化合物為藉由下列兩方法(a )和 (b )之一而製得。 步驟A 2 ( a ) 式(11)化合物可藉由令式(I)化合物,其中Q為低 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標隼局貝工消費合作社印¾ 烷 氧 m 基 > 與 2 , 3 - 二 胺 基 吡 啶 衍 生 物 或 4 , 5- 二 胺 基 嘧 啶 衍 生 物 反 應 而 製 得 〇 於 Q 為 低 烷 氣 m 基 方 面 其 較 佳 具 有 總 計 2 至 7 値 m 原 子 (即烷氣基部分具有1 至6 値碩原子), 且 可 為 直 或 支 鐽 基 〇 此 類 基 之 例 包 括 甲 氧 m 基 乙 氣 m 基 $ 丙 氣 m 基 $ 異 丙 氣 m 基 ? 丁 氣 m 基 9 異 丁 氣 羰 基 $ 第 二 丁 氧 m 基 > 第 三 丁 氣 m 基 $ 戊 氧 m 基 異 戊 氣 m 基 9 新 戊 氣 羰 基 t 2 - 甲 基 丁 氣 m 基 » 1 - 乙 基 丙 氣 m 基 t 4 - 甲 基 戊 氣 m 基 $ 3 - 甲 氣 戊 氧 m 基 * 2 - 甲 氣 戊 氣 欺 基 $ 1 - 甲 氣 戊 氣 m 基 鬌 3 , 3 - 二 甲 氣 丁 氣 羰 基 f 2 , 2 - 二 甲 氣 丁 氣 m 基 » 1, 1 - -43- 本紙伕尺度適用中國國家標準(CNS ) Λ4現格(2丨OX 297公釐) 經齊郎中失螓隼¾員Μ消費合阼i±s-ft 503237 A7 B7 五、發明説明(^ ) 二甲氣丁氧羰基,1,2 -二甲氣丁氧羰基,1,3 -二甲氧丁 氧淚基,2, 3 -二甲氧丁氯羰基,2 -乙基丁氣羰基,己氣 羰基和異己氯羰基。其中較佳為Cl - 4烷氣羰基,以 甲氧羰基,乙氯羰基,丙氣羰基,異丙氣玻基,丁氣羰 基和異丁氣羰基為較佳,且最佳為甲氯羰基和乙氣羰基。 反應一般且較佳於溶劑存在下進行。對於所使用溶劑 之性質並無待別限制,只要其對反應或所使用之試劑無 不良影鎏且可溶解試劑至少至某些程度。適當溶劑例包 括:烴類,如苯,甲苯,二甲苯,己烷或庚烷;_類, 如二乙醚,四氫呋喃或二鸣烷;醯胺類,如二甲基甲醯 胺,二甲基乙醯胺或六甲基磷酸三胺;醇類,如甲醇, 乙醇或丁醇;酸類,如醋酸或丙酸和此些溶劑之任何兩 種或以上之混合物。 反應可於廣範圍之溫度下進行,且本發明並無嚴定精 確的反應溫度。一般,其便於在加熱反應混合液之迴流 溫度下進行反應,反應所需之時間亦廣泛不同,視許多 因素,主要視反應溫度和所使用之試劑和溶劑性質而定 。然而,只要反應在上述之較佳條件下進行,則3小時 至數天之時段通常足夠。 反應最佳於溶劑不存在下,於50°C至150°C之溫度下 加熱進行5小時至2天。 步驟A 2 ( b ) 至於另一方法,式(I I)化合物可藉由令式(I)化合 物,其中Q為甲醯基,於第一階段與2 , 3 -二胺基吡啶衍 一 44- 本紙張尺度通用中國國家標隼(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) Λ衣 訂 503237 A7 B7 五、發明説明(W ) 生物或4 ,5 -二胺基嘧啶衍生物反應,且其後於第二階段 令産物以氣化劑處理而製得。 反應一般且較佳於溶劑存在下進行。對於所使用溶劑 之性質並無特別限制,只要其對反應或所使用之試劑無 不良影嚮且可溶解試劑至少至某些程度〇適當溶劑例包 括:烴類,其可為脂族或芳香族,如苯,甲苯,二甲苯 ,己烷或庚烷;醚類,如二乙醚,四氫呋喃或二噚烷; 醯胺類,如二甲基甲醯胺,二甲基乙醯胺或六甲基磷酸 三胺;醇類,如甲醇,乙醇或異丙醇;酸類,如醋酸或 丙酸;如亞硪類,如二甲基亞as ;和此些溶劑之任何兩 種或以上之混合物。 反應可於廣範圍之溫度下進行,且本發明並無駸定精 確的反應溫度。一般,其便於在約室溫或加熱,如反應 混合液之迴流溫度下進行反應,反應所需之時間亦廣泛 不同,視許多因素,主要視反應溫度和所使用之試劑和 溶劑性質而定。然而,只要反應在上述之較佳條件下進 行,則1小時至數天之時段通常足夠。 經濟部中央標準局員工消黄合作社印製 (請先閲讀背面之注意事項再填寫本頁) 産物其後於第二階段中之氯化劑處理〇對於所使用之 氣化劑性質並無待別限制,且任何此型反應中所一般使 用之氣化劑均可使用。此類氣化劑之例包活碘,氣化銀 和四醋酸鉛,其中較佳為碘β 以氣化劑處理一般且較佳於溶劑存在中進行。對於所 使用之溶劑性質並無持別限制,只要其對反應或所使用 之試劑無不良影镨且可溶解試劑至少至某些程度。適當 -45- 本紙張尺度適用中國圈家標準(CNS ) Α4現格(2!Ο Χ2们公f > 503237 A7 B7 五、發明説明(如) 類精 _ 定 為駸 佳無 較並 , 明 劑發 溶本 之且 用, 使行 所進 中下 段度 階溫 一 之 第圍 述範 上廣 括於 包可 例應 劑反 溶 應度 反溫 0 應 應反 反視 行要 進主 下 , 熱素 加因 在多 於許 便視 其 , ,同 般不 一 泛 〇 廣 度亦 溫間 應時 反之 的需 確所 上夠 在足 應常 反通 要段 只時 ,之 而天 然數 C 至 定時 而小 質 1 性則 劑 , 溶 行 和進 劑下 試件 之條 用佳 使較 所之 和述 中 其 中 物 合 驟 步 行 進 物 合 化 令 於 化可 I)基 {護 式保 於基 醯 甲 其 基 酯 甲 護 保 被 為 除 移 以 予 前 應 反 之 括-包烷 例ffl 之二 基3-醯1, 甲 , 護基 保甲 被基 類氧 此乙 0 二 如 例 基 基 甲 基 氧 甲 基 减 2 I 烷 茂 09亏 (請先閱讀背面之注意事項再填寫本頁) 和 基 烷 茂 二 除 移 法 方 統 傳 之 7知 烷熟 ^ 0 二此 3-以 1,可 ,基 護 保 基0 Π 甲 ί 。式 基令 2-如 -例 合 化 觸1Γ 接 S 下up 件ΓΟ G 條 用ve 作ti iiec 保ot 去ΡΓ 之η: 統ee 傳Gr 於 3= 劑 T 護於 保述 去記 之已 統件 傳條 與此二 物此 & 或 中 經濟部中央橾準局貝工消費合作社印製 冬紙悵尺度過州中家梯隼《CNS ) Λ4Λ格(210X 297公釐) 503237 A7 B7 Q—(ch2)ht-yThis paper size applies to Chinese National Standard (CNS) A4 (210X297 mm) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 503237 A7 B7 V. Description of the invention () In the above formula: X is as defined above, but preferably 较佳Zolopyridyl or imidazo! Syndrome; Q, Y, Yf, R and id are as defined above; H a 10 is a halogen atom. Step A1 In step A1, the compound of formula (I) is prepared by reacting a compound of formula (I I I) with a compound of formula (IV) in the presence of a base. There are no particular restrictions on the basic nature used, and any base commonly used in this type of reaction can be used. Examples of such bases include: inorganic bases, such as hydrides (such as hydrogenated pins or potassium sulfide) and sulfonates (such as potassium or sodium sulfonate); and organic bases, such as triethylamine. The reaction is generally and preferably performed in the presence of a solvent. There is no particular limitation on the nature of the solvent used, as long as it does not adversely affect the reaction or the reagents used and can dissolve the reagents to at least some extent. Examples of suitable solvents include: hydrocarbons, which are aliphatic or aromatic, such as benzene, toluene, xylene, hexane or heptane; ethers, such as diethyl ether, tetrahydrofuran or dioxane; ammonium compounds, such as dimethyl Methylformamide, dimethylacetamide, or hexamethyltriamine phosphate; and any two or more of these solvents. The reaction can be performed at a wide range of temperatures, and the present invention does not determine the precise reaction temperature. Generally, it is convenient to carry out the reaction under ice-cooling to heating, such as the reflux temperature of the reaction mixture, and the reaction time is also extensive -42. This paper size applies to China National Standard (CNS) A4g (210X297 mm) gutter ( (Please read the notes on the back before filling this page) 503237 A7 B7 V. The description of the invention (W) is different, depending on many factors, mainly depending on the reaction temperature and the nature of the reagents and solvents used. However, as long as the reaction is performed under the above-mentioned preferred conditions, a period of from 0.5 hours to several days is usually sufficient. The reaction is best performed by cooling or heating or at room temperature in the presence of sodium hydride or a mixture of at least one amidine and at least one other organic solvent in the presence of sodium hydride for 1 to 1 hour. Compounds of formula (I), which are prepared therefrom, are novel compounds and are important intermediates in the preparation of compounds of formula (I I) of the invention. Step A2 In step A2, the compound of formula (I I) is prepared by one of the following two methods (a) and (b). Step A 2 (a) The compound of formula (11) can be obtained by making the compound of formula (I), where Q is low (please read the precautions on the back before filling out this page). Alkoxy m group> is prepared by reacting with a 2, 3-diamino pyridine derivative or a 4, 5- diamino pyrimidine derivative. It is preferred that Q has a low alkane m group with a total of 2 to 7値 m atom (that is, the alkane group has 1 to 6 fluorene atoms), and may be straight or branched. Examples of such groups include methoxym group, ethyl group, m group, propyl group, m group, and isopropyl group. m group? butane m group 9 isobutane carbonyl group second butoxy m group > third butane m group group pentoxy m group iso group m group 9 neopentyl group carbonyl t 2-methyl butane group m Radicals »1-ethylpropane m radical t 4-methylpentane m radical $ 3-methylpentanyl m radical * 2-methylpentanyl radical 1-methylpentanyl radical m 3, 3 -Dimethyl butane carbonyl f 2, 2-Dimethyl butane carbonyl m » 1, 1--43- The standard of this paper is applicable to Chinese National Standards (CNS). Λ4 is present (2 丨 OX 297mm). Lost in Qilang ¾ members M consumption combined i ± s-ft 503237 A7 B7 V. Description of the Invention (^) Dimethylbutoxycarbonyl, 1,2-dimethylbutoxycarbonyl, 1,3-dimethoxybutoxy tearyl, 2, 3-dimethoxybutoxycarbonyl, 2-ethyl Butane carbonyl, hexyl carbonyl and isohexyl chlorocarbonyl. Among them, Cl-4 alkyl carbonyl is preferred, and methoxycarbonyl, ethylchlorocarbonyl, propanecarbonyl, isopropylglass, butanecarbonyl and isobutanecarbonyl are preferred, and the most preferred are methylchlorocarbonyl and Ethyl carbonyl. The reaction is generally and preferably performed in the presence of a solvent. There is no restriction on the nature of the solvent used, as long as it does not adversely affect the reaction or the reagents used and can dissolve the reagents to at least some extent. Examples of suitable solvents include: hydrocarbons such as benzene, toluene, xylene, hexane, or heptane; solvents such as diethyl ether, tetrahydrofuran, or dioxane; ammonium solvents such as dimethylformamide, dimethyl Acetylamine or hexamethyl phosphate triamine; alcohols such as methanol, ethanol or butanol; acids such as acetic acid or propionic acid and a mixture of any two or more of these solvents. The reaction can be performed at a wide range of temperatures, and the present invention does not strictly determine the precise reaction temperature. Generally, it is convenient to carry out the reaction at the reflux temperature of the heating reaction mixture, and the time required for the reaction varies widely, depending on many factors, mainly depending on the reaction temperature and the nature of the reagents and solvents used. However, as long as the reaction is performed under the above-mentioned preferred conditions, a period of 3 hours to several days is usually sufficient. The reaction is best performed in the absence of a solvent at a temperature of 50 ° C to 150 ° C for 5 hours to 2 days. Step A 2 (b) As another method, the compound of formula (II) can be obtained by letting a compound of formula (I) wherein Q is a methyl group, in the first stage with 2, 3-diaminopyridine. The size of this paper is in accordance with the Chinese National Standard (CNS) A4 (210X297 mm) (please read the precautions on the back before filling in this page) Λ Binding 503237 A7 B7 V. Description of Invention (W) Biological or 4, 5- The diaminopyrimidine derivative is reacted, and then the product is prepared by treating the product with a gasifying agent in a second stage. The reaction is generally and preferably performed in the presence of a solvent. There is no particular limitation on the nature of the solvent used, as long as it does not adversely affect the reaction or the reagents used and can dissolve the reagents to at least some degrees. Examples of suitable solvents include: hydrocarbons, which may be aliphatic or aromatic , Such as benzene, toluene, xylene, hexane or heptane; ethers, such as diethyl ether, tetrahydrofuran or dioxane; amines, such as dimethylformamide, dimethylacetamide or hexamethyl Triamine phosphate; alcohols, such as methanol, ethanol, or isopropanol; acids, such as acetic acid or propionic acid; such as fluorene, such as dimethylimide; and a mixture of any two or more of these solvents. The reaction can be performed at a wide range of temperatures, and the present invention does not determine the precise reaction temperature. Generally, it is convenient to carry out the reaction at about room temperature or heating, such as the reflux temperature of the reaction mixture, and the time required for the reaction varies widely, depending on many factors, mainly depending on the reaction temperature and the nature of the reagents and solvents used. However, as long as the reaction proceeds under the above-mentioned preferred conditions, a period of from 1 hour to several days is usually sufficient. Printed by the Huangshuang Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the notes on the back before filling this page) The product is then treated with the chlorinating agent in the second stage. There is no difference in the nature of the gasifier used Restriction, and any gasifier commonly used in this type of reaction can be used. Examples of such gasification agents include live iodine, silver gasification, and lead tetraacetate. Of these, iodine β is generally treated with a gasification agent and is preferably performed in the presence of a solvent. There is no particular restriction on the nature of the solvent used, as long as it does not adversely affect the reaction or the reagents used and can dissolve the reagents to at least some extent. Appropriate -45- This paper size is in accordance with Chinese Standards (CNS) Α4 is present (2! 〇 χ2 公公 f > 503237 A7 B7 V. Description of the invention (such as) Category fine _ It is determined as the best combination of the best The use of the agent to dissolve the essence and use it, so that the progress of the middle and lower steps of the first paragraph of the scope of the scope is broadly included in Bao Keli, the agent should be anti-solubilizing, the temperature should be 0, and the anti-reflective line should be advanced. Resugar is considered more than it is, and it is not the same. The breadth is also the same as the time. The need to be sure is enough to meet the needs of the normal backcompass, and the natural number C is the timing. The small-scale agent, the strip and the test piece under the agent should be used to make it better than what is described in the above steps and walk into the chemical compound in the chemical I) base {Protective type in the base armor Its base ester protection is divided into two groups based on the predecessor-alkane example ffl 2-yl-1, 1, and the base protection group is based on the basic oxygen. This is the second example of the methyl methyl oxide. Base reduction of 2 I alkylene oxides (please read the precautions on the back before filling this page) and base In addition metallocene two side-shift system transfer method known in the 7 ^ 0 alkoxy two cooked at this 3-1, can, Paul protecting group A group 0 [pi ί. The formula is based on 2-such as the example of combining chemical contact 1Γ and S, and then the upper part Γ〇 G, using ve as ti iiec to protect ot to Γ η: system ee pass Gr at 3 = agent T to protect the already recorded components The sermon and this two things, or printed by the Central Bureau of quasi-Ministry of Economic Affairs of the People's Republic of China Shellfish Cooperative Co., Ltd. printed the winter paper. ch2) ht-y

N〇2 步驟B2 R 五、發明説明(^ )N〇2 Step B2 R V. Description of the invention (^)

反應流程B Q—(CH2)—Halo + HY—N02 步驟 BlReaction scheme B Q— (CH2) —Halo + HY—N02 Step Bl

(III) R (V) (VI) (請先閱讀背面之注意事項再填寫本頁)(III) R (V) (VI) (Please read the notes on the back before filling this page)

Q-(CH2)E~YQ- (CH2) E ~ Y

nh2 — 63 一 R (VII) Q—(ch2)『ynh2 — 63-R (VII) Q— (ch2) 『y

COOK -5 (VIII) R Halo’COOK -5 (VIII) R Halo ’

步驟B4 - h2n-c—nh2 Y 經濟部中央樣準局貝工消费合作社印裝 Q—(ch2)ht-yStep B4-h2n-c—nh2 Y Printed by the Shellfish Consumer Cooperative of the Central Sample Bureau of the Ministry of Economy Q— (ch2) ht-y

x-(CH2)srY 步驟B5x- (CH2) srY step B5

R rv^^NH(II) I 本紙悵尺度通用中國國家標準(CNS ) A4規格(2丨0X297公釐)-47- 503237 A7 B7 五、發明説明(^ ) 於上式中,Q,Y,Y’,lT,)(,Halo和ίο如上定義; 步驟B1 於步驟B1中,式(VI)化合物為令式(III)化合物與式 (V)化合物與鹼反應而製得。此反應基本上同於反應流 程A之步驟A 1中所述者,且可使用相同試劑和反應條件 進行。 步驟B2 於步驟B2中,式(VII)化合物為藉由還原式(VI)化合 物而製得。 反應可藉由傳統之催化性氫化作用或藉由使用任何可 還原硝基之還原劑,如鋅-醋酸或錫-氫氯酸而進行。 步驟B3 於步驟B 3中,式(V I I I)化合物為藉由令式(V I I)化合 物進行Meerwein芳基化作用反應而製得 反應所使用之條件已為熟知且為類似於日本專利公開 申請案No.照55-22657中所掲示或S.Oae等人;Bull.Chem. Soc· Japan,53, 1065(1980)所報導者。 步驟B4 經濟部中央橾隼局貝工消费合作社印«. (請先閱讀背面之注意事項再填寫本頁) 於步驟B4中,式(I)化合物為藉由令式(VIII)化合物 與P或硫P反應且其後令産物水解而製得。 此反應所使用之條件已為熟知且類似於日本專利公開 申請案No.照55-22657中所掲示者。 步驟B5 於步驟B 5中,式(I I)化合物為由化合物(I)以步驟 -48- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 503237 A 7 B7 五、發明説明( A(a)和A(b)之一所製得。此反應完金同於該些步驟所示 者且可使用相同試劑和反應條件進行。 於上述步驟中,若意欲,各步驟之産物可於各反應終 了以傳統方式自反應混合液中回收,且若需要,所得之 化合物可再以傳統方式,例如以柱層析,再結晶作用, 再沈澱作用或類似的熟知步驟予以再精製。此類技術之 一例包括:於反應混合液中加入溶劑;萃取所欲之化合 物;且最後將溶劑將溶劑由萃取物中蒸除。所得殘渣可 以經由矽膠或類似吸附劑之柱層析精製,以取得所欲之 化合物,為一精製樣品。 特定化合物(I I)之實例列於下式(I - 1)至(卜2 ): (請先閱讀背面之注意事項再填寫本頁) R X—(CH2)E—R rv ^^ NH (II) I The paper size is common Chinese National Standard (CNS) A4 specification (2 丨 0X297 mm) -47-503237 A7 B7 V. Description of the invention (^) In the above formula, Q, Y, Y ', lT,) (, Halo and ίο are as defined above; Step B1 In Step B1, the compound of formula (VI) is prepared by reacting a compound of formula (III) with a compound of formula (V) and a base. This reaction is basically It is the same as described in Step A1 of Reaction Scheme A, and can be performed using the same reagents and reaction conditions. Step B2 In Step B2, the compound of formula (VII) is prepared by reducing the compound of formula (VI). Reaction This can be carried out by conventional catalytic hydrogenation or by using any reducing agent capable of reducing nitro, such as zinc-acetic acid or tin-hydrochloric acid. Step B3 In step B 3, the compound of formula (VIII) is borrowed The conditions for preparing the reaction by subjecting the compound of formula (VII) to a Meerwein arylation reaction are well known and similar to those shown in Japanese Patent Laid-open Application No. 55-22657 or S. Oae et al .; Reported by Bull.Chem. Soc. Japan, 53, 1065 (1980). Step B4. Fei Cooperative Press «. (Please read the notes on the back before filling this page) In step B4, the compound of formula (I) is obtained by reacting a compound of formula (VIII) with P or sulfur P and then hydrolyzing the product. The conditions used in this reaction are well known and similar to those shown in Japanese Patent Laid-Open Application No. 55-22657. Step B5 In step B5, the compound of formula (II) is derived from compound (I) Step-48- This paper size is made according to the Chinese National Standard (CNS) A4 specification (210X297 mm) 503237 A 7 B7 V. Illustrated invention (A (a) and A (b)). This reaction is complete In the above steps, the same reagents and reaction conditions can be used. In the above steps, if desired, the products of each step can be recovered from the reaction mixture in a conventional manner at the end of each reaction, and if necessary, the obtained The compounds can be refined in conventional ways, such as by column chromatography, recrystallization, reprecipitation, or similar well-known procedures. An example of such techniques includes: adding a solvent to the reaction mixture; extracting the desired compound ; And will eventually dissolve The solvent removes the solvent from the extract. The obtained residue can be purified by silica gel or similar adsorbent column chromatography to obtain the desired compound as a purified sample. Examples of the specific compound (II) are listed in the following formula (I -1) to (Bu 2): (Please read the notes on the back before filling this page) RX— (CH2) E—

(1-1) 經濟部中央標準局員工消費合、\ R X—(ch2)—(1-1) Consumption of employees of the Central Bureau of Standards of the Ministry of Economic Affairs, \ R X— (ch2) —

(1-2) -49- •尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 503237 A7 B7 五、發明説明() 中- I 式ί 上式: 於於寫 關縮 表 於 義 定 -ο 0 分 基 代 取 表 關 為 式 為列 1下 表用 ,使 0 0 中 中表 2於 基 基基丁 基基 醯基丁三基基基基基丙is 乙丁 異第苄乙甲苯丙異丙 I---------0—^-- (請先閲讀背面之注意事項再填寫本頁) 訂(1-2) -49- • The dimensions are applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 503237 A7 B7 V. Description of the invention () Chinese-I Formula 上 The above formula: Yu Yu Guan Guan Yu Yu Yu Ding- ο 0 Substitute the table for the formula is listed in the following table 1, so that 0 in the table 2 is based on butyl butyl fluorenyl butyl triyl propyl propyl is ethyl isobutyl benzyl ethyl toluene Isopropyl I --------- 0 — ^-(Please read the notes on the back before filling this page) Order

II 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 503237II Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs This paper is sized to the Chinese National Standard (CNS) Α4 (210X297 mm) 503237

A B 經濟部中央標準局員工消費合作社印製A B Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs

(請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 503237(Please read the precautions on the back before filling this page) This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) 503237

A B7 明説明發 %五 續 /IV 1X表 經濟部中央樣隼局貝工消費合作社印«-A B7 Explanatory Note% Five Continued / IV 1X Form Printed by the Shellfish Consumer Cooperative of the Central Sample Bureau of the Ministry of Economic Affairs «-

(請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國固家標準《CNS ) Λ4規格(2丨0X297公釐) «52- 503237 A7 B7 五、發明説明U4 ) 表1 (續) -1聲乎_ t黎务**口竭C肖tv*拿Jtpi 编號 X Y m R 1-16 λβ o I II 1-17 Me Me s 4 Cl 1-18 _/ Me o 3 OH 1-19 Βκγ^\ / 1 Me s 2 Bu 1-20 Br\^\ / XX/ 0 5 H 1-21 H〇Y^\ / iBu 0 1 H 1-22 0 1 H 本紙張尺度適州中國®家標隼(CNS)AOl格(2丨OX 297公慶) -53- (請先閱讀背面之注意事項再填寫本頁) 503237(Please read the precautions on the back before filling this page) This paper size applies the Chinese solid standard "CNS" Λ4 specification (2 丨 0X297 mm) «52- 503237 A7 B7 V. Description of the invention U4) Table 1 (continued) -1 sound _ t Li Wu ** mouth exhaustion C Xiao tv * take Jtpi number XY m R 1-16 λβ o I II 1-17 Me Me s 4 Cl 1-18 _ / Me o 3 OH 1-19 Βκγ ^ \ / 1 Me s 2 Bu 1-20 Br \ ^ \ / XX / 0 5 H 1-21 H〇Y ^ \ / iBu 0 1 H 1-22 0 1 H隼 (CNS) AOl (2 丨 OX 297 public holiday) -53- (Please read the precautions on the back before filling this page) 503237

AA

7 B 五、發明説明(4Λ ) 表1 (續) 經濟部中央標隼局員工消費合作社印¾ 编號 X Υ m R 1-23 clxCTi 1 Me υ 1 !1 1-24 ΗΟγ^χ—— 人 1 Me 0 1 H 1-25 0 1 H 1-26 0 1 H 1-27 1 〇2Νγ^—_1 Χλλ 0 1 H 1-28 1 Me 0 1 H 1-29 Χλλ 0 I H 本紙悵尺度適州中國國家標隼(CNSM4現格< 210/ 297公簸) (請先閲讀背面之注意事項再填寫本頁) -54- 503237 五、發明説明(“) 表1 (續) c M*AT P £ 卩見 编號 X Y ni R 1-30 AcHNN^n ΧλΛ Me 0 1 li 1-31 〇丄^ I Rt 0 1 H 1-32 Η υ^Λ 1 Me 0 1 H 1-33 Η Βιι-ίίί 丫、 人 i Me 0 1 H 1-34 Me Bz_N\r^\ 人 1 Me 0 1 H 1-35 H P」丫、 1 Me 0 1 H 本紙張尺度4川中《Μ家螵隼(CNS ) Λ4規格(2丨OX 2们公釐) (請先閲讀背面之注意事項再填寫本頁)7 B V. Description of the invention (4Λ) Table 1 (continued) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs ¾ No. X Υ m R 1-23 clxCTi 1 Me υ 1! 1 1-24 ΗΟγ ^ χ—— person 1 Me 0 1 H 1-25 0 1 H 1-26 0 1 H 1-27 1 〇2Νγ ^ —_ 1 AXλλ 0 1 H 1-28 1 Me 0 1 H 1-29 AXλλ 0 IH National Standards (CNSM4 is now < 210/297). (Please read the precautions on the back before filling out this page.) -54- 503237 5. Description of the invention (“) Table 1 (continued) c M * AT P £卩 See number XY ni R 1-30 AcHNN ^ n χλΛ Me 0 1 li 1-31 〇 丄 ^ I Rt 0 1 H 1-32 Η υ ^ Λ 1 Me 0 1 H 1-33 Η Βιι-ίί Human i Me 0 1 H 1-34 Me Bz_N \ r ^ \ Human 1 Me 0 1 H 1-35 HP "Ah, 1 Me 0 1 H Paper size 4 Chuanzhong" M 家 螵 隼 (CNS) Λ4 Specification (2丨 OX 2mm) (Please read the notes on the back before filling in this page)

,tT 503237 A7 B7 五、發明説明U〇 表1 (續), TT 503237 A7 B7 V. Description of invention U〇 Table 1 (continued)

經濟部中夹樣隼馬員X消費合作社印U 編號 X Y m R 1-36 ACHNY^s 1 Η s 2 Me 1-37 °'""to 1 Πυ o Λ NieO 1-38 Cl X 1 Me 0 1 H 1-39 ,OMe 人 1 Me 0 1 H 1-40 _ 人 1 Me 0 l H 1-41 ! Et 0 2 Cl M2 1 Me 0 1 H 本紙张尺度通州中國國家標隼(CNS ) Λ4規格(210X297公釐) -56" (請先閱讀背面之注意事項再填寫本頁) 503237In the Ministry of Economy, the sample horseman X consumer cooperative seal U number XY m R 1-36 ACHNY ^ s 1 Η s 2 Me 1-37 ° '" " to 1 Πυ o Λ NieO 1-38 Cl X 1 Me 0 1 H 1-39, OMe person 1 Me 0 1 H 1-40 _ person 1 Me 0 l H 1-41! Et 0 2 Cl M2 1 Me 0 1 H This paper size Tongzhou China National Standard (CNS) Λ4 Specifications (210X297 mm) -56 " (Please read the precautions on the back before filling this page) 503237

T B 五、發明説明() 表1 (續) 經濟部中央樣隼局員工消費合作社印裝 编號 X Y IU \\ 1-43 Me〇^\ Me0^S 人 Me 0 4 H 1-44 〇 1 人 MeO Η s I li 1-45 ΌΦ A 0 1 H 1-46 Όφ Me 0 l H 1-47 /丨1 Bu 0 2 H 1-48 s 1 Me 1-49 xt? 山e 0 4 Me 本紙張尺度適用中國國家標隼(CNS ) A4«L格(210X297公釐) -57- (請先閱讀背面之注意事項再填寫本頁) 503237 A7 B7 五、發明説明(4S ) 表1 (續) 經濟部中央標隼局貝工消资合作社印» 編就 X Y m R 1-50 Λ 1 Η 0 1 H 1-51 Λ 1 Me o 1 \ H 1-52 0 i Me 0 2 H 1-53 rS 1 iPr 0 2 Me 1-54 rVi Bu s 3 H 1-55 0 1 Me 0 I McO 本紙張尺度通用中國國家標率(CNS)A4At格(2丨〇/ 297公缝) -58- (請先閱讀背面之注意事項再填寫本頁) 503237 A7 B7 五、發明説明卜9 ) 表1 (續) 編號 X Y m R 1-56 Λ~ί ώβ s 1 H 1-57 Or1 1 ο 2 H 1-58 Me0x<^N w 1 0 4 Me 1-59 _ 0 1 H 1-60 i^sN_ 人 1 H 0 2 H 1-61 〇Λ s 3 H 1-62 0 1 H 表紙张尺度遢用中國«家標準(CNS ) A4現格(2丨0X297公釐) -59- (請先閲讀背面之注意事項再填寫本頁) I裝- 訂 503237 A7 B7 五、發明説明(⑺) 表1 (績) 經濟部中央標率局員工消費合作社印¾ 編烷 X Y ni R 1-63 [^Χ_ 1 Me 0 2 H 1-64 1 Me o !f 1-65 _ 1 Me s l H 1-66 1 Et 0 1 H 1-67 _ 人 1 Pr 0 2 MeO 1-68 _ 1 Bu 0 I H 1-69 _ 1 Me s . 5 H 本紙張尺度適用中國《家標隼(CNS)A4規格(2丨〇犬297公釐) -60- (請先閱讀背面之注意事項再填寫本頁)TB V. Description of the invention () Table 1 (continued) Printing Co., Ltd. of the Consumer Cooperatives of the Central Sample Bureau of the Ministry of Economic Affairs XY IU \\ 1-43 Me〇 ^ \ Me0 ^ S people Me 0 4 H 1-44 〇1 people MeO s s I li 1-45 ΌΦ A 0 1 H 1-46 Όφ Me 0 l H 1-47 / 丨 1 Bu 0 2 H 1-48 s 1 Me 1-49 xt? Mountain e 0 4 Me paper size Applicable to China National Standards (CNS) A4 «L (210X297mm) -57- (Please read the notes on the back before filling out this page) 503237 A7 B7 V. Description of Invention (4S) Table 1 (Continued) Ministry of Economic Affairs Printed by the Central Bureau of Standards and Industry Cooperatives »Edited XY m R 1-50 Λ 1 Η 0 1 H 1-51 Λ 1 Me o 1 \ H 1-52 0 i Me 0 2 H 1-53 rS 1 iPr 0 2 Me 1-54 rVi Bu s 3 H 1-55 0 1 Me 0 I McO The paper size is common Chinese National Standard (CNS) A4At grid (2 丨 〇 / 297 cm) -58- (Please read the back first Please note this page and fill in this page again) 503237 A7 B7 V. Description of invention 9) Table 1 (continued) No. XY m R 1-56 Λ ~ ί ώ β s 1 H 1-57 Or1 1 ο 2 H 1-58 Me0x < ^ N w 1 0 4 Me 1-59 _ 0 1 H 1-60 i ^ sN_ person 1 H 0 2 H 1-61 〇Λ s 3 H 1-62 0 1 H遢 Use Chinese «Home Standard (CNS) A4 (2 丨 0X297mm) -59- (Please read the precautions on the back before filling out this page) I Pack-Order 503237 A7 B7 V. Description of Invention (⑺) Form 1 (Performance) Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs ¾ Nitrile XY ni R 1-63 [^ × _ 1 Me 0 2 H 1-64 1 Me o! F 1-65 _ 1 Me sl H 1-66 1 Et 0 1 H 1-67 _ person 1 Pr 0 2 MeO 1-68 _ 1 Bu 0 IH 1-69 _ 1 Me s. 5 H This paper size applies to China's "House Standard 隼 (CNS) A4 Specification (2 丨〇 Dog 297 mm) -60- (Please read the precautions on the back before filling in this page)

、1T 503237 A7 B7 五、發明説明(d )1T 503237 A7 B7 V. Description of the invention (d)

績 C -1 ; 表I 經濟部中夹懞隼馬員工消費合作it印«.Achievements C -1; Table I Consumption Cooperation between Mongolian and Mongolian Employees in the Ministry of Economic Affairs

e (請先閲讀背面之注意事項再填寫本頁)e (Please read the notes on the back before filling this page)

,1T 503237 A7 B7 五、發明説明( r>, 1T 503237 A7 B7 V. Description of the invention (r >

續 C 1表I 經濟部中夹標隼局員工消費合作社印裝Continued C 1 Form I Printed by the Ministry of Economic Affairs' Consumer Cooperatives

(請先閱讀背面之注意事項再填寫本頁) Λ衣· 訂 503237 A7 B7 五、發明説明(以 績 Γν 1 表(Please read the precautions on the back before filling out this page) Λ Clothing · Order 503237 A7 B7 V. Description of the invention (with Γν 1 table

木紙張尺度適州中國國家標率(CNS ) Λ4規格(2丨0X297公釐) (請先閲讀背面之注意事項再填寫本頁) ¥ 訂 -63- 503237 A7 B7 五、發明説明(w) 表1 (續) 經濟部中央標準局員工消費合作社印«.Wood Paper Standards Shizhou China National Standards (CNS) Λ4 Specification (2 丨 0X297mm) (Please read the precautions on the back before filling this page) ¥ Order-63- 503237 A7 B7 V. Description of Invention (w) Form 1 (continued) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs «.

(請先閲讀背面之注意事項再填寫本頁) ._年(Please read the notes on the back before filling this page) ._year

、tT -64- 503237 ( Μ Β 五、發明説明(β) 表1, TT -64- 503237 (Μ Β V. Description of the invention (β) Table 1

續 CContinued C

X γ m-X γ m-

IR 1-103IR 1-103

NN

I Me ο 2I Me ο 2

H 1-104H 1-104

NN

-N ο 2 Η N- 1-105-N ο 2 Η N- 1-105

NN

-N ο 4 Π N- (請先閱讀背面之注意事項再填寫本頁) 1-106 N- ΊΤ ο Η 1-107-N ο 4 Π N- (Please read the notes on the back before filling this page) 1-106 N- ΊΤ ο Η 1-107

CU ο 2 ΙΗ [-108CU ο 2 ΙΗ [-108

ο Η [-109ο Η [-109

S Η 經濟部中央樣隼局員工消費合作社印ft 1-110 .111S 印 Consumer Cooperative Cooperatives, Central Provincial Bureau of Economic Affairs, Ministry of Economic Affairs ft 1-110 .111

CkN^N- ο ο 本紙译避用中國國名择於(CNS) Α4坭格(2丨0X297公釐) -65« Η Η 503237 A7 B7 五、發明説明(H ) 表1 (續) x y m r 編號 «5C-- (請先閲讀背面之注意事項再填寫本頁)CkN ^ N- ο ο Chinese translation of this paper avoids the use of Chinese country names (CNS) Α4 坭 格 (2 丨 0X297mm) -65 «Η Η 503237 A7 B7 V. Description of the invention (H) Table 1 (continued) xymr number «5C-- (Please read the notes on the back before filling out this page)

1-116 N-1-116 N-

N MeN Me

O Η 1-117 sO Η 1-117 s

HH

N Me 1-118N Me 1-118

A N-A N-

OO

H 經濟部中央樣準局員工消費合作社印裝 fcN- 1-119 [-120 N.H Printed by the Consumer Cooperatives of the Central Procurement Bureau of the Ministry of Economy fcN- 1-119 [-120 N.

II

OO

Me N-Me N-

N EtN Et

OO

MeOMeO

-66- 本紙張尺度適用中國國家標隼(CNS ) Λ4現格(2丨〇〆297公釐) 4 503237 A7 B7 編號 X Y m R M21 CXX k 0 1 H 1-122 Γ^Ίΐ—Ν, 人Ν人 0 1 H 1-123 ζχχ Me 0 3 H 1-124 Me Γ^Γ——N 义N人 άβ 0 1 H 1-125 0 1 H 1-126 Γ^Ί~N, c丨人人人 0 1 H 1-127 j〇n c丨八V人 Ph 0 3 H 1-128 /νχ 8入A Me 0 1 H 本紙承尺/t適用t國國多气準(CNS ) Λ4規格(2丨0><297公釐) (請先閲讀背面之注意事項再填寫本頁) 、1Τ -67- 503237 A7 B7 五、發明説明(β ) 表1 (續)-66- The size of this paper is applicable to Chinese National Standards (CNS) Λ4 is present (2 丨 〇〆297 mm) 4 503237 A7 B7 No. XY m R M21 CXX k 0 1 H 1-122 Γ ^ Ίΐ—Ν, person Ν 人 0 1 H 1-123 ζχχ Me 0 3 H 1-124 Me Γ ^ Γ——N 义 N 人 άβ 0 1 H 1-125 0 1 H 1-126 Γ ^ Ί ~ N, c 丨 everyone 0 1 H 1-127 j〇nc 丨 Eight V people Ph 0 3 H 1-128 / νχ 8 into A Me 0 1 H Paper ruler / t Applicable t country multinational standard (CNS) Λ4 specification (2 丨 0 > < 297 mm) (Please read the notes on the back before filling out this page), 1T -67- 503237 A7 B7 V. Description of the invention (β) Table 1 (continued)

Me -----------#篆-- (請先閱讀背面之注意事項再填寫本頁) M31 1-132 1-133Me ----------- # 篆-(Please read the notes on the back before filling this page) M31 1-132 1-133

Ν Ν I Βζ •ΝΝ Ν I Βζ • Ν

Ο Ο Ο 4 Η Η Η ΊΤ 經濟部中央標隼局貝工消費合作社印装 1-134 1-135Ο Ο Ο 4 Η Η Η ΊΤ Printed by Shellfish Consumer Cooperative, Central Bureau of Standards, Ministry of Economic Affairs 1-134 1-135

Ο Ο 本紙張尺度適中國阎家標率(CNS ) Λ4規格(2Ι〇κ 297公釐) Η Η 503237〇 〇 This paper is suitable for China Yanjia Standard (CNS) Λ4 size (2Ι〇κ 297mm) Η Η 503237

A 7 Β 五 .、發明説明(η ) 表1 ( 績 χ γ m-A 7 Β V. Description of the invention (η) Table 1 (Performance χ γ m-

R .136R .136

Ν Ν I β-PhBzΝ Ν I β-PhBz

ο .137 [-138 1-139 1-140 [-141 1-142ο .137 [-138 1-139 1-140 [-141 1-142

BrBr

Ν ΝI Ph -ΝΝ ΝI Ph -Ν

Ν-I MeΝ-I Me

-Ν Λ X Λ MeO Ν ΝI Me-Ν Λ X Λ MeO Ν ΝI Me

ο Η Η (請先閱讀背面之注意事項再填寫本頁) -裝 訂ο Η Η (Please read the notes on the back before filling this page)-Binding

S ο ο ο Η Η Η 本紙張尺度適用中國國家標率(CNS > Λ4現格(2丨OX 297公釐) - 69- 503237 Α7 Β7 五、發明説明 表1 (續) 编號 1-143 1-144 1-145 [-146 .147S ο ο ο Η Η Η This paper size is applicable to China's national standard (CNS > Λ4 spot (2 丨 OX 297 mm)-69- 503237 Α7 Β7 V. Description of the invention Table 1 (continued) No. 1-143 1-144 1-145 [-146 .147

XX

Y mY m

RR

MeOMeO

McOMcO

MeOMeO

MeOMeO

MeOMeO

Ο Ο Π Η Η Η Η 經濟部t夹樣隼局員工消費合作枝印裝Ο Ο Π Η Η Η Η 消费 The Ministry of Economic Affairs t-clip sample bureau staff consumption cooperation printing

冬紙张尺度適用中國國家標率(CNS>M此格(2Ιϋκ 297公楚) 503237 A7 B7 五、發明説明(“ 表1 (績) 编竑The winter paper scale is applicable to China's national standard (CNS > M this grid (2Ιϋκ 297)) 503237 A7 B7 V. Description of the invention ("Table 1 (achievement)

XX

Y m-Y m-

R 1-150 1-151R 1-150 1-151

Me o Η [-152Me o Η [-152

Mxc m-cikMxc m-cik

o Η (請先閱讀背面之注意事項再填寫本頁) 裝· [-153o Η (Please read the precautions on the back before filling out this page) 装 · [-153

o Η 訂 1-154 -N ho人人N人 I Eto 订 Order 1-154 -N ho Renren Nren I Et

o Η 1-155 竣齊郎4-矢舔隼¾員.11¾費合咋fl.中装 .156 •157o Η 1-155 Jun Jilang 4-ya licking 隼 members. 11 ¾ fee together 咋 fl. Medium. 156 • 157

-N N I Bz-N N I Bz

o o Η Ηo o Η Η

-N-N

N I MeN I Me

〇A 3 Η 表紙张尺度適用 國國家標隼(CNS } Λ4坭格(210X297公缝) 503237 A7 B7 五、發明説明(k ) 73 表1 (續) 經濟部+夬樣隼垮員-1:省费含咋^¥&〇A 3 Η The paper size of the table is applicable to the national standard of the country (CNS) Λ4 grid (210X297 cm) 503237 A7 B7 V. Description of the invention (k) 73 Table 1 (continued) Ministry of Economic Affairs + Samples: -1: Savings include 咋 ^ ¥ &

-72 - 本紙張尺度適;Π中國國家標隼(CNS)A4現格(210X297公釐) 503237 A7 B7 五、發明説明(Η ) 表1 (續) 編號 X Y m R M65 o ! II 1-166 —θα o-Me^h o 1 H M67 J 0 m- -N 1 -CIPh 0 3 H ~ M68 MeO〆 0 rrhN ie〇k 0 1 H 1-169 Me、 HO^ U -N 山e 0 1 H 1-170 Xj MeO N -N 、N人 0 i H 1-171 0 -N 0 2 H -73- (請先閱讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國®家標率(CNS)A4現格(2丨0X297公釐) 503237 A7 B7 五、發明説明(W ) 表1 (續) 經濟部中央樣隼局員工消費合作社印«.-72-The size of this paper is suitable; Π Chinese National Standard (CNS) A4 is now available (210X297 mm) 503237 A7 B7 V. Description of the invention (Η) Table 1 (continued) No. XY m R M65 o! II 1-166 --Θα o-Me ^ ho 1 H M67 J 0 m- -N 1 -CIPh 0 3 H ~ M68 MeO〆0 rrhN ie〇k 0 1 H 1-169 Me, HO ^ U -N mountain e 0 1 H 1 -170 Xj MeO N -N, N people 0 i H 1-171 0 -N 0 2 H -73- (Please read the precautions on the back before filling this page) The paper size of the paper is applicable to China® house standard rate (CNS ) A4 is now available (2 丨 0X297 mm) 503237 A7 B7 V. Description of invention (W) Table 1 (continued) Printed by the Consumers' Cooperative of the Central Bureau of Samples of the Ministry of Economic Affairs «.

本紙悵尺度適用中國《家螵隼(CNS > A4現格(2丨OX297公釐) 503237 ¾濟郎中夬懞隼馬員x-消费合阼it印获 A7 B7 五、發明説明(V ) 表1 (續) >ft^b 編踗 X Y m R 1-179 Ph人人N人 1 Me o ! u 1-180 jf)7l 1 Me 0 3 H 1-181 tBu -N HO—^ S入 N 人IJi 人^ )~^ Me tBu 0 1 H 1-182 I Me 0 1 H 1-183 -N iPK)人人N々 _ 1 Me 0 1 H 1-184 MeO χ. 1 Me 0 1 H 1-185 1 Me 0 1 H -75 - (請先閲讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國®家標隼(CNS ) Λ4坭格(210X 297公釐) 503237 A7 B7 五、發明説明(W ) 表I (續) 經濟部中央標隼局貝工消費合作社印装The size of this paper is applicable to China's "Home furniture (CNS > A4 present grid (2 丨 OX297 mm) 503237 ¾ Jilang Zhongmeng Mongolian horseman x-consumption combination it printed A7 B7 V. Description of invention (V) 1 (continued) > ft ^ b Edit XY m R 1-179 Ph Renren N Ren 1 Me o! U 1-180 jf) 7l 1 Me 0 3 H 1-181 tBu -N HO— ^ S 入 N Human IJi Human ^) ~ ^ Me tBu 0 1 H 1-182 I Me 0 1 H 1-183 -N iPK) Ren Ren N々_ 1 Me 0 1 H 1-184 MeO χ. 1 Me 0 1 H 1- 185 1 Me 0 1 H -75-(Please read the notes on the back before filling in this page) The size of the paper used in this edition is China® House Standard (CNS) Λ4 grid (210X 297 mm) 503237 A7 B7 V. Invention Explanation (W) Table I (continued) Printed by Shellfish Consumer Cooperatives, Central Bureau of Standards, Ministry of Economic Affairs

-76· (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標隼(CNS)A4現格(2丨0X297公釐) 503237 A7 B7 五、發明説明(W ) 表1 (續)-76 · (Please read the notes on the back before filling this page) This paper size is applicable to China National Standard (CNS) A4 (2 丨 0X297 mm) 503237 A7 B7 V. Description of the invention (W) Table 1 ( Continued)

(請先閱讀背面之注意事項再填寫本頁) -77- 503237 A7 _B7_ 五、發明説明Uif ) 表1 (續) 經濟部中央樣隼馬員X消費合泎社印«.(Please read the precautions on the back before filling out this page) -77- 503237 A7 _B7_ V. Description of Invention Uif) Table 1 (continued) Printed by the Central Sample Horseman X Consumer Union of the Ministry of Economic Affairs «.

(請先閱讀背面之注意事項再填寫本頁) •笨. 訂 本紙張尺度適用中國®家標率(CNS > Λ4現格(210X297公釐) 503237 A7 B7 五、發明説明(Μ ) 表1 (續)(Please read the precautions on the back before filling this page) • Stupid. The paper size of the book is applicable to the China® house standard rate (CNS > Λ4 is now (210X297 mm) 503237 A7 B7 V. Description of the invention (Μ) Table 1 (Continued)

XX

Y mY m

R 1-206R 1-206

BuCONH -----n Βυ \\ 1-207 Η/ί)BuCONH ----- n Βυ \\ 1-207 Η / ί)

Η 1-208 ΒζΟΗ 1-208 ΒζΟ

Η (請先閲讀背面之注意事項再填寫本頁) Λ衣 09 -2Η (Please read the precautions on the back before filling this page) Λ 衣 09 -2

Η 2 Η 訂 ο -2Η 2 Η Order ο -2

Ν—Η ΟΗ 2 Η -2 經濟邦中夹樣隼馬貝工消費合作江印*.Ν—Η ΟΗ 2 Η -2 Jiangyin, a kind of consumption cooperation between Jiangbei and Mabei in the economic state *.

νιπμμ^νιπμμ ^

h NIPh NIP

OF 2 ΗOF 2 Η

表紙張尺度適用中國®家標準(CNS)A4規格(210X 297公缝) 503237 A7 B7 五、發明説明(m 表1 (續) ηThe paper size of the table is applicable to China® Home Standard (CNS) A4 specification (210X 297 cm) 503237 A7 B7 V. Description of the invention (m Table 1 (continued) η

1-215 1-216 1-217 1-2181-215 1-216 1-217 1-218

X mlX ml

RR

Ν J N \sBuI BzΝ J N \ sBuI Bz

tBuNHtBuNH

-NA A Λ tBuNH Ν N " I-NA A Λ tBuNH Ν N " I

Pr ο 2 (請先閱讀背面之注意事項再填寫本頁) ,裝‘ 0Pr ο 2 (Please read the notes on the back before filling this page), install ‘0

HH

H 訂H order

—N—N

Me ΟMe Ο

H Η 經濟部中央標隼局員工消費合作社印装H 印 Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs

MeMe

-Ν 、Ν-I Me 1-219-N, Ν-I Me 1-219

MeMe

、Ν mClPh Ο Η 本紙張尺度適用中國國家標隼(CNS ) Λ4規格(2丨0X297公釐) -80_ 503237 A7 _B7 五、發明説明(V ) 表1 (績)、 Ν mClPh 〇 Η This paper size is applicable to China National Standard (CNS) Λ4 specification (2 丨 0X297 mm) -80_ 503237 A7 _B7 V. Description of invention (V) Table 1 (Performance)

(請先閲讀背面之注意事項再填寫本頁)(Please read the notes on the back before filling this page)

—0 -項再填A 一衣- 訂 本紙張尺度適用中國«家櫺率(CNSM4規格(2丨0X297公釐) 503237 A7 B7 五、發明説明(^ ) 表2 經濟部中央樣準局員工消費合作社印¾ 编號 X Υ m R 2-1 CU 1 0 2 H 2-2 丨1丨 0 一 2 H 2-3 r^/CPh3 1 ϋ 2 H 2-4 0 2 H 2-5 0 1 H 2-6 ώβ 0 1 H 2-7 ώβ 0 2 H 2-8 Co. & 0 I H 本紙張尺度適用中國《家橾率(CNS ) Λ4現格(210 X297公釐) >82~ (請先閲讀背面之注意事項再填寫本頁) .-衣· 訂 503237 A7 B7 五、發明説明(τ〇 經濟部中央樣隼局員工消費合作社印¾ 表2 (續) 編號 X Y m R 2-9 Cc/ Ο .1 11 2-10 0 1 Η 2-11 W ώβ 0 5 Me 2-12 / iPr S 1 Η 2-13 丨’ Me 0 2 MeO 2-14 υψ Me 0 1 Η 2-15 η°υ^ί / Et 0 1 Η 3 8 (請先閱讀背面之注意事項再填寫本頁) :Ε_ 訂 本紙張尺度適用中國國家標隼(CNS ) Λ4現格(2丨0X297公釐) 503237 A7 B7 五、發明説明(Μ ) 表2 (續) 經濟部中央樣隼局員工消費合作社印¾ 编號 X Y in R 2-16 Πυ〇^^ / Ogi 1 Me Ο 1 II 2-17 Me Me Me s 4 Cl 2-18 __/ 0 3 OH 2-19 s 2 Bu 2-20 Xv 0 5 H 2-21 H0^\ / iBu 0 1 H 2-22 ΧλΛ 0 1 H 本紙張尺度適用中國國家標隼(CNS ) Λ4規格(2丨0X297公釐) -84- (請先閱讀背面之注意事項再填寫本頁)—0-Refill A with one item-The size of the paper is applicable to China's furniture ratio (CNSM4 specification (2 丨 0X297mm) 503237 A7 B7 V. Description of the invention (^) Table 2 Employee consumption of the Central Procurement Bureau of the Ministry of Economic Affairs Co-operative seal ¾ No. X Υ m R 2-1 CU 1 0 2 H 2-2 丨 1 丨 0-2 H 2-3 r ^ / CPh3 1 ϋ 2 H 2-4 0 2 H 2-5 0 1 H 2-6 FREE β 0 1 H 2-7 FREE β 0 2 H 2-8 Co. & 0 IH This paper size is applicable to China's "Furniture Ratio (CNS) Λ4 Appearance (210 X297 mm) > 82 ~ (Please Read the notes on the back before filling in this page.)-Clothes · Order 503237 A7 B7 V. Description of the invention (τ〇 Printed by the Consumer Cooperatives of the Central Sample Bureau of the Ministry of Economy ¾ Table 2 (Continued) No. XY m R 2-9 Cc / 〇 .1 11 2-10 0 1 Η 2-11 W FREE β 0 5 Me 2-12 / iPr S 1 Η 2-13 丨 'Me 0 2 MeO 2-14 υψ Me 0 1 Η 2-15 η ° υ ^ ί / Et 0 1 Η 3 8 (Please read the notes on the back before filling in this page): Ε_ The size of the paper is applicable to the Chinese national standard (CNS) Λ4 now (2 丨 0X297 mm) 503237 A7 B7 5 2. Description of invention (Μ) Table 2 (continued) Printed by the company ¾ No. XY in R 2-16 Πυ〇 ^^ / Ogi 1 Me Ο 1 II 2-17 Me Me Me s 4 Cl 2-18 __ / 0 3 OH 2-19 s 2 Bu 2-20 Xv 0 5 H 2-21 H0 ^ \ / iBu 0 1 H 2-22 ΧλΛ 0 1 H This paper size applies to China National Standard (CNS) Λ4 specification (2 丨 0X297 mm) -84- (Please read the back (Please fill in this page again)

、1T 503237, 1T 503237

經濟郎申失4|赛垮員11肖费合咋f±.¥it 五、發明説明(^) 表2 (續) 编號 X Y m R 2-23 1 Me o 1 It 2-24 人 1 Me 0 1 H 2-25 1 Me 0 i H 2-26 ΒΓνυ^ί I Me 0 1 H 2-27 T i i 1 Et 0 l H 2«28 1 Me 0 1 H 2-29 h2n^. 1 Me 0 l H -85_ (請先閱讀背面之注意事項再填寫本頁) 本紙恨尺度適用中國國家標隼(CNS ) Λ4現格(2丨0X297公釐) 503237 A7 B7 五、發明説明(4 ) 表2 (靖) 經濟部中央標窣局貝工消費合作社印*- 编號 X Υ ιπ R 2-30 AcHN、^s XXx Me ο t II 2-31 ο 1 Η 2-32 Me2N^^\ ΧλΛ 0 ι Η 2-33 Η * Bu—丨 ΧΧ\ 0 1 Η 2-34 Me ΧλΛ 0 1 Η 2-35 Η Ph—山 ΧλΛ 0 1 Η -86- (請先閲讀背面之注意事項再填寫本頁) 本紙张尺度適用中《國家標窣(CNS>A4現格(2丨0X 297公康) 503237 Α7 Β7 五、發明説明() 經濟部中央樣隼局員工消费合作社印¾ 表2 (續) 编號 X Y m R 2-36 AcNH^\ s 2 Me 2-37 ι 0 4 MeO 2-38 L 0 1 H 2-39 ,OMe 1 tBu 0 1 H 2-40 L 0 1 H 2-41 jOl火 c丨人乂7人 Et 0 2 Ci 2-42 jOl火 Me0人^人 Me 0 1 H 本紙伕尺度通用中國國家標隼(CNS> A4規格(210Χ 297公釐) -87« (請先閱讀背面之注意事項再填寫本頁)Keijiro loses 4 | Matches 11 Shao Fei combined f ±. ¥ it V. Description of the invention (^) Table 2 (continued) Number XY m R 2-23 1 Me o 1 It 2-24 people 1 Me 0 1 H 2-25 1 Me 0 i H 2-26 ΒΓνυ ^ ί I Me 0 1 H 2-27 T ii 1 Et 0 l H 2 «28 1 Me 0 1 H 2-29 h2n ^. 1 Me 0 l H -85_ (Please read the precautions on the back before filling this page) This paper applies Chinese National Standards (CNS) Λ4 Appearance (2 丨 0X297 mm) 503237 A7 B7 V. Description of Invention (4) Table 2 ( Jing) Printed by the Shellfish Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs *-No. X Υ ιπ R 2-30 AcHN, ^ s XXx Me ο t II 2-31 ο 1 Η 2-32 Me2N ^^ \ χλΛ 0 ι Η 2-33 Η * Bu— 丨 Χ × \ 0 1 Η 2-34 Me ΧλΛ 0 1 Η 2-35 Η Ph— 山 ΧλΛ 0 1 Η -86- (Please read the precautions on the back before filling this page) This paper In the standard application, "National Standard (CNS > A4 is now available (2 丨 0X 297 public health) 503237 Α7 Β7 V. Description of the invention () Printed by the Consumer Cooperatives of the Central Procurement Bureau of the Ministry of Economic Affairs. 2-36 AcNH ^ \ s 2 Me 2-37 ι 0 4 MeO 2-38 L 0 1 H 2-39, OMe 1 tBu 0 1 H 2-40 L 0 1 H 2-41 jOl fire c 丨 people 乂 7 people Et 0 2 Ci 2-42 jOl fire Me0 people ^ people Me 0 1 H The paper standard is common Chinese national standard (CNS > A4 specification ( 210 × 297 mm) -87 «(Please read the notes on the back before filling in this page)

503237 ·Α7 Β7 五、發明説明(W ) 表2 (續) 經濟部中央樣準局貝工消费合作社印装 编竑 X Y m R 2-4.1 Me〇-^A Me υ 4 II 2-44 0 i MeO Η s 1 H 2-45 XU O 1 H 2-46 0 1 H 2-47 _ uy Bu 0 2 H 2-48 x〇 s 1 Me 2-49 XX? L 0 4 Me -88~ (請先閱讀背面之注意事項再填寫本頁)503237 · Α7 Β7 V. Description of the invention (W) Table 2 (continued) Printed and edited by the Shell Specimen Consumer Cooperative of the Central Samples Bureau of the Ministry of Economic Affairs XY m R 2-4.1 Me〇- ^ A Me υ 4 II 2-44 0 i MeO s s 1 H 2-45 XU O 1 H 2-46 0 1 H 2-47 _ uy Bu 0 2 H 2-48 x〇s 1 Me 2-49 XX? L 0 4 Me -88 ~ (Please first (Read the notes on the back and fill out this page)

、1T i# 本紙張尺度適州中國國家標準(CNS ) Λ4現格(2丨0X297公釐) 503237、 1T i # This paper is in accordance with China State Standard (CNS) Λ4, and it is 2 × 0X297 mm. 503237

A B 五、發明説明(π ) 表2 (績) 编魷 X Y m R 2-50 _ k Ο ! 11 2-51 Me ο I u 2-52 S -2 H 2-53 & Spr 0 2 Me 2-54 έο S 3 H 2-55 _ Me 0 1 MeO -89- 本紙張尺度適州中國國家標準(CNS)A4说格(210X297公筹) (請先閱讀背面之注意事項再填寫本頁) 503237 A7 B7 五、發明説明(和) 表2 (續) 經濟部中央標準局員工消费合作社印装 編號| X Y ill R 2-56 s l H 2-57 Λ 1 0 2 H 2-58 1 0 4 Me 2-59 CXx 0 1 H 2-60 〇Λ 0 2 H 2-61 勹 s 3 H 2-62 Λ rile 0 I H - 90- ----裝------訂-----— (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中《W家標丰(CNS ) Λ4現格(210X 297公釐) 503237AB V. Description of the invention (π) Table 2 (Performance) XY m R 2-50 _ k Ο! 11 2-51 Me ο I u 2-52 S -2 H 2-53 & Spr 0 2 Me 2 -54 έο S 3 H 2-55 _ Me 0 1 MeO -89- This paper size is suitable for China National Standard (CNS) A4 (210X297) (Please read the precautions on the back before filling this page) 503237 A7 B7 V. Description of the invention (and) Table 2 (continued) Printing number of the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs | XY ill R 2-56 sl H 2-57 Λ 1 0 2 H 2-58 1 0 4 Me 2 -59 CXx 0 1 H 2-60 〇Λ 0 2 H 2-61 勹 s 3 H 2-62 Λ rile 0 IH-90- ---- install ------ order ------- ( Please read the precautions on the back before filling out this page.) This paper is applicable to "W Jiabiaofeng (CNS) Λ4 grid (210X 297 mm) 503237

AA

7 7 B 五、發明説明() 經濟部中央標準局貝工消费合作杜印製 表2 (續) 编號 X Y ηι R 2-63 _ 人 Ο 2 (i 2-64 Λ 0 3 H 2-65 Λ s 1 H 2-66 〇Λ L 0 1 H 2-67 Cxx 0 2 MeO 2-68 ΟΛ 0 1 H 2-69 人 s 5 H -91 - (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適州中國國家標準(CNS ) A4規格(210X297公釐) 503237 A7 B7 五、發明説明(^ ) \»y 續 c 2表 一|編7 7 B V. Description of the invention () Printed by the Consumers' Cooperatives of the Central Bureau of Standards of the Ministry of Economy 2 (Continued) No. XY ηι R 2-63 _ person 0 2 (i 2-64 Λ 0 3 H 2-65 Λ s 1 H 2-66 〇Λ L 0 1 H 2-67 Cxx 0 2 MeO 2-68 ΟΛ 0 1 H 2-69 people 5 H -91-(Please read the precautions on the back before filling this page) The size of this paper is in accordance with China State Standard (CNS) A4 (210X297 mm) 503237 A7 B7 V. Description of the invention (^) \ »y Continued c 2Table 1 | Edit

X γ 0X γ 0

R ο -7 2-R ο -7 2-

y ( ( 2y ((2

ο Η 2 -7 2-ο Η 2 -7 2-

ο (請先閲讀背面之注意事項再填寫本頁) 裝- 2 Η 73 2-ο (Please read the notes on the back before filling this page) Pack-2 Η 73 2-

Ν丨 CΝ 丨 C

S ΗS Η

、1T 74 2-1T 74 2-

Ν— f Ν ο 4 Η 2- 經濟部中央樣隼局員工消費合作社印¾ 76 I 2 2Ν— f Ν ο 4 Η 2-Stamped by the Consumer Cooperatives of the Central Sample Bureau of the Ministry of Economic Affairs ¾ 76 I 2 2

ΝIΗ 、 ν Ν Ν—ΗΝIΗ, ν Ν Ν—Η

ο Η ο ο 本紙^尺度遴用中闺囱象嫌本(CNS )八4坭格(2ί〇 Χ—2幼公* ) 3 Η ϊ fr -92- 503237 A7 五、發明説明(G )ο Η ο ο The paper ^ scale selection in the guinea pigs (CNS) 8 4 grid (2ί〇 χ-2 young male *) 3 Η ϊ fr -92- 503237 A7 V. Description of the invention (G)

(請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) Λ4規格(2丨〇κ297公釐) 503237 Α7 Β7 五、發明説明(抑) 表2 (續 I編(Please read the precautions on the back before filling in this page) The paper size applies to the Chinese National Standard (CNS) Λ4 specification (2 丨 〇κ297 mm) 503237 Α7 Β7 V. Description of the invention (Suppression) Table 2 (Continued I)

X γ mlX γ ml

R 2- 6 8 2- 2- 2-88 2-89 ο -9 2-R 2- 6 8 2- 2- 2-88 2-89 ο -9 2-

Ν e N—EtΝ e N—Et

ΓΓ

ο ο ο Ο 2 Κ Κ Η (請先閲讀背面之注意事項再填寫本頁) ¥ e Μ 4 2 Η Η 經濟部中央標率局貝工消費合作社印«. 2-< -9ο ο ο Ο 2 Κ Κ Η (Please read the notes on the back before filling out this page) ¥ e Μ 4 2 Η Η Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs «. 2- < -9

ΝΝ

S Η Ν Ν J-S Η Ν Ν J-

Ν Η ο Η Ν ΝΝ Η ο Η Ν Ν

ο 2 Ηο 2 Η

Ν Η 本紙張尺度適用中《*家標隼(〔奶>八4現格(2丨0犬297公康) 503237 A7 B7 五、發明説明(K ) 表2 (續) ¾存郎中失舔奉垮員!.省费含咋社中裝Ν Η Applicable to the standard of this paper "* 家 标 隼" ([Milk> 8; 4 present (2 丨 0 dogs 297 public health) 503237 A7 B7 V. Description of the invention (K) Table 2 (continued) Breaking down !: Save on fees including Hanshe

.(請先閱讀背面之注意事項再填寫本頁) -95-本紙张尺度遢用中國國家榡率(CNS>A4現格(2丨OX297公釐) 503237 A7 B7 五、發明説明(“) 表2 (續) ¾齊郎中矢嘌养苟員11寫^^卞ijl.f获 编號 X Y in R 2-102 η 1 1 Me 0 1 H 2-103 r r 1 1 Me 0 2 H 2-104 r 、I 1 0 2 H 2-105 n 1 j 1 0 4 H 2-106 aNj 0 1 H 2-107 Me & 0 .2 H 2-108 Br 0 3 H 2-109 〇Λ s 1 H -96- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) Λ衣. 503237 AB* 五、發明説明(ο ) 表2 (續) 编號 X Y m R 2-110 Γ^Ν~~ίΐ 人 OH 0 1 H 2-111 XXx 0 i H 2-112 C,Y^N—π 0 2 H 2-113 s 1 H 2-114 r^Nπ 0 1 H 2-115 广Ν—Π 0 3 H 2-116 r^N—π 人 Me 0 1 H 2-117 广N—1 人 Me s 2 H 2-118 0 1 H -97- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標率(CNS ) Α4規格(210Χ 297公蠖} 503237 A7 B7 五、發明説明(Μ ) 表2 (續). (Please read the precautions on the back before filling this page) -95- This paper size uses the Chinese national rate (CNS > A4 now (2 丨 OX297 mm) 503237 A7 B7 V. Description of invention (") 2 (continued) ¾ Qilang Zhongya Puyangyang member 11 writes ^^ 卞 ijl.f gets number XY in R 2-102 η 1 1 Me 0 1 H 2-103 rr 1 1 Me 0 2 H 2-104 r , I 1 0 2 H 2-105 n 1 j 1 0 4 H 2-106 aNj 0 1 H 2-107 Me & 0 .2 H 2-108 Br 0 3 H 2-109 〇Λ s 1 H -96 -This paper size applies Chinese National Standard (CNS) Λ4 specification (210X297 mm) (Please read the precautions on the back before filling this page) Λ Clothing. 503237 AB * V. Description of the invention (ο) Table 2 (continued) No. XY m R 2-110 Γ ^ Ν ~~ ίΐ person OH 0 1 H 2-111 XXx 0 i H 2-112 C, Y ^ N—π 0 2 H 2-113 s 1 H 2-114 r ^ Nπ 0 1 H 2-115 Can N—Π 0 3 H 2-116 r ^ N—π People Me 0 1 H 2-117 Can N—1 People Me s 2 H 2-118 0 1 H -97- (Please first Read the notes on the reverse side and fill in this page) This paper size is applicable to China National Standards (CNS) Α4 specification (210 × 297 G 蠖) 503237 A7 B7 V. Description of the invention (M ) Table 2 (continued)

編魷 X Y m R 2-119 〇 5 Me 2-120 广N—π 人 Et 0 1 MeO (請先閲讀背面之注意事項再填寫本頁) 裝- 訂 ~98~ 各紙張尺度通州中家撑窣(CNS ) A4g( 2丨0X297公釐) 503237 A7 B7 五、發明説明(烈) 表3 編號 X Y m R 3-1 CO I 0 2 H 3-2 cu" Η 0 2 H 3-3 八 CPh. W 1 0 2 H 3-4 w Me 0 2 H 3-5 0 1 H 3-6 ULA 0 I H 3-7 0 2 H 3-8 ULA k 0 1 H 本紙張尺度適用中國圉家標隼(CNS)A4At格(2丨ΟΧ297公釐) (請先閲讀背面之注意事項再填寫本頁) :裝·Squid XY m R 2-119 〇5 Me 2-120 Can N—π person Et 0 1 MeO (Please read the notes on the back before filling in this page) Binding-Order ~ 98 ~ Tongzhou Zhongjia Support Co., Ltd. (CNS) A4g (2 丨 0X297 mm) 503237 A7 B7 V. Description of the invention (strong) Table 3 Number XY m R 3-1 CO I 0 2 H 3-2 cu " Η 0 2 H 3-3 Eight CPh. W 1 0 2 H 3-4 w Me 0 2 H 3-5 0 1 H 3-6 ULA 0 IH 3-7 0 2 H 3-8 ULA k 0 1 H This paper size is applicable to the Chinese standard (CNS) ) A4At (2 丨 〇 × 297mm) (Please read the precautions on the back before filling this page):

、1T -99- 503237, 1T -99- 503237

A 表3 (靖) 經濟部中央樣隼局員工消費合作社印衮 編號 X Y m R 3-9 o 3 McU 3-10 XXX。 0 1 H 3-11 W 0 5 Me 3-12 k s 1 H 3-13 V / Me 0 2 MeO 3-14 Me0\^\ / Me 0 1 H 3-15 HOr)^c Me Me 0 l H -100~ (請先閲讀背面之注意事項再填寫本頁) ·装-A Table 3 (Jing) Employees 'Cooperatives' Seal of the Central Sample Bureau of the Ministry of Economic Affairs No. X Y m R 3-9 o 3 McU 3-10 XXX. 0 1 H 3-11 W 0 5 Me 3-12 ks 1 H 3-13 V / Me 0 2 MeO 3-14 Me0 \ ^ \ / Me 0 1 H 3-15 HOr) ^ Me Me 0 l H- 100 ~ (Please read the precautions on the back before filling this page)

、1T 本紙張尺度適用中國國家標隼(CNS ) Λ4Λ格(210X297公釐) 503237 A7 B7 五、發明説明() 表3 (續) 化合物 编就 X Y m R j-16 W 1 Me Ο 1 H 3-17 Me Me Me s 4 Cl 3-18 rw MeA^S Me 0 3 OH 3-19 c,xy Me s 2 Bu 3-20 〔1 1 H 0 5 H 3-21 TO |iBu 0 1 H 3-22 0 1 H 表紙張尺度適用中國國家橾準(CNS)A4規格(210X297公雕) -10卜 (請先閲讀背面之注意事項再填寫本頁) 503237 A7 B7 五、發明説明(P ) 經 濟 部 中 夬 樣 隼 貝 X. Μ f % it 表3 (靖) 編號 X Υ m R 3-23 & 0 1 H 3-24 H〇XXx 0 i H 3-25 XXx 0 1 H 3-26 s 1 H 3-27 〇2ΝΌζ\ 0 1 H 3-28 0 l H 3-29 XX\ 0 1 H -102 - 請 先 閲 讀 背 δ 之 注 意 事 項 再 填 % 本 頁 本紙悵尺度適州中*W家撑率(CNS ) Α4現格(210x297公釐) 503237、 1T This paper size applies to Chinese National Standards (CNS) Λ4Λ grid (210X297 mm) 503237 A7 B7 V. Description of the invention () Table 3 (continued) Compounds are compiled XY m R j-16 W 1 Me 〇 1 H 3 -17 Me Me Me s 4 Cl 3-18 rw MeA ^ S Me 0 3 OH 3-19 c, xy Me s 2 Bu 3-20 〔1 1 H 0 5 H 3-21 TO | iBu 0 1 H 3- 22 0 1 H Table paper size is applicable to China National Standard (CNS) A4 specification (210X297 engraving) -10 (please read the notes on the back before filling this page) 503237 A7 B7 V. Description of Invention (P) Ministry of Economic Affairs Medium sample X. Μ f% it Table 3 (jing) Number X Υ m R 3-23 & 0 1 H 3-24 H〇XXx 0 i H 3-25 XXx 0 1 H 3-26 s 1 H 3-27 〇2ΝΌζ \ 0 1 H 3-28 0 l H 3-29 XX \ 0 1 H -102-Please read the notes on the back δ and fill in the% Rate (CNS) Α4 (210x297 mm) 503237

A B7 五、發明説明(w ) 表3 (續) 编躭 X Υ m R 3-30 AcNH、^\ ΧλΛ 0 1 Η 3-31 k ο 1 Η 3-32 MeNHY^\ 0 1 Η 3-33 Η ΧΧΛ Me 0 1 Η 3-34 Me Bz~Ny^\ 人 ο 1 Η 3-35 Me Ph- Όζ\ 0 1 Η (請先閲讀背面之注意事項再填寫本頁) 裝.A B7 V. Description of the invention (w) Table 3 (continued) X Υ m R 3-30 AcNH, ^ \ ΧλΛ 0 1 Η 3-31 k ο 1 Η 3-32 MeNHY ^ \ 0 1 Η 3-33 Χ ΧΧΛMe 0 1 Η 3-34 Me Bz ~ Ny ^ \ person ο 1 Η 3-35 Me Ph- Όζ \ 0 1 Η (Please read the precautions on the back before filling this page).

、1T -103-本紙張尺度適用中國國家標準(CNS ) Μ規格(2丨〇><297公廣) 503237 A7 B7 五、發明説明(94 ) 表3 (續) 編躭 3-36 3-37、 1T -103- This paper size is applicable to Chinese National Standard (CNS) M specifications (2 丨 〇 < 297 public broadcasting) 503237 A7 B7 V. Description of the invention (94) Table 3 (continued) Ed. 3-36 3 -37

XX

Y ηιY ηι

RR

MeMe

N I HN I H

OO

MeO (請先閱讀背面之注意事項再填寫本頁)MeO (Please read the notes on the back before filling out this page)

本紙张尺度適用中國國家標隼(CNS ) A4現格(2丨0X297公釐) 503237This paper size is applicable to China National Standard (CNS) A4 (2 丨 0X297mm) 503237

B 五、發明説明(^ ) 表3 (蜻) 編龁 X Y m R 3-43 Me〇AAA Me 0 4 H 3-44 人 MeO Η s I H 3-45 χ〇 i 0 1 H 3-46 W 0 1 H 3-47 tBu 0 2 H 3-48 x〇 k s 1 Me 3-49 Xp 0 4 Me -105 - (請先閲讀背面之注意事項再填寫本頁) -裝‘ 訂 本紙悵尺度適用中國國家標率(CNS) A4現格(210X 297公麾) 503237 A7 B7 五、發明説明(% ) 表3 (續) 绫齊年4-*:^赛苟霣1:寫奢釜拿士 *pi 编就 X Y m R 3-50 o I 11 3-51 1 j Y Me 0 1 Fi 3-52 1 j · Y Me 0 2 H 3-53 !ργ 0 2 Me 3-54 Bu s 3 H 3-55 0φ Me 0 1 MeO -106- (請先閱讀背面之注意事項再填寫本頁) 裝- 訂 本紙张尺度遢Λ中《«家梯率(CNS> A4規格(2!〇X297公釐) 503237 A7 B7 五、發明説明(W ) 表3 (續) 編就 X Υ m R 3-56 s 1 II 3-57 1 0 2 H 3-58 Me0-y^X 1 0 4 Me 3-59 Λ i 0 1 H 3-60 〇 h 0 2 H 3-61 Ox b s 3 H 3-62 Λ 0 1 H -10? - (請先閱讀背面之注意事項再填寫本頁) 装·B V. Description of the invention (^) Table 3 (Dragon) Edit XY m R 3-43 Me〇AAA Me 0 4 H 3-44 Human MeO s s IH 3-45 χ〇i 0 1 H 3-46 W 0 1 H 3-47 tBu 0 2 H 3-48 x〇ks 1 Me 3-49 Xp 0 4 Me -105-(Please read the notes on the back before filling out this page)-Binding 'The size of the paper is suitable for China Standard rate (CNS) A4 is now available (210X 297 male) 503237 A7 B7 V. Description of invention (%) Table 3 (continued) For XY m R 3-50 o I 11 3-51 1 j Y Me 0 1 Fi 3-52 1 jY Me 0 2 H 3-53! Ργ 0 2 Me 3-54 Bu s 3 H 3-55 0φ Me 0 1 MeO -106- (Please read the notes on the back before filling in this page) Binding-Book size 遢 Λ 《«Home Slope (CNS > A4 size (2! 〇X297mm) 503237 A7 B7 V. Description of the invention (W) Table 3 (continued) X Υ m R 3-56 s 1 II 3-57 1 0 2 H 3-58 Me0-y ^ X 1 0 4 Me 3-59 Λ i 0 1 H 3-60 〇h 0 2 H 3-61 Ox bs 3 H 3-62 Λ 0 1 H -10?-(Please read the precautions on the back before filling this page)

、1T 本紙悵尺度適用中國國家標隼(CNS ) A4現格(210 X297公釐) 503237 A7 B7 五、發明説明(对) 表3 (續) 經濟部中央標準局貝工消費合作社印黎 編號 X Y m R 3-63 〇Λ ώβ υ 2 11 3-64 U ! Me \ 0 3 H 3-65 u 、〆 i Me \ s 1 H 3-66 Et 0 1 H 3-67 0 2 MeO 3-68 L· 0 1 H 3-69 0 s 5 H -108·~ (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標隼(CNS ) Α4現格(2丨0X297公釐) 503237、 1T The standard of this paper is applicable to Chinese National Standard (CNS) A4 (210 X297 mm) 503237 A7 B7 V. Description of the invention (pair) m R 3-63 〇Λ ώβ υ 2 11 3-64 U! Me \ 0 3 H 3-65 u, 〆i Me \ s 1 H 3-66 Et 0 1 H 3-67 0 2 MeO 3-68 L · 0 1 H 3-69 0 s 5 H -108 · ~ (Please read the precautions on the back before filling in this page) This paper size is applicable to China National Standard (CNS) Α4 now (2 丨 0X297 mm) 503237

7 7 A B 五、發明説明() 表3 (續) 經濟部中央標準局員工消費合作社印製 ^^0 编號 X Y m R 3-70 人 0 1 Cl 3-71 Ιργ ο 1 H 3-72 1 0 2 H 3-73 1 s 3 H 3-74 〇 1 1 0 4 H 3-75 Cu^ b 0 1 H 3-76 〇/ 0 3 H 3-77 / ζχχ 1 Me 0 1 H 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)-109- I 裝 訂 (請先閲讀背面之注意事項再填寫本頁) 5032377 7 AB V. Description of the invention () Table 3 (continued) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs ^^ 0 No. XY m R 3-70 People 0 1 Cl 3-71 Ιργ ο 1 H 3-72 1 0 2 H 3-73 1 s 3 H 3-74 〇1 1 0 4 H 3-75 Cu ^ b 0 1 H 3-76 〇 / 0 3 H 3-77 / ζχχ 1 Me 0 1 H This paper size is applicable China National Standard (CNS) A4 Specification (210X297mm) -109-I Binding (Please read the precautions on the back before filling this page) 503237

A B 明 説 明 發 五 續 c 3 表A B Explaining the fifth statement c3

0 本紙张尺度適用中國W家標隼(CNS)A4現格< 210X297公釐) --------裝— (請先閲讀背面之注意事項再填寫本頁)0 This paper size is applicable to China W House Standard (CNS) A4 now < 210X297 mm) -------- Installation— (Please read the precautions on the back before filling this page)

,1T 503237 A7 B7 ................... II丨· ' 1 TgfllMiii ................................................................................. _ 丨丨 ι ................ ιι_ 五、發明説明(ICM ) 表3 (續), 1T 503237 A7 B7 ......... II 丨 · '1 TgfllMiii .......... ........................................ ........... _ 丨 丨 ι ................ ιι_ V. Description of the Invention (ICM) Table 3 (Continued)

(請先閲讀背面之注意事項再填寫本頁)(Please read the notes on the back before filling this page)

、1T 本紙悵尺度適用中國國家標準(CNS ) A4規格(2丨OX 297公釐) 503237、 1T The standard of this paper is applicable to China National Standard (CNS) A4 specification (2 丨 OX 297 mm) 503237

3-97 - Pr H cx •>r3-97-Pr H cx • > r

3-98 3-993-98 3-99

,Me, Me

HH

N N -N-N N -N-

經濟部中夹樣隼馬貝X消費合作it印ttXia Mabei X Consumer Cooperation

N N 3-100 3-101 ,Me -N-N N 3-100 3-101, Me -N-

MeMe

N N-N N-

OO

OO

OO

MeOMeO

ClCl

H 表紙張尺度適用中國國家標隼(CNS) Λ4現格(2丨O X M7公釐) -112- 503237 經濟部中央標率局貝工消費合作社印¾ A7 B7 五、發明説明(…) 表3 (續)The paper size of H sheet is applicable to Chinese National Standard (CNS) Λ4 is present (2 丨 OX M7 mm) -112- 503237 Printed by the Bayer Consumer Cooperative of the Central Standards Bureau of the Ministry of Economy ¾ A7 B7 5. Description of the invention (…) Table 3 (Continued)

編竑 X Y m R 3-102 r T 1 I Me o I H 3-103 r r 1 、、N〆 1 Me ' 0 2 H 3-104 、j 1 0 2 H 3-105 n 1 j 1 0 4 H 3-106 r^N—π 0 1 H 3-107 Me r^Nπ \ 0 2 H 3-108 ΒΓγ^Ν__ 人 Br 0 3 H 3-109 s 1 H --------------IT------0 (請先閲讀背面之注意事項再填寫本頁) -113- 本紙張尺度適用中家標率(CNS)A4况格(2IOX297公簸) 503237Edit XY m R 3-102 r T 1 I Me o IH 3-103 rr 1, N 、 1 Me '0 2 H 3-104, j 1 0 2 H 3-105 n 1 j 1 0 4 H 3 -106 r ^ N—π 0 1 H 3-107 Me r ^ Nπ \ 0 2 H 3-108 ΒΓγ ^ N__ person Br 0 3 H 3-109 s 1 H ------------ --IT ------ 0 (Please read the precautions on the back before filling out this page) -113- This paper size is applicable to the standard of domestic standard (CNS) A4 (2IOX297)

7 7 A B7 7 A B

5-1 10 3-111 3-11: 3-113 3-114 3-115 M16 3-117 發明説明(w ) 表3 ( 續 编號 M !85-1 10 3-111 3-11: 3-113 3-114 3-115 M16 3-117 Description of the invention (w) Table 3 (Continued number M! 8

ClCl

ClCl

XX

Y mlY ml

RR

N-N-

N N-N N-

I N-I N-

N- ο Η 2 Η (請先閲讀背面之注意事項再填寫本頁)N- ο Η 2 Η (Please read the notes on the back before filling this page)

S 3 Η Η ΗS 3 Η Η Η

、1T N-, 1T N-

N- Η N-N- Η N-

N MeN Me

S 2 Η N-S 2 Η N-

N Me N- ο ri f^i 表紙张足度適/η中國國家標率(CNS ) Λ4規格(210Χ297公釐) 503237 A7 B7 五、發明説明(\< ) 表3 (續)N Me N- ο ri f ^ i Table paper adequateness / η China National Standard (CNS) Λ4 specification (210 × 297 mm) 503237 A7 B7 V. Description of invention (\ <) Table 3 (continued)

(請先閱讀背面之注意事項再填寫本頁) 裝· 、11 -115 -本紙悵尺度適用中國國家標隼《CNS ) Λ4現格(2丨0X 297公釐) 503237(Please read the precautions on the back before filling out this page.) Installation, 11 -115-This paper's standard is applicable to the Chinese national standard "CNS" Λ4 is present (2 丨 0X 297 mm) 503237

AA

7 B 經濟郎中夹舔麥苟貝11劣f含阼&lt;11¥裝 五、發明説明(4) 表47 B Economy Lang licking wheat Goubei 11 Inferior f containing 阼 <11 ¥ pack V. Description of invention (4) Table 4

編既 X Y m R 4-! 1 o 2 Π 4-2 CX/ 1 Π 0 2 H 4-3 八 CPh飞 / 1 1 1 0 2 H 4-4 Me 0 2 H 4-5 ζΧλ A 0 1 H 4-6 / 1 1 0 1 H 4-7 [f| 1 0 2 H 4-8 _ k 0 i H (請先閲讀背面之注意事項再填寫本頁) -裝- 訂 木紙張尺度適用中國國家標率(CNS ) A4規格(2!OX297公釐) -116- 503237 A7 B7 五、發明説明(W ) 表4 (續) 經濟部中央標準局貝工消費合作社印«.XY m R 4-! 1 o 2 Π 4-2 CX / 1 Π 0 2 H 4-3 Eight CPh fly / 1 1 1 0 2 H 4-4 Me 0 2 H 4-5 ζχλ A 0 1 H 4-6 / 1 1 0 1 H 4-7 [f | 1 0 2 H 4-8 _ k 0 i H (Please read the notes on the back before filling out this page)-Binding-Ordering paper size for China Standard rate (CNS) A4 specification (2! OX297 mm) -116- 503237 A7 B7 V. Description of invention (W) Table 4 (continued) Printed by the Bayer Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs «.

編號 X Y m R 4-9 1 3-PhPr u J II 4-10 ________/ ClNjC, o 1 H 4-1 1 0 5 丨 Me 4-12 0 s 1 H 4-13 CtX 0 2 MeO 4-14 Me0\^\ / 0 I H 4-15 Me 0 1 II -117- (請先閲讀背面之注意事項再填寫本頁) 裝- 訂 本紙張尺度適用中國國家梯率(CNS)八4現格(2!〇Χ297公釐) 503237 A7 B7 五、發明説明) 表4 (續) L· . 編號 X Y m R 4-16 1 Me 0 1 U 4-17 Me όΐ-/ VS Me Me s 4 Cl 4-18 _/ L 0 3 OH 4-19 β、ι^ί 〆 s 2 Bu 4-20 ^ 1 1 0 5 H 4-21 L 0 l H 4-22 / 1 1 1 Me 0 i H -118- 本紙iiL尺度適用中《國家標準(CNS ) Λ4現格(21〇X 297公釐) (請先閲讀背面之注意事項再填寫本頁) 裝· -一α 503237 A7 _B7 五'發明説明(W) 表4 (續) 編號 X Y m R 4-23 1 1 1 Me o ! H 4-24 HOn i 1 Me 0 1 H 4-25 Me〇Y^ 人 0 i H 4-26 1 Me 0 1 H 4-27 Χλλ 0 ! H 4-28 Me\r^r\ 人 1 Me 0 1 H 4-29 T i i rile o l H -119- (請先閲讀背面之注意事項再填寫本頁) 裝 訂 本紙張尺度適州中《«家秫攀(CNS ) Λ4現格《210X297公釐) 503237 A7 B7 五、發明説明(u。) 表4 (續)XY m R 4-9 1 3-PhPr u J II 4-10 ________ / ClNjC, o 1 H 4-1 1 0 5 丨 Me 4-12 0 s 1 H 4-13 CtX 0 2 MeO 4-14 Me0 \ ^ \ / 0 IH 4-15 Me 0 1 II -117- (Please read the precautions on the back before filling this page) Binding-The size of the paper is applicable to China National Slope (CNS) 8 and 4 (2! 〇 × 297 mm) 503237 A7 B7 V. Description of the invention) Table 4 (continued) L ·. Number XY m R 4-16 1 Me 0 1 U 4-17 Me ΐ- / VS Me Me s 4 Cl 4-18 / L 0 3 OH 4-19 β, ι ^ ί 〆s 2 Bu 4-20 ^ 1 1 0 5 H 4-21 L 0 l H 4-22 / 1 1 1 Me 0 i H -118- iiL scale Applicable "National Standards (CNS) Λ4 now (21〇X 297 mm) (Please read the precautions on the back before filling out this page). Installation ·-一 α 503237 A7 _B7 Five 'Invention Description (W) Table 4 ( Continued) Number XY m R 4-23 1 1 1 Me o! H 4-24 HOn i 1 Me 0 1 H 4-25 Me〇Y ^ Person 0 i H 4-26 1 Me 0 1 H 4-27 χλλ 0 ! H 4-28 Me \ r ^ r \ person 1 Me 0 1 H 4-29 T ii rile ol H -119- (Please read the precautions on the back before filling this page) Binding this paper size Shizhou "« Home Furnishing (CNS) 4 now grid "210X297 mm) 503237 A7 B7 V. invention is described in (u.) Table 4 (Continued)

-120- (請先閱讀背面之注意事項再填寫本頁) 裝 、1Τ 本紙张尺度適州中國國家標隼(CNS ) A4現格(210x 297公缝 503237 A7 B7 五、發明説明l·'、) 表4 (續) 編號 X Y m R 4-36 Λ〇Νίί^\ \丨1 s 2 Me 4-37 r ULA 1 fhi o 4 MeO 4-38 Ci Λ-π 1 1 0 l H 4-39 ,0Me 0 l H 4-40 〔II 0 1 H 4-41 0 2 CI 4-42 _ 0 1 H -121- 本紙張尺度適用中國國家標準(CNS) A4現格(2丨〇Χ 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝· TJ- In II · -5 503237 A7 B7 五、發明説明(^ ) 表4 (續)-120- (Please read the precautions on the back before filling this page) Packing, 1T This paper size is suitable for China National Standard (CNS) A4 (210x 297 public seam 503237 A7 B7) V. Description of the invention l · ', ) Table 4 (continued) Number XY m R 4-36 Λ〇Νί ^ \ \ 丨 1 s 2 Me 4-37 r ULA 1 fhi o 4 MeO 4-38 Ci Λ-π 1 1 0 l H 4-39, 0Me 0 l H 4-40 〔II 0 1 H 4-41 0 2 CI 4-42 _ 0 1 H -121- This paper size is applicable to the Chinese National Standard (CNS) A4 (2 丨 〇 × 297 mm) (Please read the precautions on the back before filling this page) Equipment · TJ- In II · -5 503237 A7 B7 V. Description of the invention (^) Table 4 (continued)

-122- (請先閲讀背面之注意事項再填寫本頁) 裝- -5 表紙张尺度適用中國阁家梯準(〔1^)八4現格(210/297公廢&gt; 503237 A7 _B7 五、發明説明(&quot;^ ) 表4 (靖) 编號 X Y 111 R 4-50 _ o I ii 4-51 W 0 !, R 4-52 _ 1 Me 0 2 H 4-53 / 1 1 !pr 0 2 Me 4-54 W fL s 3 H 4-55 / 1 1 Me 0 1 McO -123- (請先閱讀背面之注意事項再填寫本頁) 裝· 訂 本紙張尺度適用中®阐家撐牵&lt; CNS ) Λ4規格(2丨OX297公釐) 503237 A7 B7 五、發明説明( ι4- 表4 (續) 編號 X Y m R 4-56 1 Bz s 2 H 4-57 _ 、」N ’’ 1 0 2 H 4-58 1 0 4 Me 4-59 Λ 人 1 H 0 I H 4-60 _ 人 ! H 0 2 H 4-61 _ s 3 H 4-62 勹 rile 0 1 ll (請先閱讀背面之注意事項再填寫本頁) 装·-122- (Please read the precautions on the back before filling out this page) Packing--5 The paper size is applicable to the Chinese cabinet ladder standard ((1 ^) 8 4 standard (210/297 public waste &gt; 503237 A7 _B7 5) & Explanation of the invention (&quot; ^) Table 4 (jing) No. XY 111 R 4-50 _ o I ii 4-51 W 0!, R 4-52 _ 1 Me 0 2 H 4-53 / 1 1! Pr 0 2 Me 4-54 W fL s 3 H 4-55 / 1 1 Me 0 1 McO -123- (Please read the notes on the back before filling out this page) Binding and binding &lt; CNS) Λ4 specification (2 丨 OX297 mm) 503237 A7 B7 V. Description of the invention (ι4- Table 4 (continued) No. XY m R 4-56 1 Bz s 2 H 4-57 _ ”N '' 1 0 2 H 4-58 1 0 4 Me 4-59 Λ person 1 H 0 IH 4-60 _ person! H 0 2 H 4-61 _ s 3 H 4-62 勹 rile 0 1 ll (Please read the back (Please fill in this page for attention)

、1T -124-本紙張尺度適/fl中國國家標率(.CNS ) Λ4現格(2i0x297公釐) 503237 A7、 1T -124- This paper is suitable for the standard / fl China National Standard (.CNS) Λ4 is present (2i0x297 mm) 503237 A7

__ W 五、發明説明(&quot;&lt; ) 表4 (績) 編踗 X Y m R 4-63 〇 2 Π 4-64 〇 人 0 3 Η 4-65 _ 人 S 1 Bu 4-66 Et 0 1 Η 4-67 _ 0 2 MeO 4-68 έυ 0 1 Η 4-69 _ 山e S 5 Η -125- (請先閱讀背面之注意事項再填寫本頁) ,·!* 本紙張尺度適州中國國家標隼(CNS ) A4現格(2丨0X297公釐) 503237 A7 B7__ W 5. Description of the invention (&quot; &lt;) Table 4 (Performance) Editor XY m R 4-63 〇2 Π 4-64 〇 person 0 3 Η 4-65 _ person S 1 Bu 4-66 Et 0 1 Η 4-67 _ 0 2 MeO 4-68 έυ 0 1 Η 4-69 _ Mountain e S 5 Η -125- (Please read the precautions on the back before filling out this page), *! * This paper size is suitable for China China National standard (CNS) A4 now (2 丨 0X297 mm) 503237 A7 B7

(請先閱讀背面之注意事項再填寫本頁) 503237 五、發明説明(π ) A7 B7 128 表4 (續) 编號 4-78 4-79 4-80 4-81 4-82 4-83 4-84(Please read the precautions on the back before filling this page) 503237 V. Description of the invention (π) A7 B7 128 Table 4 (continued) No. 4-78 4-79 4-80 4-81 4-82 4-83 4 -84

XX

Y ΓΠY ΓΠ

RR

Me ΗMe Η

MeMe

Cl Η Η Εί Η (請先閱讀背面之注意事項再填寫本頁) 裝· 訂 本紙张尺度通州中《«家螵率(CNS ) Λ4現格(21〇X 297公釐) -127- 503237 A7 B7 五、發明说明(^ ) 表4 (續)Cl Η Η Εί Η (Please read the notes on the back before filling out this page) Binding and binding paper size Tongzhou "« Furniture Ratio (CNS) Λ4 now (21〇X 297 mm) -127- 503237 A7 B7 V. Description of Invention (^) Table 4 (Continued)

-128- (請先閱讀背面之注意事項再填寫本頁) 裝' 本紙张尺度適用中國國家標隼(CNS &gt; A4現格(210x 297公釐) 503237 A7 B7 五、發明説明() 表4 (續)-128- (Please read the precautions on the back before filling this page). The size of this paper is applicable to the Chinese national standard (CNS &gt; A4 now (210x 297 mm) 503237 A7 B7 5. Description of the invention () Table 4 (Continued)

(請先閱讀背面之注意事項再填寫本頁) 琴 .丨靡 -129- 本紙張尺度適用中國《家標隼(CNS &gt; Λ4現格(2丨〇X 297公釐) 503237 ¾奔年 ^員ΙΙΛιδτ^拿fJL.fx^ A7 B7 五、發明説明(…) 表4 (續) 編號 X Y m R 4-102 〇 1 、N〆 1 Me \ 0 1 H 4-103 1 0 2 H 4-104 η 1-N 1 0 2 H 4-105 ri -N 1 s 4 H 4-106 ——r 0 1 H 4-107 UNJ \ 0 2 H 4-108 ΒΓγ^Ν—π Br 0 3 H 4-109 cu s l H -130- (請先閱讀背面之注意事項再填寫本頁) 裝· -1口 本紙张尺度適州中國圈家標準(CNS ) A4说格(2丨ΟΧ2&lt;Π公熳) 503237 A7 B7 五、發明説明() 表4 (精) 编魷 X Υ m R 4-110 Π ΟΗ 0 1 Η 4-111 C1、 广Ν—Π 0 1 Η 4-112 Xu 0 2 Η 4-113 Cl、 於Ν—π \ S 1 Η 4-114 ——r 0 1 Η 4-115 Xu 0 3 Η 4-116 、Me 0 1 Η 4-117 / Me r^N—~, S 2 Η 4-118 0 1 Η 本紙張尺度通州中*«家秫率(CNS)A4規格(2丨0X297公釐) &lt;131- (請先閱讀背面之注意事項再填寫本頁) 裝- 訂 503237(Please read the notes on the back before filling in this page) Qin. 丨 MI-129- This paper size is applicable to China's "House Standard Card (CNS &gt; Λ4) (2 丨 〇X 297 mm) 503237 ¾ Bennian ^ Member ΙΙΛιδτ ^ Take fJL.fx ^ A7 B7 V. Description of the invention (…) Table 4 (continued) Number XY m R 4-102 〇1, N〆1 Me \ 0 1 H 4-103 1 0 2 H 4-104 η 1-N 1 0 2 H 4-105 ri -N 1 s 4 H 4-106 ——r 0 1 H 4-107 UNJ \ 0 2 H 4-108 ΒΓγ ^ N—π Br 0 3 H 4-109 cu sl H -130- (Please read the precautions on the back before filling out this page) Packing · -1 mouth This paper size is the standard of the Chinese circle of China (CNS) A4 Grid (2 丨 〇 × 2 &lt; Π 公) 503237 A7 B7 V. Description of the invention () Table 4 (Fine) Editing squid X Υ m R 4-110 Π Ο Η 0 1 Η 4-111 C1, Guang N—Π 0 1 Η 4-112 Xu 0 2 Η 4-113 Cl, In N—π \ S 1 Η 4-114 ——r 0 1 Η 4-115 Xu 0 3 Η 4-116, Me 0 1 Η 4-117 / Me r ^ N— ~, S 2 Η 4-118 0 1 Η The paper size in Tongzhou * «Furniture Ratio (CNS) A4 Specification (2 丨 0X297mm) &lt; 131- (Please read the notes on the back before filling This page) equipment - 503 237 Order

7 7 A B 五、發明説明() 表4 ( ·續)7 7 A B V. Description of the invention () Table 4 (· continued)

--------•.衮------、玎------- (請先閱讀背面之注意事項再填寫本頁) -132-本紙張尺度通用中國國家標隼(CNS ) A4洗格&lt; 2丨O x 297公釐) 503237 A7 B7 五、發明説明(H ) 表5-------- •. 衮 ------, 玎 ------- (Please read the precautions on the back before filling out this page) -132- This paper standard is generally Chinese national standard 隼(CNS) A4 wash case &lt; 2 丨 O x 297 mm) 503237 A7 B7 V. Description of the invention (H) Table 5

(請先閱讀背面之注意事項再填寫本頁) 裝· 訂 -133· 本紙张尺度通用中國®家梯率(CNS)A4洗格(2丨0X297公慶) 503237 A7 B7 II ιιιιιιιιιιιι _ ....................-111111111 111111---------------111111111麵1111111------------- ·埤 一 五、發明説明) 表5 (靖) 經濟部中央標準局貝工消费合作社印装(Please read the precautions on the back before filling in this page) Binding · Binding-133 · This paper size is universal China® Home Slope (CNS) A4 Washing Grid (2 丨 0X297 Public Celebration) 503237 A7 B7 II ιιιιιιιιιιιι ι ... .......- 111111111 111111 --------------- 111111111 surface 1111111 ------------ -· 25. Description of the invention) Table 5 (Jing) Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

编耽 X Y m R 5-9 0 3 H 5-10 XXX 0 1 H 5-11 ΗΟγ^\ / 0 5 Me 5-12 CX/ U s 1 H 5-13 〔II 、^人a Me 0 2 MeO 5-14 Me〇Y^ / Me 0 1 H 5-15 jC Mc Me 0 i H -134- (請先閲讀背面之注意事項再填寫本頁) 士 -----111I -==11=11-................................—1« _l'll1,··'·ιι - TJ i .............- nn ml i In * 免 ·ν吞 本紙張尺度適用中國國家標隼(CNS ) Μ現格(2丨οκ 297公趣) 503237Editing delay XY m R 5-9 0 3 H 5-10 XXX 0 1 H 5-11 Η〇γ ^ \ / 0 5 Me 5-12 CX / U s 1 H 5-13 〔II, ^ a a 0 0 MeO 5-14 Me〇Y ^ / Me 0 1 H 5-15 jC Mc Me 0 i H -134- (Please read the precautions on the back before filling this page) 士 ----- 111I-== 11 = 11 -................................— 1 «_l'll1, ... '· ιι-TJ i .. ...........- nn ml i In * Free · ν Swallow This paper size applies to China National Standards (CNS) Μ Presentation (2 丨 οκ 297 public interest) 503237

本紙張尺度遢/fl中《*家櫺丰(CNS)八4说格(2丨0X297公釐) 503237 A7 B7 五、發明説明(^ ) 表5 (續) 编魷 X Y in R 5-23 1 1 Me 0 1 H 5-24 1 Me 0 1 H 5-25 Μ6〇γ^ 人 I Me 0 1 H 5-26 1 Me 0 1 H 5-27 1 Et 0 1 H 5-28 ΧΛΛ 1 Me 0 1 H 5-29 1 Me 0 l H -136- ---------- (請先閲讀背面之注意事項再填寫本頁) 訂 本紙张尺度適州中國阐家標隼(CNS &gt; Α4現格(2丨〇Χ 297公釐) 503237 A7 B7 五、發明説明() 表5 (續) 编统 X Y m R 5-30 Bz 1 AcN\^X 人 1 Me 0 I H 5-31 ^ν&quot;Πλ k 0 I H 5-32 Prri\ 1 Me 0 1 H 5-33 Η Βυ_Νγ^Χ 1 Me 0 1 H 5-34 Me Βζ-Νγ^\ I Me 0 1 H 5-35 H Ph-N’丫' 人 1 Me 0 1 H 137- i (睛先閲漬背面之注意事項再填寫本頁) 訂 503237In this paper's standard 遢 / fl, "Jia Jiafeng (CNS) 8 4 grid (2 丨 0X297 mm) 503237 A7 B7 V. Description of the invention (^) Table 5 (continued) Editing squid XY in R 5-23 1 1 Me 0 1 H 5-24 1 Me 0 1 H 5-25 Μ6〇γ ^ Human I Me 0 1 H 5-26 1 Me 0 1 H 5-27 1 Et 0 1 H 5-28 χΛΛ 1 Me 0 1 H 5-29 1 Me 0 l H -136- ---------- (Please read the notes on the back before filling out this page) Α4 is present (2 丨 〇 × 297 mm) 503237 A7 B7 V. Description of the invention () Table 5 (continued) Compilation system XY m R 5-30 Bz 1 AcN \ ^ X person 1 Me 0 IH 5-31 ^ ν &quot; Πλ k 0 IH 5-32 Prri \ 1 Me 0 1 H 5-33 Η Βυ_Νγ ^ χ 1 Me 0 1 H 5-34 Me Βζ-Νγ ^ \ I Me 0 1 H 5-35 H Ph-N 'Ya 'Person 1 Me 0 1 H 137- i (Please read the precautions on the back of the eye before filling this page) Order 503237

A B 經濟部中央懔隼馬貝工消費合作社¥载 五、發明説明(^ ) 表5 (績) 编蚝 X Y m R 5-36 AcN%^ XXx s 2 Me 5-37 L 0 4 MeO 5-38 Cl 6cx w 0 1 H 5-39 /0Me CXa Me 0 1 H 5-40 〔II 0 1 H 5-41 XX火 Et 0 2 Cl 5-42 j〇 i Me0从ΐ人 Me 0 l H -138- (請先閲讀背面之注意事項再填寫本頁) 1:- 本紙張尺度適用家榡率(CNS &gt; Λ4洗格(2丨0X:W公簸) 503237 A7 B7 五、發明説明) 表5 (續) 编烷 X Y ill R 5-43 0 4 H 5-44 〇 1 人 MeO Η s 1 H 5-45 ΧΧι A 0 1 H 5-46 0 1 H 5-47 0 2 H 5-48 s 1 Me 5-49 Me 0 4 Me 本紙张尺度遘州中國W家標奉(CNS ) A4現格(210X297公釐) -139- (請先閲讀背面之注意事項再填寫本頁) 503237AB Central Central Mabei Workers Consumer Cooperative Co., Ltd. ¥ Included 5. Description of the invention (^) Table 5 (Performance) XY m R 5-36 AcN% ^ XXx s 2 Me 5-37 L 0 4 MeO 5-38 Cl 6cx w 0 1 H 5-39 / 0Me CXa Me 0 1 H 5-40 〔II 0 1 H 5-41 XXFire Et 0 2 Cl 5-42 j〇i Me0 ΐ 人 Me 0 l H -138- (Please read the precautions on the back before filling this page) 1:-The paper size is applicable to the furniture ratio (CNS &gt; Λ4 wash case (2 丨 0X: W)) 503237 A7 B7 V. Description of the invention Table 5 ( Continued) Knitting XY ill R 5-43 0 4 H 5-44 〇1 Human MeO Η s 1 H 5-45 XY A 0 1 H 5-46 0 1 H 5-47 0 2 H 5-48 s 1 Me 5-49 Me 0 4 Me This paper is a Chinese standard Wuzhou standard house (CNS) A4 (210X297 mm) -139- (Please read the precautions on the back before filling this page) 503237

Me 本紙張尺度逍用中國國家標隼(CNS)A4况格(210X297公釐) —140-Me The paper size is in accordance with China National Standard (CNS) A4 (210X297 mm) —140-

503237 A7 B7 五、發明説明(…) ) 磧 C 5表i 經濟部中央樣隼局貝工消费合作社印袈503237 A7 B7 V. Description of the invention (…)) 碛 C 5 Form i Printed by the Shellfish Consumer Cooperative of the Central Sample Bureau of the Ministry of Economic Affairs

(請先閲讀背面之注意事項再填寫本頁) -C0 本紙悵尺度適用中國阐家櫺準(CNS ) A4At格(2丨OX297公釐) 503237 A7 B7 五、發明説明(如) 表5 (績) 编烷 X Υ m R 5-63 〇Λ 0 2 Η 5-64 0 3 Η 5-65 Λ S 1 Η 5-66 勹—λ 0 1 Η 5-67 _ 人 ir 0 2 MeO 5-68 i^s_ 0 1 Η 5-69 f^N_ S 5 Η -142- 本紙張尺度適州中國國家標率(CNS &gt; A4此格(2丨〇^ 297公簷) (請先閱讀背面之注意事項再填寫本頁) .裝' 、·ιτ 503237 經濟部中央標準局員工消費合作社印裝 A7 B7 五、發明説明() 表5 (續)(Please read the notes on the back before filling in this page) -C0 The paper size is applicable to Chinese interpreter standards (CNS) A4At grid (2 丨 OX297 mm) 503237 A7 B7 V. Description of the invention (eg) Table 5 (Performance ) Kane X Υ m R 5-63 〇Λ 0 2 Η 5-64 0 3 Η 5-65 Λ S 1 Η 5-66 勹 —λ 0 1 Η 5-67 _ person ir 0 2 MeO 5-68 i ^ s_ 0 1 Η 5-69 f ^ N_ S 5 Η -142- The paper size is suitable for the national standard of China (CNS &gt; A4 this grid (2 丨 〇 ^ 297 eaves) (Please read the precautions on the back first) (Fill in this page again.) Packing 、 · ιτ 503237 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention () Table 5 (continued)

5 -7 5 76 - 5 (請先閲讀背面之注意事項再填寫本頁)5 -7 5 76-5 (Please read the notes on the back before filling this page)

—Η—Η

Ν \ eΝΙΜ οΝ \ eΝΙΜ ο

H Η Η 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) -143- 503237H Η Η This paper size applies to China National Standard (CNS) Α4 size (210X297 mm) -143- 503237

A λ /fl\ 明 説 明 發 五 ) 續 C 6 表A λ / fl \ Explicitly explain 5) Continued C 6

-X-X

Y m-Y m-

R 〆e NIM c ο 2 Η 79 5-R 〆e NIM c ο 2 Η 79 5-

s 3s 3

e M —-------裝— (請先閱讀背面之注意事項再填寫本頁) -8 q-n o 2 cl -8e M —------- install— (Please read the precautions on the back before filling this page) -8 q-n o 2 cl -8

H -8H -8

NN

NIM 0 2NIM 0 2

H -8H -8

oo

H 5-84H 5-84

Η 本紙張尺度適中國固家標隼(CNS ) A4現格(2!〇κ 297公缝) -144- 503237Η The size of this paper is suitable for China Gujia standard 隼 (CNS) A4 (2! 〇κ 297 cm) -144- 503237

本紙張尺度適用中家秫準(CNS &gt;八4此格(2丨OX 297公釐) -145- 503237 ΛΊThe standard of this paper is applicable to Chinese standard (CNS &gt; 8 4 grids (2 丨 OX 297 mm) -145- 503237 ΛΊ

Ml 五、發明説明(4 ) 表5 (續) ^耷黎疼Ml V. Description of the invention (4) Table 5 (continued)

(請先閲讀背面之注意事項再填寫本頁) &gt;.裝 、v5 •146 - 本紙伕尺度適用中國國家標隼(CNS)A4此格(2丨()X2W公簷) 503237 A7 B7 五、發明説明(⑻) 表5 (續)(Please read the precautions on the back before filling this page) &gt; .Installation, v5 • 146-This paper's standard is applicable to China National Standard (CNS) A4 (2 丨 () X2W public eaves) 503237 A7 B7 V.发明 发明 (⑻) Table 5 (continued)

XX

Y mY m

R 5-102R 5-102

Ο Η 5-103 5-104 5-105 5-106 5-107Ο Η 5-103 5-104 5-105 5-106 5-107

Ο 2 Η 請 先 閲 讀 背 面 意 事 項 再 填 窝 本 頁 ΝΟ 2 Η Please read the backside items before filling in this page Ν

-Ν Ο Η Ν- Ν-Ν Ο Η Ν- Ν

Ν Ο 4 Η 訂 Ν- — Ο Ο Η ΗΝ Ο 4 Η Order Ν- — Ο Ο Η Η

MeMe

Ν 經濟部中央標準局員工消资合作社印装Ν Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

BrBr

ΝΝ

ΝΝ

Br 09 ΝBr 09 Ν

Ν ο Η s Η 本紙悵尺度通用中國®家標隼(CNS)A4現格(2!0Χ297公釐) 503237 A7 B7 五、發明説明(,W ) 表5 (續) 經濟部中央標率局貝工消費合作杜印装Ν ο s s Η The standard of this paper is China® House Standard (CNS) A4 (2! 0 × 297 mm) 503237 A7 B7 V. Description of the invention (, W) Table 5 (continued) Industrial and consumer cooperation

(請先閱讀背面之注意事項再填寫本頁) 訂 -148· 本紙張尺度適用中國國家標準(CNS ) Λ4現格(2丨OX 297公釐) 503237 經濟部中央樣率局貝工消費合作社印¾ A7 B7 五、發明説明(^ ) 表5 (續)(Please read the precautions on the back before filling this page) BOOK-148 · This paper size is applicable to Chinese National Standard (CNS) Λ4 is present (2 丨 OX 297 mm) 503237 Printed by the Shell Sample Consumer Cooperative of the Central Sample Rate Bureau of the Ministry of Economic Affairs ¾ A7 B7 V. Description of the invention (^) Table 5 (continued)

-149- (請先閲讀背面之注意事項再填寫本頁) 1--149- (Please read the notes on the back before filling this page) 1-

*1T 本紙張尺度通用中國國家標隼(CNS ) A4規格(2丨0X297公釐) 經濟部中央樣準局貝工消費合作杜印¾ 503237 A7 B7 五、發明説明) 上列化合物中,待佳為下列,即為化合物N 〇 . 1 - 1, 卜2,卜3,1-6,1_57, 1-59 ,1-62,1-72,1-81,1-91,1-93, 1-106, 1-121, 1-122, 1-125, 1-130 ,1-134, 1-135, 1-137, 1-140,1-142,卜 153,卜 156,卜 158, 1-161 ,1-177,1-179, 1 - 180, 1 - 1 82, 1 - 1 83, 1 -207及 1-218,其中以化合 ^ No. 1-1, 1-57, 1-62, 1-91, 1-93, 1-106, 1-122, 1-125, 1-130, 1-134 ,1-137,卜 140, 1-142, 1-153 ,1-156, 1-1 7 7, 1-179,卜180,卜182,卜183, 1-207 及 1-218 更佳 。又更佳化合物為化合物Ν ο · 1 - 6 2,1 - 9 3,1 - 1 2 5 ,卜1 3 4 , 1一140, 1-1 42, 1-153,1—177, 1-179, 1-182, 1-183 ¾ 1 — 207〇 最佳化合物為化合物N 〇 : 1 - 9 3 5- (4-(3 -甲基眯唑並 〔5,4-b〕毗啶-2-基甲氧 基)苄基)瞎唑聢-2,4-二國; 1-125 5- {4-(5 -氯-3-甲基眯唑並〔5, 4-b〕吡啶-2-基 甲氧基)苄基}哮唑啶- 2,4-二顚| 1-142 5- {4-(5 -甲氧基-3-甲基眯唑並 〔5, 4-b〕吡啶 -2 -基甲氣基)苄基}喀唑啶- 2,4 -二麵 1-153 5- (4-(5 -羥基-3-甲基眯唑並〔5, 4-b〕吡啶- 2-基甲氣基)苄基} Ϊ畜唑啶-2,4 -二酬; 1-182 5- {4-(5 -乙氧基-3-甲基眯唑並〔5, 4-b〕吡啶-2-基甲氣基)苄基)瞎唑啶-2, 4-二酮; 1-183 5- {4-(5 -異丙氧基-3-甲基眯唑並〔5,4-b〕吡 啶-2-基甲氣基)节基}瞎唑啶-2,4-二_ 。 -150- 本紙張尺度適用中國國家標準(CNS)A4規格(210X297公釐) ----------_·策------1T,------# (請先閱讀背面之注意事項再填寫本頁) 503237* 1T This paper is in accordance with China National Standard (CNS) A4 (2 丨 0X297 mm). The Central Bureau of Standards, Ministry of Economic Affairs, Shellfish Consumption Cooperation, Du Yin ¾ 503237 A7 B7 V. Description of the invention) Is the following, which is the compound N 0.1-1, Bu 2, Bu 3,1-6, 1-57, 1-59, 1-62, 1-72, 1-81, 1-91, 1-93, 1 -106, 1-121, 1-122, 1-125, 1-130, 1-134, 1-135, 1-137, 1-140, 1-142, BU 153, BU 156, BU 158, 1- 161, 1-177,1-179, 1-180, 1-1 82, 1-1 83, 1 -207 and 1-218, of which the compound ^ No. 1-1, 1-57, 1-62, 1-91, 1-93, 1-106, 1-122, 1-125, 1-130, 1-134, 1-137, Bu 140, 1-142, 1-153, 1-156, 1-1 7 7, 1-179, BU 180, BU 182, BU 183, 1-207 and 1-218 are more preferred. Still more preferred compounds are compounds N ο · 1-6 2, 1-9 3, 1-1 2 5, Bu 1 3 4, 1-140, 1-1 42, 1-153, 1-177, 1-179 , 1-182, 1-183 ¾ 1 — 207 〇 The best compound is compound N 〇: 1-9 3 5- (4- (3-methyloxazolo [5,4-b] pyrimidine-2- Methoxy) benzyl) triazolidine-2,4-dimeric; 1-125 5- {4- (5-chloro-3-methyloxazo [5, 4-b] pyridine-2- Methoxy) benzyl} pyrazolidine-2,4-difluorene | 1-142 5- {4- (5-methoxy-3-methyloxazo [5, 4-b] pyridine- 2-methylmethylamino) benzyl} carbazolidine-2,4-dihedral 1-153 5- (4- (5-hydroxy-3-methyloxazolo [5, 4-b] pyridine-2 -Ylmethylamino) benzyl} oxazosin-2,4 -diphenyl; 1-182 5- {4- (5 -ethoxy-3-methyloxazolo [5, 4-b] Pyridin-2-ylmethylamino) benzyl) pyrazolidine-2,4-dione; 1-183 5- {4- (5-isopropoxy-3-methyloxazolo [5,4 -b] pyridin-2-ylmethylamino) benzyl} pyrazolidine-2,4-di_. -150- This paper size applies to China National Standard (CNS) A4 (210X297 mm) ----------_ · 策 ------ 1T, ------ # (Please (Please read the notes on the back before filling out this page) 503237

AA

7 B 經濟部中央標準局員工消費合作社印製 五、發明説明() 表1及2中若干化合物之物理性質如下表3。 表 3 化合物No, 熔點 (°C) 化合物No. 熔點 (°〇) 1-59 55.8 - 58.2 1-130 212-214 1-62 46.1 - 48.9 1-158 244 - 246 1-57 132.8 - 135.6 1-134 211-213 1-2 42.6 - 44.5 1-135 189-191 1-3 66.6 - 70.0 1-137 204 - 205 1-1 42.3 - 44.6 1-140 203 - 205 1-93 223 - 225 1-156 264 - 265 1-72 200.0 - 202.4 1-81 183-185 1-106 197 - 202 1-161 88-91 1-6 174.3 - 175.5 1-177 166-168 1-107 205.9 - 207.0 1-207 210-211 1-121 210-212 1-153 240 - 242 1-122 231 - 232 1-182 245 - 246 1-123 185-186 1-183 210-212 1-91 247 - 248 1-190 96-100 1-124 205 - 207 1-179 211-213 1-125 222 - 223 1-142 258 - 260 1-218 226 - 228 1-142 鹽酸鹽 255 - 262 1-218 三氟乙酸鹽 229-230 1-142 富馬酸鹽 245 - 253 -151- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 503237 A 7 B7 五、發明説明() 牛物活件 式(II)化合物和其鹽類具有降低血糖濃度,減緩肥胖 症,缓和受損之葡萄糖耐受,抑制肝糖新生,降低血脂 濃度和抑制IS糖還原酶之活性。因此其可用於預防和/ 或治療高血糖症,肥胖症,高脂血症,糖尿病併發症( 包括視網膜病,腎病,神經病,白内障,冠狀動脈疾病 和動脈硬化)及再者用於肥胖關連性高血壓和骨質疏鬆 症。 化合物(I I )可以各種此藝熟知之型式投予,視欲治 療疾病和患者年齡,狀況和體重而定。例如,於經口投 予化合物方面,其可配方成藥H,膠囊,顆粒,粉末或 糖漿;或於非經腸投予方面,其可配方成注射劑(靜脈 内,肌肉内或皮下),擴散滴劑或栓劑。於以眼黏膜途 徑方面,其可配方成眼滴劑或眼藥音。此些配方可以傳 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 統方式製備,a若意欲,可將活性成分與任何傳統添加 物,如賦形藥,結合劑,崩散劑,潤滑劑,矯味劑,肋 溶劑,懸浮肋劑,乳化劑或覆被劑。雖然劑量視患者症 狀,年龄和體重,欲治療或預防疾病之性質和駸重性, 投予途徑和藥物型式之定,然而通常成人患者被建議之 每天劑量為〇·〇1至20GQ毫克之化合物,且其可以單一劑 量或分開劑量投予。 化合物(I I )之活性以下列試驗說明。 -152- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 503237 A7 B7 五、發明説明() 試驗1 隆rfn搪话袢 使用各具有至少40克體重之KK株高血糖公鼠做為試驗 動物。試驗用化合物為與1: 1體積比之聚乙二醇400和 水混合液混合。各動物被經口投予以下表6所示量之試 驗化合物且於其後令以自由餵食1 8小時。於此時間終了 ,未麻醉而由尾靜脈集血。血糖濃度(BGL)以葡萄糖分 析儀(GL-101,由三薆化成公司製造或Glucoroder.F,由 新野試驗公司製造)測定。 降血糖功率以下列公式計算: 降血糖功率(%)= 〔BGLS -BGLt)/ BGLS 〕 X100 其中: B G L s為僅投予溶劑,但無活性化合物群中之血糖濃 度;和 BGLt為投予試驗化合物群中之血糖濃度。 結果示於下表4中,其中各化合锪(I I)為以下列說明 其製備之實施例號碼予以認明。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) -153- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 503237 A7 _B7五、發明説明(、☆) 表 4 經濟部中央櫺隼局員工消費合作社印装 化合物之 實施例N 〇 · 劑量 (毫克/公斤) 降血糖功效 (% ) 1~59 10 13.2 1-62 1 2 7.7 1-57 10 2 7.0 1-3 10 16.2 1~1 10 2 0.9 1-93 1 2 4.7 1-106 10 2 7.6 卜6 1 11.6 1-122 1 3 4.0 卜91 1 13.8 1-125 1 37.1 1-134 1 2 4.5 1-137 1 10.2 卜140 1 2 1.7 如表4所關明,化合物(II)展現出優異之活性。 忒驗2 硌搪僚鹿釀之抑制作用 ^ S.Hymani〇 J.H. Kinoshita[J.Biol.Chem. ,240, -154- 冬紙張尺度適用中國國家橾準(CNS ) Λ4現格(2丨ox 297公釐) (請先閲讀背面之注意事項再填寫本頁) ♦ 503237 A7 B7 五、發明説明(似) 8 7 7 ( 1 9 6 5 )) f0 K.Inagaki,I.MiwafO J.Okuda [Arch. Biochero· Biophys·,316,377(1 982)1 之方1 去分離並部分 精製牛晶狀體醛糖還原酶,且其活性以Varma等人之方 法[B i 〇 c h e m . P h a r ni a c .,2 5,2 5 0 5 ( 1 9 7 6 ))光學地 _1定〇 測量化合物(II)於5 # g/ m [濃度之酵素活性抑制作用 ,且此測量值用以計算I C 值。結果示於下表5。 表 5 化合物之 於5/ig/ml I C5〇 實施例Ν ο · 之抑制作用(% ) (m g/inl) (請先閲讀背面之注意事項再填寫本頁) 經濟部中夹樣隼馬員工消費含泎f-t印¾ 1-59 54.5 - 1-62 58,1 3.2 1-57 麵 3.7 1-2 - 2.3 1-1 47 - 1-93 - 1.0 1-106 53.3 - 卜121 - 1.7 1-122 - 2.6 1-123 53.9 - 1-91 - 2.4 1-124 59.1 2 .Ί 1-125 - 1.8 1-130 76.3 0.8Θ 1-134 61.6 1.8 1-137 77.2 1.8 1-140 94.9 1.3 1-156 Θ1.6 0.89 1-161 91.8 0.85 -155- 本紙張尺度適/fl中國國家標隼(CNS ) Λ4悦格(210X 297公釐) 503237 A7 B7 五、發明説明() 試驗3 毒性 化合物(II)之毒性以分成5群之F34 4公鼠測試。試驗 化合物為以50毫克/公斤體重/天之劑量經口投予至各 試驗動物2星期。所使用之試驗化合物為編號卜9 3及 1 -12 5。動物連續觀察2週,且於此時段間,其並未顯示 出起因於試驗化合物之不正常。鑑於投予至各動物之實 質劑量,其零致命率顯示出化合物(II)具有非常低的毒 性。 本發明再以下列非侷限實施例予以說明。於此些實施 例中,於此些實施例中若干最後物質的製備以後續之製 備例說明。 例1 、 5-「4-(2-乙氬羰甲氬甚)苄某1睐_啶-2.4-二胭 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 將100克4 -(2 -溴-2-丁氣羧乙基)苯氣基醋酸甲酯(如 製備例3所述製備)和22克硫P之200毫升乙醇溶液於迴 流下加熱2 · 5小時。此後加入2 N鹽酸水溶液,並於迴流 下加熱5小時。於此時間終了,減壓蒸除溶劑,殘渣以 水稀釋後,以醋酸乙酯萃取。萃取物以無水硫酸鎂乾燥 ,並減壓蒸除溶劑。所得殘渣以矽膠柱層析精製,使用 2 : 5體積比之醋酸乙酯和己烷混合液做為洗提液,可得 1 9 . 4克之標題化合物,於1 0 5 - 1 0 6 °C熔解。 -15 6- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 503237 A 7 B7 五、發明説明() 例 2 R-「4-(2.2 -二 7, MZ.ffi 甚)爷甚 Ί 睐_啶-2.4-二_ 於冰冷卻下,將5 3 Q毫克之5 - ( 4 -羥苄基)ff唑啶-2,4 -二酮加至2 6 0毫克氫化銷(為於礦油中之5 5 %重量比分散 液,且事先以甲苯清洗)之5毫升二甲基甲醯胺懸浮液 中,並於室溫下攪拌3 0分鐘於此時間终了,於冰冷卻 下,將0 . 7 3毫升之溴乙醒二乙基乙縮醛加至混合液中, 並於5 0 °C下攪拌3小時。減壓蒸除二甲基甲醯胺。殘渣 以水稀釋並以加入1 N鹽酸水溶液將其調整至P Η 2〜3後, 以醋酸乙酯萃取。萃取物以氛化鈉飽和水溶嵌清洗並以 無水硫酸鈉乾燥後,減壓蒸除溶劑。殘渣以矽膠柱層析 精製,使用2 :〖體積比之己烷和醋酸乙酯混合液做為洗 提液,可得6 0 0毫克之標題化合物,具有R f = 0 · 4 6 (於矽 膠薄層層析上,使用2:1體積比之己烷和醋酸乙酯混合 液做為展開溶劑)。 例 3 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 氩乙氛某)节某1 睐_啶- 2,4 -二_ 將20毫升之6!&lt;鹽酸水溶液加至10.07克5-〔4-(2,2-二 乙氧乙氣基)苄基〕_唑啶-2, 4 -二麵(如例2所逑 製備)之80毫升四氫呋喃溶液中,並令於室溫下靜置過 夜。於此時間终了,減壓蒸除溶劑。殘渣以水稀釋後, 以醋酸乙酯萃取。萃取物以無水硫酸鈉乾燥並減壓蒸除 溶劑〇殘渣以矽膠柱層析精製,使用2:3體積比之己烷 和醋酸乙酯混合液做為洗提液,可得5 . 9 2克之標題化合 -157- 本紙張尺度適用中國國家標率(CNS ) Α4規格(210X297公釐) ~ 5032377 B Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of Invention () The physical properties of some of the compounds in Tables 1 and 2 are shown in Table 3. Table 3 Compound No, melting point (° C) Compound No. melting point (° 〇) 1-59 55.8-58.2 1-130 212-214 1-62 46.1-48.9 1-158 244-246 1-57 132.8-135.6 1- 134 211-213 1-2 42.6-44.5 1-135 189-191 1-3 66.6-70.0 1-137 204-205 1-1 42.3-44.6 1-140 203-205 1-93 223-225 1-156 264 -265 1-72 200.0-202.4 1-81 183-185 1-106 197-202 1-161 88-91 1-6 174.3-175.5 1-177 166-168 1-107 205.9-207.0 1-207 210-211 1-121 210-212 1-153 240-242 1-122 231-232 1-182 245-246 1-123 185-186 1-183 210-212 1-91 247-248 1-190 96-100 1- 124 205-207 1-179 211-213 1-125 222-223 1-142 258-260 1-218 226-228 1-142 Hydrochloride 255-262 1-218 Trifluoroacetate 229-230 1-142 Fumarate 245-253 -151- (Please read the notes on the back before filling in this page) This paper size applies to Chinese National Standard (CNS) A4 specification (210X297 mm) 503237 A 7 B7 V. Description of the invention () Bovine living compounds of formula (II) and their salts have lower blood glucose concentration, slow obesity, and alleviate impaired glucose tolerance , Suppress of hepatic regeneration, reducing blood lipid levels and the inhibitory activity of aldose reductase IS. Therefore it can be used for the prevention and / or treatment of hyperglycemia, obesity, hyperlipidemia, diabetic complications (including retinopathy, nephropathy, neuropathy, cataracts, coronary artery disease and arteriosclerosis) and also for obesity related Hypertension and osteoporosis. Compound (I I) can be administered in a variety of forms well known in the art, depending on the disease to be treated and the age, condition and weight of the patient. For example, it can be formulated as a drug H, capsule, granule, powder, or syrup for oral administration of a compound; or it can be formulated as an injection (intravenous, intramuscular or subcutaneous) for parenteral administration, and diffusely dripped. Or suppository. In terms of ocular mucosal pathway, it can be formulated as eye drops or eye drops. These formulas can be printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions on the back before filling this page) in a unified way. A If desired, the active ingredients can be combined with any traditional additives, such as excipients. , Binding agent, disintegrating agent, lubricant, flavoring agent, rib solvent, suspended rib agent, emulsifier or coating agent. Although the dosage depends on the patient's symptoms, age and weight, the nature and severity of the disease to be treated or prevented, the route of administration and the type of drug, but the recommended daily dosage for adults is generally 0.01 to 20 GQ mg And it can be administered in a single dose or in divided doses. The activity of the compound (I I) is illustrated by the following test. -152- This paper size is in accordance with Chinese National Standard (CNS) A4 (210X297 mm) 503237 A7 B7 V. Description of the invention () Test 1 Long rfn enamel 袢 Use KK hyperglycemic male rats each with a weight of at least 40 grams As a test animal. The test compound was mixed with a 1: 1 mixture of polyethylene glycol 400 and water. Each animal was orally administered with the test compound in the amount shown in Table 6 below, and thereafter fed freely for 18 hours. At the end of this time, blood was collected from the tail vein without anesthesia. The blood glucose concentration (BGL) was measured with a glucose analyzer (GL-101, manufactured by Mikasa Kasei Corporation or Glucoroder.F, manufactured by Shino Test Co., Ltd.). Hypoglycemic power is calculated by the following formula: Hypoglycemic power (%) = [BGLS -BGLt) / BGLS] X100 where: BGL s is the blood glucose concentration in the solvent-only group but no active compound group; and BGLt is the administration test Blood glucose concentration in a compound group. The results are shown in Table 4 below, where each compound (I I) is identified by the number of the example prepared as described below. Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the notes on the back before filling this page) -153- This paper size applies to China National Standard (CNS) A4 (210X297 mm) 503237 A7 _B7 V. Description of the invention (, ☆) Table 4 Example N of the compound printed by the Consumer Cooperative of the Central Government Bureau of the Ministry of Economic Affairs. Dose (mg / kg) Hypoglycemic effect (%) 1 ~ 59 10 13.2 1-62 1 2 7.7 1-57 10 2 7.0 1-3 10 16.2 1 ~ 1 10 2 0.9 1-93 1 2 4.7 1-106 10 2 7.6 Bu 6 1 11.6 1-122 1 3 4.0 Bu 91 1 13.8 1-125 1 37.1 1-134 1 2 4.5 1-137 1 10.2 BU 140 1 2 1.7 As shown in Table 4, compound (II) exhibited excellent activity. Test 2 抑制 Inhibitory effect of savage deer brew ^ S.Hymani〇JH Kinoshita [J.Biol.Chem., 240, -154- Winter paper size is applicable to China National Standards (CNS) Λ4 present grid (2 丨 ox 297 (Mm) (Please read the notes on the back before filling this page) ♦ 503237 A7 B7 V. Description of the invention (like) 8 7 7 (1 9 6 5)) f0 K.Inagaki, I. MiwafO J.Okuda [Arch Biochero · Biophys ·, 316,377 (1 982) 1 Formula 1 is used to isolate and partially purify bovine lens aldose reductase, and its activity is determined by Varma et al. [B i 〇chem. P har ni ac., 2 5 (2 5 0 5 (197 6)) optically -1 determination 〇 Measure the inhibitory effect of compound (II) at 5 # g / m [concentration of enzyme activity, and this measurement value is used to calculate the IC value. The results are shown in Table 5 below. Table 5 Inhibition of compounds in 5 / ig / ml I C50. Example N ο · Inhibition (%) (mg / inl) (Please read the precautions on the back before filling this page) Employees in the Ministry of Economic Affairs Consumption inclusive ¾ 1-59 54.5-1-62 58,1 3.2 1-57 noodles 3.7 1-2-2.3 1-1 47-1-93-1.0 1-106 53.3-Bu 121-1.7 1-122 -2.6 1-123 53.9-1-91-2.4 1-124 59.1 2 .Ί 1-125-1.8 1-130 76.3 0.8Θ 1-134 61.6 1.8 1-137 77.2 1.8 1-140 94.9 1.3 1-156 Θ1. 6 0.89 1-161 91.8 0.85 -155- The size of this paper is suitable / fl Chinese National Standard (CNS) Λ4 Yuege (210X 297 mm) 503237 A7 B7 V. Description of the invention () Test 3 Toxicity of toxic compound (II) Tested in 5 groups of F34 4 male mice. The test compound was administered orally to each test animal at a dose of 50 mg / kg body weight / day for 2 weeks. The test compounds used were Nos. 9 and 1-12. The animals were observed continuously for 2 weeks, and during this period, they did not show abnormalities due to the test compound. In view of the actual dose administered to each animal, its zero lethality shows that compound (II) has very low toxicity. The invention is illustrated by the following non-limiting examples. In these examples, the preparation of some final substances in these examples is illustrated by the subsequent preparation examples. Example 1, 5- "4- (2-Ethyl argon, methyl argon, and even benzyl) benzine 1 favor_pyridine-2.4-Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (Please read the precautions on the back before filling in this Page) 100 g of 4- (2-bromo-2-butyrocarboxyethyl) benzeneaminoacetic acid methyl ester (prepared as described in Preparation Example 3) and 22 g of sulfur P in 200 ml of ethanol solution are heated under reflux 2 · 5 hours. Thereafter, a 2 N aqueous hydrochloric acid solution was added and heated under reflux for 5 hours. At the end of this time, the solvent was distilled off under reduced pressure, the residue was diluted with water and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, The solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography using a 2: 5 volume ratio of ethyl acetate and hexane as an eluent to obtain 19.4 g of the title compound in 105. -1 0 6 ° C melting. -15 6- This paper size applies Chinese National Standard (CNS) A4 (210 X 297 mm) 503237 A 7 B7 V. Description of the invention () Example 2 R- "4- (2.2 -Di 7, MZ.ffi even) Ye very much favor _pyridine-2.4-di_ Under ice cooling, 5 3 Q mg of 5-(4-hydroxybenzyl) ffazolidine-2,4-dione Add to 260 mg of hydrogenated pin (a 55% by weight dispersion in mineral oil and washed with toluene in advance) in 5 ml of dimethylformamide suspension, and stirred at room temperature for 30 minutes at At the end of this time, 0.73 ml of bromoethionyl diethyl acetal was added to the mixture under ice cooling, and the mixture was stirred at 50 ° C for 3 hours. The dimethylformate was distilled off under reduced pressure. Ammonium amine. The residue was diluted with water and adjusted to P 加入 by adding 1 N aqueous hydrochloric acid solution, and then extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydroxide and dried over anhydrous sodium sulfate. The solvent was removed by autoclaving. The residue was purified by silica gel column chromatography using a mixture ratio of hexane and ethyl acetate as the eluent in a volume ratio of 2: 600 to obtain 60 mg of the title compound with R f = 0 · 4 6 (On silica thin layer chromatography, a 2: 1 mixture of hexane and ethyl acetate was used as the developing solvent.) Example 3 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the back Please fill in this page again) Argon acetone) Jie 1 favor _ pyridine-2,4-two _ will dissolve 20 ml of 6! &Lt; hydrochloric acid in water Add 10.07 g of 5- [4- (2,2-diethoxyethoxy) benzyl] -oxazolyl-2,4-dihexyl (prepared as in Example 2) in 80 ml of tetrahydrofuran, and Let it stand at room temperature overnight. At the end of this time, the solvent was distilled off under reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The residue was passed through a silica gel column. Chromatographic purification, using a 2: 3 volume ratio of hexane and ethyl acetate as the eluent, 5.92 g of the title compound -157- This paper size applies to China National Standards (CNS) Α4 specifications (210X297 mm) ~ 503237

物,具有Rf=〇.37(於矽膠薄層層析上,使用1:2體積比 之己烷和醋酸乙酯混合液做為展開溶劑)。 例4 5 ~ ί 4 ~ ί 2~(1.3~~二获咢戊院-2-基)乙氣基 J 节基I 噻唑啶-2,4-二酮 ' 重覆類似例2所述步驟,除了使用1 5 . 0克之5 - ( 4 -羥苄基)喀唑啶-2 , 4 -二嗣,8 · 8 0克之氫化鈉(為於礦油 中之5 5 %重量比分散液),1 7毫升之2,- ( 2 -溴乙基)-1,3 -二枵茂烷和80毫升之二甲基甲醯胺,並將産物以矽柱 層析精製,使用1:1體積比之己烷和醋酸酸乙酯混合液 做為洗提液,可得6 · 6 7克之標題化合物,於102 - 1 Q 4 °C 熔解。 例 5 5-「4-(3-氩丙氩某)爷甚1眩_啶-2.4-二_ 將6.30克5- (4-〔 2-(1,3 -二嗜戊烷-2-基)乙氧基〕 苄基}瞎唑啶- 2,4 -二顚1 (如例4所述製備)之50 經濟部中央標準局貝工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 毫升4 : 1醋酸和水混合液於6 G T下攪拌6小時。於此時 間終了,減壓蒸除溶劑〇殘渣以矽膠柱層析精製,使用 1 : 1體積比之己烷和醋酸乙酯混合液做為洗提液,可得 2. 20克之標題化合物,於48-51 °C熔解。 製備例1 4-㈣荣氛甚酷酴甲酷 將56克4 -硝苯酚,90克溴醋酸甲酯和100克磺酸鉀之 500毫升二甲基甲醯胺溶液於室溫下攪拌2天。於此時 -15 8- 本紙張尺度適用中國國家樣準(CNS ) A4規格(210X297公釐) 503237 A7 B7 五、發明説明() 間終了,減壓蒸除二甲基甲醯胺。所得殘渣以水稀釋後 ,以醋酸乙酯萃取,萃取物以水清洗並以無水硫酸銷乾 燥後,減壓蒸除溶劑。殘渣以己烷碾製結晶化,可得 6 3 . 3克之標題化合物,於9 8 - 9 9 °C熔解。 製備例2 · 4-胺苯氧基醋酸甲酯 30,δ克之4-硝苯氣基醋酸甲酯(如製備例1所述製備 ),5 , 0克之10% w/w耙/磺和500毫升之甲醇,在氫大 氣室溫30分,601C 2小時及801C 3小時之攪拌後,濾除 觸媒,減壓濃縮,層析在矽膠柱(己烷:乙酸乙酯= 2 : 1),可得25. δ克之標題化合物,具有Rf二0.79 (於 矽膠薄層層析上,使用醋酸乙酯做為展開溶劑)。 製備例3 4-(2-溴-2-丁氧羰乙基)苯氧基醋酸甲酯 於冰冷卻下,將9 8克之4 7 % w / v氫溴酸水溶液且績 將含有12.8克亞硝酸納之33毫升水溶液逐滴加至25.8克 4 -胺苯氣基醋酸甲酯(如製備例2所述製備)之263毫升 2 : 5體積比之甲醇和丙酮混合液溶液中,並於冰冷卻下With Rf = 0.37 (on silica thin layer chromatography, using a 1: 2 volume ratio of hexane and ethyl acetate as the developing solvent). Example 4 5 ~ ί 4 ~ ί 2 ~ (1.3 ~~ Secondary pentamyl-2-yl) ethoxy group J Benzyl I thiazolidine-2,4-dione 'Repeat steps similar to those described in Example 2, In addition to using 15.0 grams of 5-(4-hydroxybenzyl) carbazolidine-2, 4-dihydrazone, 8.80 grams of sodium hydride (a 55% by weight dispersion in mineral oil), 17 ml of 2,-(2-bromoethyl) -1,3-dioxane and 80 ml of dimethylformamide, and the product was purified by silica gel column chromatography using a 1: 1 volume ratio A mixed solution of hexane and ethyl acetate was used as an eluent to obtain 6.67 g of the title compound, which was melted at 102-1 Q 4 ° C. Example 5 5- (4- (3-argon-propargonium) alkoxide 1-pyridine-2.4-di-_ 6.30 g 5- (4- [2- (1,3 -di-pentopent-2-yl ) Ethoxy] Benzyl} Blazolidine-2,4-Dihydrazine 1 (prepared as described in Example 4) 50 Printed by the Shellfish Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (Please read the notes on the back before filling (In this page) A mixture of 4: 1 acetic acid and water is stirred for 6 hours at 6 GT. At the end of this time, the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography using 1: 1 volume ratio of hexane and acetic acid. The ethyl acetate mixture was used as an eluent to obtain 2. 20 g of the title compound, which was melted at 48-51 ° C. Preparation Example 1 4-Phosphorus is very cool. Pyrosol is 56 g of 4-nitrophenol, 90 g. A solution of methyl bromoacetate and 500 g of dimethylformamide in 100 g of potassium sulfonate was stirred at room temperature for 2 days. At this time -15 8- This paper size applies to China National Standard (CNS) A4 (210X297) (Mm) 503237 A7 B7 V. Explanation of the invention () At the end of the period, dimethylformamide was distilled off under reduced pressure. The obtained residue was diluted with water and extracted with ethyl acetate. The extract was washed with water and dried over anhydrous sulfuric acid. After decompression The solvent was removed. The residue was ground and crystallized with hexane to obtain 63.3 g of the title compound, which was melted at 9 8-9 9 ° C. Preparation Example 2 · 4-Aminophenoxyacetic acid methyl ester 30, δ 4 -Methyl phenylbenzene acetoacetate (prepared as described in Preparation Example 1), 10% w / w rake / sulfur of 5.0 g and 500 ml of methanol, 30 minutes at room temperature in a hydrogen atmosphere, 601C for 2 hours and 801C 3 After stirring for an hour, the catalyst was filtered off, concentrated under reduced pressure, and chromatographed on a silica gel column (hexane: ethyl acetate = 2: 1) to obtain 25. δ of the title compound having Rf di 0.79 (in a thin layer of silica gel) Chromatographically, ethyl acetate was used as the developing solvent. Preparation Example 3 4- (2-Bromo-2-butoxycarbonylethyl) phenoxyacetic acid methyl ester was cooled to 47% of 98 g under ice cooling. w / v Hydrobromic acid aqueous solution and 33 ml of an aqueous solution containing 12.8 g of sodium nitrite was added dropwise to 263 ml of 25.8 g of 4-aminobenzyl methyl acetate (prepared as described in Preparation Example 2) 2: 5 Volume ratio of methanol and acetone mixed solution, under ice cooling

It拌3 Q分鐘。其後加入1 8 . 2克之丙烯酸丁酯。混合液於 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) ; 冰冷卻下ϋ拌3 0分鐘後加入3 . 2克之溴化銅(I )並於室溫 下搜拌過夜〇於此時間终了,減壓蒸除溶劑,殘渣以氯 化鈉水溶液稀釋並以醋酸乙酯萃取。萃取物以氯化鈉水 溶液清洗並以無水硫酸鈉乾燥後,減壓蒸除溶劑,可得 51.7克之内含標題化合物之粗産物且具有反[=0.46(於 -159- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) _ 503237 A7 B7 五、發明説明() 矽膠薄層層析上,使用5:1體積比之己烷和醋酸乙酯混 合液做為展開溶劑)。 製備例4 5-ί4-(1Η -咪脾祐 「4.5-bl 毗啶-2-某甲氬甚1 苄甚} 隊唑啶-2 . 4 -二(化合物N 〇 .〗-9 1 ) 將1.13克之4-(乙氧羰基甲氣基)苄基喀唑啶-2, 4-二 酬(如例1所逑例1 )加至200毫克之2, 3 -二胺基毗 啶中,並於1 1 〇 °C下攪拌2天。於此時間終了,將反應 混液以3 N鹽酸水溶液處理並績以加入氨水使其呈鹼性。 水狀混合液於減壓下蒸發至乾,並將殘渣以矽膠柱層析 精製,使用梯度洗提法,以至10·· 1體積比之醋酸乙 酯和甲醇混合液做為洗提液。産物以醋酸乙酯碾製結晶 化,可得4 Q Q毫克之標題化合物,於2 4 7 - 2 4 8 °C熔解。 製備例5 S- (4-(2-甲甚-6 -三氩甲某眯「5.4-hl 吡啶- 2-甚甲氬甚)苄基1 睐_啶-2.4-二_(&gt;fh合物Hn.1-1:^) 經濟部中央標準局員工消費合作社印裝 (請先閱讀背面之注意事項再填寫本頁) 將4·16克之5-(4-(2-氧乙氧基)苄基)瞎唑啶-2,4-二 國(如例3所述製備)加至3. 00克3 -胺基-2 -甲胺基 -5-三氟甲基吡啶之6毫升乙醇和6毫升醋酸混合液溶 液中,並於室溫下攪拌4小時。於此時間終了,減壓蒸 除溶劑。於殘渣中加入50毫升之1,2 -二甲氣基乙烷和5.2 克之碘,並於60°C下攪拌一天。於此時間终了,將反應 混液倒入水中後,以醋酸乙酯萃取。萃取物以氨化鈉水 -16 0- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ 503237 A7 B7 五、發明説明() 溶液清洗並以無水硫酸銷乾燥後,減壓蒸除溶劑。殘渣 以矽膠柱層析精製,使用1:1體積比之己烷和醋酸乙酯 混合液做為洗提液。産物以醋酸乙酯碾製結晶化,可得 5 2 0毫克之標題化合物,於2 1 2 - 2 1 4 °C熔解。 製備例6 . 5-(4-(3-(4-氣苄甚)眯_# 毗啶-2-甚田 氣甚)苄甚)睹_啶- 2.4 -二圈(化合物No. 1-1 34 ) 重覆類似製備例5所述步驟,除了使用1.2Q克之3 -胺 基- 2- (4 -氛苄基)胺基吡啶(如製備例]3所述製備),1.36 克之5-〔 4-(2-氣乙氣基)苄基〕晴唑啶- 2,4-二顚1 (如 例3所述製備),3毫升之乙醇,3毫升之醋酸,1.69 克之碘和25毫升之1,2 -二甲氣基乙烷,可得標題化合物 ,為一粗産物。此粗産物以矽膠柱層析精製,使用梯度 洗提法,以1 : 1至1 : 2體積比之己烷和醋酸乙酯混合液 做為洗提液,可得(Κ 4 〇克之檫題化合物,於2 1 1 - 2 1 3 °C 熔解〇 製備例7 硝基-2-苯胺基吡啶 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 在冰冷下令15克2-氯-3-硝基毗啶,13, 22克苯胺和 25.07克硕酸鈉於180毫升甲苯中反應。在室溫攪拌8 小時後,蒸除甲苯,加水而以乙酸乙酯萃取,以食鹽 水洗淨,以硫酸鈉乾燥,減壓蒸除溶劑。所得粗産物 以矽_柱層析精製,使用1:5體積比之醋酸乙酯和己 烷混合液,可得6, 9克之標題化合物,於66-68 °C熔解。 -16卜 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇ϋ97公釐) ~ 503237 A7 B7 五、發明説明() 靱備例8 ^-m m -2-^ m m m, 重覆頫似製備例2所述步驟,除:r今6 · 9克3 -硝基-2 -苯胺基吡啶(如製備例7所述製備)於150毫升乙醇和50 毫升二&quot;院混合液中,1.38克10% w/w把/碳存在下 進行氫化。産物依實施例6所述操作後,可得4 · 2克之 標題化合物,於1 3 7 - 1 4 0 °C熔解。 製備例9 5-(4-(3-荣某眯_#「5.441卅啶-2-某甲氳某) 策―丄喀唑症-2 , 4 -二_!(化合物N 〇 . 1 -161) 重覆類似製備例5所述步驟,除了使用2 · 7 8克之3 -胺 基-2-苯胺基吡啶(如製備例8所述製備),3.98克之5-〔4-(2 -氣乙氧基)苄基瞎唑啶-2, 4 -二闕(如實施例3所 述製備),4·9克之碘,6毫之乙醇,6毫升之醋酸和50 毫升之1 , 2 -二甲氣基乙烷。産物如製備例5所述操作後 ,將所得之粗産物以矽膠柱層析精製,使用1:2體積比 之己烷和醋酸乙酯混合液做為洗提液,可得400毫克之 標題化合物,於88-91 °C熔解。 舞備例1 0 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 田粽甚-硝基1啶 重覆類似製備例7所述步驟,除了令2 4 · 9克之2 -氛-3 -硝基吡啶,41.7克之磺酸鈉,22·7毫升甲基胺之3ϋ %乙 醇溶液於2 5 0毫升甲苯中反應。産物依製備例7«所述操作 後,所得粗産物以異丙醇碾製結晶化,可得2 4 · 0克之標 ' 題化合物,於5 2 - 5 3 °C熔解。 -162- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 經濟部中央標準局員工消費合作社印製 503237 A7 B7 五、發明説明() 製備例11 -防某-2 - _甚胺甚附啶 重覆類似製備例2所述步驟,除了今5 . Q 0克之2 -甲胺 基-3 -硝基吡啶(如製備例1 0所述製備)於8 0毫升I , 4 -二 P咢烷中,1 · 〇 ϋ克1 〇 % w / w ϊ巴/碳存在下_行氫化。産 物依製備例2所述操作後,可得3 · 8 7克之標題化合物, 於9 Q - 9 2 °C熔解。 製備例1 2 IS - f 4 - Γ 2 - ( ·3 -甲甚眯唑祐 Γ 5 . 4 - b 1 附游-2 -甚),氩 甚)苄某)蹀_啶-2.4 -二酿1 (化合物) 重覆類似製備例5所述步驟,除了使用Q . 3 4克之3 -胺 基-2-甲胺基吡啶(如製備例11所述製備),2. 10克之5-〔4-(3 -氧丙氧基)苄基〕if唑啶-2, 4 -二麵(如製備例5 所述製備),6毫升之乙醇,3毫升之醋酸,2. 32克之 碘和30毫升之1,2 -二甲氧.基乙烷。産物如製備例5所述 操作後,將所得粗産物以矽膠柱層析精製,使用醋酸乙 酯做為洗提液。可得85克之標題化合物,於96-100 °C熔 解。 製備例1 3 3-胺基- 2-(4-氯苄基)胺基毗啶 混合5.00克之2-(4-氯苄基)胺基-3-硝基吡啶(如製 備例14所述製備),21,4克之二氯化錫(II)二水合物, 及150毫升9:1體積比之醋酸乙酯和2 -甲基-2-丙醇,在 60¾攪拌1小時後加0 · 36克之硼氫化鈉和在60Ρ攪拌3 -163 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210^297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 d 503237 A7 B7 五、發明説明() 小時後,減壓蒸除溶劑,所得殘渣以水稀釋並加入磺酸 鉀水溶液中和後,以醋酸乙酯萃取。萃取物以氯化鈉水 溶液清洗並以無水硫酸鈉乾燥後,減壓蒸除溶劑。所得 殘渣以醋酸乙酯和己烷混合液碾製結晶化,可得3 . 55克 之標額化合物,於1 2 3 - 1 2 5 °C熔解。 製備例1 4 ? - U -氣苄甚)胺甚Ί磘某蚍啶 將1 0 . 3克2 -羥基-3 -硝基吡啶和2 5 . 5毫升亞硫醯氯之 混合液於迺流下加熱2 . 5小時後,快速加入1 . 1毫升之二 甲基甲醯胺,且其後於迴硫下加熱2 . 5小時。於此時間 终了,減壓蒸除溶劑。於所得殘渣中加入80毫升之甲苯 和19.1克之碩酸鈉,且其後逐滴加入12.3毫升4 -氛苄基 胺之2 Q毫升甲苯溶液,其後於8 5 °C攪拌4小時。於此時 間終了,濾除不溶物。過濾物以水清洗並以無水硫酸鈉 乾燥後,減壓蒸除溶劑。殘渣以2 -丙醇碾製結晶化,可 得1 2 . 0克之標題化合物,於9 5 - 9 6 °C熔解。 請 先 閱 讀 背 Λ 之 注 意 事 項 頁 經濟部中央標準局員工消費合作社印製 -164 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐)It mixes for 3 Q minutes. Thereafter, 18.2 g of butyl acrylate was added. The mixture is printed at the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs (please read the precautions on the back before filling this page); stir for 30 minutes under ice cooling and add 3.2 grams of copper bromide (I) and mix in the room. The mixture was stirred at room temperature overnight. At the end of this time, the solvent was distilled off under reduced pressure. The residue was diluted with aqueous sodium chloride solution and extracted with ethyl acetate. After the extract was washed with an aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain 51.7 g of a crude product containing the title compound and having a counter-productivity [= 0.46 (in -159- this paper is applicable to Chinese countries) Standard (CNS) A4 specification (210X297 mm) _ 503237 A7 B7 V. Description of the invention () For thin layer silica gel chromatography, a 5: 1 volume ratio of hexane and ethyl acetate mixed solution is used as the developing solvent). Production Example 4 5-ί4- (1Η-Mipiyou, "4.5-bl pyridin-2-one methylargonyl 1 benzyl) oxazodine-2. 4-di (compound N 0. -9-9) will be 1.13 grams of 4- (ethoxycarbonylmethylamino) benzylcarbazolidine-2,4-diamine (as in Example 1 and Example 1) was added to 200 mg of 2,3-diaminopyridine, and Stir for 2 days at 110 ° C. At the end of this time, treat the reaction mixture with a 3 N aqueous hydrochloric acid solution and add ammonia to make it alkaline. The aqueous mixture is evaporated to dryness under reduced pressure, and The residue was purified by silica gel column chromatography, and a gradient elution method was used to obtain a 10 ·· 1 volume ratio of ethyl acetate and methanol as the eluent. The product was milled and crystallized with ethyl acetate to obtain 4 QQ mg. The title compound was melted at 2 4 7-2 4 8 ° C. Preparation Example 5 S- (4- (2-methyl-6-6-trimethylamine) "5.4-hl pyridine-2- 2-methylargine" Benzyl 1 favors _pyridine-2.4-di _ (&f; fh compound Hn.1-1: ^) Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling this page) · 16 grams of 5- (4- (2-oxethoxy) benzyl) pyrazolid-2,4-two countries (as described in Example 3 Preparation) Add 3.00 g of 3-amino-2-methylamino-5-trifluoromethylpyridine to a solution of 6 ml of ethanol and 6 ml of acetic acid, and stir at room temperature for 4 hours. At the end of the time, the solvent was evaporated under reduced pressure. To the residue were added 50 ml of 1,2-dimethylaminoethane and 5.2 g of iodine, and the mixture was stirred at 60 ° C for one day. At the end of this time, the reaction mixture was poured into After the water, it was extracted with ethyl acetate. The extract was extracted with sodium ammonium water-16 0- This paper size is applicable to Chinese National Standard (CNS) A4 (210X297 mm) ~ 503237 A7 B7 V. Description of the invention () Solution cleaning and After drying with anhydrous sulfuric acid pin, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography, using a 1: 1 volume ratio of hexane and ethyl acetate as the eluent. The product was rolled and crystallized with ethyl acetate 52.0 mg of the title compound was melted at 2 1 2-2 1 4 ° C. Preparation Example 6. 5- (4- (3- (4-Gabenzyl)) _ # pyridin-2 -Yita Tianqi) benzyl) _ pyridine-2.4-two circles (Compound No. 1-1 34) Repeat the procedure similar to that described in Preparation Example 5 except that 1.2Q g of 3-amino- 2- (4- atmosphere Benzyl) aminopyridine (prepared as described in Preparation Example 3), 1.36 g of 5- [4- (2-Gasethylbenzyl) benzyl] Qazolidin-2,4-Difluorene 1 (as in Example 3 The preparation), 3 ml of ethanol, 3 ml of acetic acid, 1.69 g of iodine, and 25 ml of 1,2-dimethylaminoethane, the title compound was obtained as a crude product. This crude product was purified by silica gel column chromatography, and a gradient elution method was used, and a mixed solution of hexane and ethyl acetate in a volume ratio of 1: 1 to 1: 2 was used as an eluent to obtain (κ 4 〇 檫 of the title Compound, melted at 2 1 1-2 1 3 ° C. Preparation Example 7 Printed by the Consumer Cooperatives of the Central Standards Bureau, Ministry of Economic Affairs, Nitro-2-anilinopyridine (Please read the precautions on the back before filling this page). Order 15 g of 2-chloro-3-nitropyridine, 13, 22 g of aniline, and 25.07 g of sodium sulfonate in 180 ml of toluene. After stirring at room temperature for 8 hours, toluene was distilled off, water was added and ethyl acetate was added. Extraction, washing with brine, drying over sodium sulfate, and distilling off the solvent under reduced pressure. The obtained crude product was purified by silica-column chromatography using a 1: 5 volume ratio of ethyl acetate and hexane mixed solution to obtain 6, 9 Gram of the title compound, which melts at 66-68 ° C. -16 The paper size is applicable to Chinese National Standard (CNS) A4 (21〇2197 mm) ~ 503237 A7 B7 5. Description of the invention () 靱 Preparation Example 8 ^- mm -2- ^ mmm, repeating the steps described in Preparation Example 2, except: r 6.9 g of 3-nitro-2 -anilinopyridine (such as Prepared in Preparation Example 7) Hydrogenation was performed in the presence of 1.38 g of 10% w / w carbon / carbon in 150 ml of ethanol and 50 ml of the dilute compound solution. After the product was operated as described in Example 6, 4 was obtained. · 2 g of the title compound, which melted at 1 37-1 40 ° C. Preparation Example 9 5- (4- (3- 荣 某 眯 _ # 「5.441 卅 定 -2- 某甲 氲 某) Policy-Taka Azole-2, 4-di-! (Compound No. 0.1-161) Repeat the procedure similar to that described in Preparation Example 5 except that 2.78 g of 3-amino-2-anilinopyridine (as in Preparation Example (Prepared as described in 8), 3.98 grams of 5- [4- (2-gasethoxy) benzylpyrazolidine-2,4-dihydrazone (prepared as described in Example 3), 4.9 grams of iodine, 6 Ethanol, 6 ml of acetic acid and 50 ml of 1,2-dimethylaminoethane. After the product was operated as described in Preparation 5, the crude product obtained was purified by silica gel column chromatography using a volume of 1: 2. Compared with hexane and ethyl acetate mixed liquid as the eluent, 400 mg of the title compound can be obtained and melted at 88-91 ° C. Dance Preparation Example 10 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please first (Read the notes on the back and fill out this page) The even-nitro 1-pyridine was repeated in a similar manner to that described in Preparation Example 7 except that 2 4 · 9 g of 2-ammonia-3-nitropyridine, 41.7 g of sodium sulfonate, and 22.7 ml of methylamine 3% ethanol The solution was reacted in 250 ml of toluene. After the product was operated as described in Preparation Example 7 «, the obtained crude product was ground and crystallized by isopropanol to obtain 2 4 · 0 g of the standard compound in 5 2-5 Dissolve at 3 ° C. -162- This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) _ Printed by the Employees' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 503237 A7 B7 V. Description of the invention () Preparation example 11-Fang-2-_ Very amine and even apyridine were repeated in the same steps as in Preparation Example 2 except that 5. Q 0 g of 2-methylamino-3 -nitropyridine (prepared as described in Preparation Example 10) in 80 ml of I, 4 -Dipyridane, hydrogenated in the presence of 1.0 g of 10% w / w barium / carbon. After the product was worked up as described in Preparation Example 2, 3.87 g of the title compound was obtained, and was melted at 9 Q-9 2 ° C. Production Example 1 2 IS-f 4-Γ 2-(· 3 -methyazolazole Γ 5. 4-b 1 Fuyou -2-even), argon)) hydrazine-2.4-second brew 1 (Compound) Repeat steps similar to those described in Preparation Example 5, except that Q. 34 grams of 3-amino-2-methylaminopyridine (prepared as described in Preparation Example 11), 2. 10 grams of 5- [4 -(3-oxopropoxy) benzyl] ifazolidine-2,4-dihedron (prepared as described in Preparation 5), 6 ml of ethanol, 3 ml of acetic acid, 2.32 g of iodine and 30 ml Of 1,2-dimethoxy.ylethane. After the product was operated as described in Preparation Example 5, the obtained crude product was purified by silica gel column chromatography using ethyl acetate as an eluent. 85 g of the title compound were obtained and were melted at 96-100 ° C. Preparation Example 1 3 3-amino-2- (4-chlorobenzyl) aminopyridine was mixed with 5.00 g of 2- (4-chlorobenzyl) amino-3-nitropyridine (prepared as described in Preparation Example 14). ), 21.4 g of tin (II) dichloride dihydrate, and 150 ml of 9: 1 volume ratio of ethyl acetate and 2-methyl-2-propanol, stirred at 60¾ for 1 hour and then added 0 · 36 Gram of sodium borohydride and stirring at 60P 3 -163-This paper size applies the Chinese National Standard (CNS) A4 specification (210 ^ 297 mm) (Please read the precautions on the back before filling this page) Order 503237 A7 B7 5 2. Description of the invention After () hours, the solvent was distilled off under reduced pressure. The obtained residue was diluted with water and neutralized by adding a potassium sulfonate aqueous solution, and then extracted with ethyl acetate. After the extract was washed with an aqueous sodium chloride solution and dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The obtained residue was ground and crystallized by using a mixed solution of ethyl acetate and hexane to obtain 3.55 g of a standard compound, which was melted at 1 2-1 2 5 ° C. Preparation Example 1 4 -U-Gabenzylamine) Pyridine A mixture of 10.3 g of 2-hydroxy-3-nitropyridine and 25.5 ml of thionyl chloride was put under a stream of water. After 2.5 hours of heating, 1.1 ml of dimethylformamide was quickly added, and then heated for 2.5 hours under sulfur return. At the end of this time, the solvent was evaporated under reduced pressure. To the obtained residue were added 80 ml of toluene and 19.1 g of sodium geranate, and then 12.3 ml of 2-Q benzylamine in 2 Q ml of a toluene solution was added dropwise, followed by stirring at 8 5 ° C for 4 hours. At the end of this time, insoluble matter was filtered off. The filtrate was washed with water and dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The residue was crystallized by milling with 2-propanol to obtain 12.0 g of the title compound, which was melted at 95-96 ° C. Please read the note at the back of the page first printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs -164 This paper size applies to the Chinese National Standard (CNS) Α4 specification (210X297 mm)

Claims (1)

503237503237 503237 六、申請專利範圍 5. 如申請專利範圍第1項之化合物,其 6. 如申請專利範圍第1項之化合物,其 7. 如申請專利範圍第1項之化合物,其 8. 如申請專利範圍第1項之化合物,其 硫。 9. 如申請專利範圍第8項之化合物,其 院基,1.4院氧基或鹵原子。 10. 如申請專利範圍第8項之化合物,其 甲氧基,乙氧基,氟原子或氯原子。 11. 如申請專利範圍第8項之化合物,其 甲氧基。 12如申請專利範圍第8項之化合物,其 中R爲氫原子。 中Y爲氧原子。 中Y’爲硫原子。 中Y爲氧,Y’爲 中R爲氫原子, 中R爲氫原子, 中R爲氫原子, 中R爲氫原子。503237 6. Apply for a patent scope 5. If the compound of the patent scope item 1 is applied, it 6. If the patent scope of the application item 1 is applied, it 7. If the patent scope of the application item 1 is applied, it 8. If the patent is applied for The compound of the scope item 1, its sulfur. 9. If the compound in the scope of patent application No. 8 is applied, its compound group, 1.4 compound oxygen or halogen atom. 10. As for the compound in the scope of patent application item 8, its methoxy, ethoxy, fluorine atom or chlorine atom. 11. As for the compound in the scope of patent application No. 8, its methoxy group. 12 The compound as claimed in claim 8 wherein R is a hydrogen atom. Where Y is an oxygen atom. Where Y 'is a sulfur atom. Where Y is oxygen, Y 'is where R is a hydrogen atom, where R is a hydrogen atom, where R is a hydrogen atom, and where R is a hydrogen atom.
TW087114283A 1994-04-11 1995-04-11 Intermediate in manufacture of heterocyclic compounds having anti-diabetic activity TW503237B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7208394 1994-04-11

Publications (1)

Publication Number Publication Date
TW503237B true TW503237B (en) 2002-09-21

Family

ID=13479165

Family Applications (2)

Application Number Title Priority Date Filing Date
TW087114283A TW503237B (en) 1994-04-11 1995-04-11 Intermediate in manufacture of heterocyclic compounds having anti-diabetic activity
TW084103469A TW407156B (en) 1994-04-11 1995-04-11 Heterocyclic compounds having anti-diabetic activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW084103469A TW407156B (en) 1994-04-11 1995-04-11 Heterocyclic compounds having anti-diabetic activity

Country Status (22)

Country Link
US (6) US5624935A (en)
EP (2) EP1022274B1 (en)
KR (1) KR950032188A (en)
CN (1) CN1060173C (en)
AT (2) ATE207488T1 (en)
AU (1) AU683348B2 (en)
CA (1) CA2146701A1 (en)
CZ (1) CZ289317B6 (en)
DE (2) DE69528000T2 (en)
DK (2) DK0676398T3 (en)
ES (2) ES2165895T3 (en)
FI (1) FI951731A (en)
HK (2) HK1029338A1 (en)
HU (1) HU219887B (en)
ID (1) ID20564A (en)
IL (1) IL113313A (en)
NO (2) NO305987B1 (en)
NZ (1) NZ270917A (en)
PT (2) PT676398E (en)
RU (2) RU2114844C1 (en)
TW (2) TW503237B (en)
ZA (1) ZA952990B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ289317B6 (en) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyclic compound, pharmaceutical preparations in which the compound is comprised and use thereof
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimidazole derivatives and pharmaceutical compositions containing the same
NO318765B1 (en) * 1995-07-03 2005-05-02 Sankyo Co Use of an HMG-CoA reductase inhibitor and an insulin sensitizer to prepare a drug for the prevention or treatment of arteriosclerosis or xanthoma, as well as packaged pharmaceutical preparation comprising the two agents in separate portions.
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (en) * 1996-07-01 2011-10-04 heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU2823797A (en) * 1997-05-02 1997-11-19 Dr. Reddy's Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
HU228193B1 (en) 1997-10-08 2013-01-28 Sankyo Co Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use
HUP9902721A2 (en) 1997-11-25 1999-12-28 The Procter & Gamble Co. Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor
JP2002510283A (en) * 1997-12-02 2002-04-02 ドクター・レディーズ・リサーチ・ファウンデーション Substituted thiazolinedione and oxazolidinedione having antidiabetic, hypolipidemic and antihypertensive properties
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
AU757729B2 (en) * 1999-04-07 2003-03-06 Sankyo Company Limited Amine derivatives
AU3670900A (en) * 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
IL130169A (en) 1999-05-27 2006-08-20 Neurim Pharma 1991 Derivatives of indole, and pharmaceutical, skin-protective and cosmetic compositions containing them
DE60032898T2 (en) * 1999-06-18 2007-10-25 Merck & Co., Inc. ARYLTHIAZOLIDEINDION AND ARYLOXAZOLIDINE DERIVATIVES
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
ITRM20020016A1 (en) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti FENYL ACID DERIVATIVES (ALCHYL) CARBOXYL AND DYNIC PHENYLALKYL THEROCYCLIC DERIVATIVES, THEIR USE AS MEDICATIONS WITH HYPOGLYCEMIC ACTIVITY
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
CN101076334A (en) * 2004-05-28 2007-11-21 默克公司 Benzoureas having anti-diabetic activity
WO2006080524A1 (en) * 2005-01-31 2006-08-03 Ajinomoto Co., Inc. Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent
WO2006138328A1 (en) * 2005-06-14 2006-12-28 Merck & Co., Inc. Process for the production of antidiabetic oxazolidinediones
EP1909789A4 (en) * 2005-07-20 2009-10-21 Merck & Co Inc Antidiabetic oxazolidinediones and thiazolidinediones
KR101331768B1 (en) 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Heterocyclic modulators of ATP-binding cassette transporters
WO2008141119A2 (en) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
KR101537830B1 (en) * 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 Thiazolidinedione analogues for the treatment of hypertension
US8143280B2 (en) * 2007-09-27 2012-03-27 Hoffmann-La Roche Inc. Glucocorticoid receptor antagonists
KR20150066608A (en) 2007-12-07 2015-06-16 버텍스 파마슈티칼스 인코포레이티드 Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
SG186638A1 (en) 2007-12-07 2013-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
CN101463031B (en) * 2007-12-20 2014-02-12 中国医学科学院药物研究所 Indazole and tetrahydrochysene indazole compounds, and preparation, pharmaceutical composition and use thereof
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
TWI461423B (en) * 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
RU2592368C2 (en) 2010-04-07 2016-07-20 Вертекс Фармасьютикалз Инкорпорейтед PHARMACEUTICAL COMPOSITIONS CONTAINING 3-(2, 2-DIFLUOROBENZO[d][1, 3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDINE-2-YL)BENZOIC ACID, AND ADMINISTRATION THEREOF
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
JP6494757B2 (en) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Process for high-throughput high performance liquid chromatography
CN111883832A (en) * 2020-07-24 2020-11-03 香河昆仑化学制品有限公司 Lithium ion battery electrolyte, battery cathode and electrochemical energy storage device

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097594A (en) * 1977-03-30 1978-06-27 Fmc Corporation Mono-5-substituted-3-chloro-4H-1,2,6-thiadiazin-4-one antifungal agents
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
JPS60226873A (en) * 1984-03-28 1985-11-12 Sankyo Co Ltd 1,3-benzoxazole derivative and its preparation
CN1003445B (en) * 1984-10-03 1989-03-01 武田药品工业株式会社 The preparation method of thiazolidine diketone derivative
DK173350B1 (en) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidine derivatives, their preparation and pharmaceutical composition containing them
JPH06779B2 (en) * 1985-06-10 1994-01-05 武田薬品工業株式会社 Thiazolidione derivative and pharmaceutical composition comprising the same
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
JPH0764866B2 (en) * 1987-02-24 1995-07-12 財団法人微生物化学研究会 1-N- (4-amino-3-fluoro-2-hydroxybutyryl) kanamycin
DE3856378T2 (en) * 1987-09-04 2000-05-11 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
DE69132713D1 (en) * 1990-04-27 2001-10-11 Sankyo Co Benzylidenthiazolidine derivatives, their preparation and their use as lipid peroxide inhibitors
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
US5334604A (en) * 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
CZ196693A3 (en) * 1991-04-11 1994-05-18 Upjohn Co Thiazolidinedione derivatives, and process for preparing thereof
FR2680512B1 (en) * 1991-08-20 1995-01-20 Adir NOVEL 2,4-THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
NO302519B1 (en) * 1991-12-26 1998-03-16 Sankyo Co Thiazolidine compounds containing a quinone group, and pharmaceutical composition
EP0590793B1 (en) * 1992-08-31 1999-10-13 Sankyo Company Limited Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
US5614544A (en) * 1993-09-14 1997-03-25 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
CZ289317B6 (en) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyclic compound, pharmaceutical preparations in which the compound is comprised and use thereof

Also Published As

Publication number Publication date
NO305987B1 (en) 1999-08-30
HU9501040D0 (en) 1995-06-28
EP0676398A3 (en) 1998-07-01
IL113313A (en) 1999-09-22
CN1060173C (en) 2001-01-03
HUT73765A (en) 1996-09-30
DE69523358D1 (en) 2001-11-29
NO951398L (en) 1995-10-12
IL113313A0 (en) 1995-07-31
US5739345A (en) 1998-04-14
PT676398E (en) 2002-03-28
US5977365A (en) 1999-11-02
PT1022274E (en) 2002-11-29
AU683348B2 (en) 1997-11-06
CZ91095A3 (en) 1997-12-17
ID20564A (en) 1999-01-14
FI951731A (en) 1995-10-12
ES2180477T3 (en) 2003-02-16
NO307299B1 (en) 2000-03-13
HK1011365A1 (en) 1999-07-09
ATE222895T1 (en) 2002-09-15
US5624935A (en) 1997-04-29
NO951398D0 (en) 1995-04-10
EP0676398B1 (en) 2001-10-24
DE69523358T2 (en) 2002-07-11
RU2114844C1 (en) 1998-07-10
DK1022274T3 (en) 2002-10-28
RU2151145C1 (en) 2000-06-20
TW407156B (en) 2000-10-01
ES2165895T3 (en) 2002-04-01
RU95105423A (en) 1997-03-20
HK1029338A1 (en) 2001-03-30
US6117893A (en) 2000-09-12
KR950032188A (en) 1995-12-20
EP0676398A2 (en) 1995-10-11
DE69528000D1 (en) 2002-10-02
US5834501A (en) 1998-11-10
AU1638395A (en) 1995-10-19
NO983900L (en) 1995-10-12
DE69528000T2 (en) 2003-05-28
CZ289317B6 (en) 2002-01-16
CA2146701A1 (en) 1995-10-12
ZA952990B (en) 1995-12-21
EP1022274B1 (en) 2002-08-28
HU219887B (en) 2001-08-28
ATE207488T1 (en) 2001-11-15
DK0676398T3 (en) 2001-12-10
NO983900D0 (en) 1998-08-25
CN1118781A (en) 1996-03-20
EP1022274A1 (en) 2000-07-26
NZ270917A (en) 1996-12-20
FI951731A0 (en) 1995-04-11
US5962470A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
TW503237B (en) Intermediate in manufacture of heterocyclic compounds having anti-diabetic activity
TW449594B (en) Benzimidazole compounds, hydrochlorated thereof and pharmaceutical compositions thereof
AU737303B2 (en) Cyclic amino compounds
TW475931B (en) A substituted condensed heterocyclic compound
AU686426B2 (en) Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
US4296126A (en) 3-Aryloxy-3-aryl-propaneamines and their method of use
JPH07506838A (en) Pyridopyrimidinone anti-angina drugs
CA2998034C (en) A group of compounds used for the treatment or prevention of hyperuricemia or gout
PT2035379E (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN102083818A (en) Substituted 1-(diazinyl) pyrazole-4-yl-acetic acids, method for the production thereof, and use thereof as herbicides and plant growth regulators
JPH10503488A (en) Heterocyclic compounds, their production and their therapeutic use
AU2961599A (en) Sulfonamide derivatives
NO158432B (en) DEVICE FOR FLOORS FOR FLOORS.
AU618898B2 (en) Process for the preparation of oxophthalazinyl acetic acids and analogs thereof
TW200408628A (en) Resorcinol and its derivatives
JP2001163786A (en) Enzyme inhibitor containing sulfonamide derivative
JP2001131067A (en) Platelet coagulation inhibitor and arteriosclerosis- evolving inhibitor
US20050080100A1 (en) Pyridylamino compounds and methods of use thereof
PT100013A (en) PROCESS FOR THE PREPARATION OF 2,4-DIOXO-PYRIDO ACID (2,3) PYRIMIDINE-3-ACETATES AND ITS SALTS AND ESTERS
Petrow Part VII. 4-Chloro-2'-methyl-3-sulphamoylbenzanilide
FR2669928A1 (en) New pyrimidine derivatives which are antagonists of angiotensin-II receptors, processes for their preparation and pharmaceutical compositions containing them
CZ20003626A3 (en) Sulfonamide derivatives
FR2663930A1 (en) New pyrimidine derivatives which are antagonists of angiotensin-II receptors; processes for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees